ClinicalTrials.gg
CompletedNCT00583362Updated Jul 23, 2019Results posted

A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02

A Phase 2 interventional study of Belimumab in Systemic Lupus Erythematosus, sponsored by Human Genome Sciences Inc., a GSK Company. Completed at 57 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-07-23.

Sponsored by Human Genome Sciences Inc., a GSK Company (part of GlaxoSmithKline) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled May 2005, registered Dec 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
298
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing belimumab in Lupus Erythematosus, Systemic — 4 open to participants now, 7 under way, none of them phase 3. belimumab · Lupus Erythematosus, Systemic.

Enrollment
11th of 36
298 · median 81
Started
2005
the only one that year
Phase 2
8 of 36
2 open now
Registered
4th of 36
by date
Lead sponsor
7 of 36
Human Genome Sciences Inc., a GSK Company

Among the 36 studies testing belimumab in Lupus Erythematosus, Systemic, this one is the 11th largest by enrollment, is the only one that started in 2005, is one of 8 in phase 2, and was the 4th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

4 of the 36 studies testing belimumab in Lupus Erythematosus, Systemic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About belimumab

belimumab: first FDA approval 2011 (BENLYSTA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing belimumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

This is a continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with SLE disease, that completed study LBSL02 and benefitted from treatment.

Read the detailed description

The purpose of this continuation study to evaluate the long-term safety and efficacy of LymphoStat-B™ in subjects with Systemic Lupus Erythematosus (SLE), that completed study LBSL02 and benefitted from treatment.

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • SLE
  • Lupus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Primary Inclusion Criteria

  1. Have completed the LBSL02 trial and achieved a satisfactory response.

Primary Exclusion Criteria

  1. Required more than 2 courses of for treatment of severe SLE flares in the last 5 months of LBSL02.
  2. Had an SLE flare during the last 30 days of LBSL02 and through the 1st dose in LBSL99.
  3. Used any of the following prohibited medications during their participation in LBSL02:

    • Other agents.
    • Biologic therapeutic agents: adalimumab (Humira™), etanercept (Enbrel™), infliximab (Remicade™), and rituximab (Rituxan™).
    • Intravenous cyclophosphamide.
    • Corticosteroids >100 mg/day prednisone equivalent for reasons other than severe SLE flare.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
298 participants (actual)

Study arms

  • Experimental
    Belimumab 10 mg/kg

    Belimumab 10 mg/kg IV over one hour every 28 days.

    Biological: Belimumab

Interventions

  • BiologicalBelimumab

    Belimumab 10mg/kg IV over one hour every 28 days

    Also known as: LymphoStat-B™, HGS1006, BENLYSTA

06

What researchers measure

Primary outcomes

  1. Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)

    An AE is defined as any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. This includes worsening (example \[eg\], increase in frequency or severity) of pre-existing conditions. An SAE is defined as an AE resulting in any of the following outcomes: death, is life threatening (that is, an immediate threat to life), inpatient hospitalization, prolongation of an existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and is medically important.

    Time frame: Approximately up to 13 years

  2. Adverse Event (AE) Rates by System Organ Class (SOC) During the Study

    AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent AEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365).

    Time frame: Approximately up to 13 years

  3. SAE Rates by System Organ Class (SOC) During the Study

    SAE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent SAEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pretreatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365).

    Time frame: Approximately up to 13 years

  4. Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points

    Hematology parameters were assessed at Baseline, Week 8, 16, 24, 40, and 48 during Year 1 to 8; Week 8, 16, 24, and 40 during Year 9; Week 24 and 40 during Year 10; Week 48 during Year 11; Week 32 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  5. Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points

    Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils segmented and platelets is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  6. Change From Baseline in Erythrocytes at the Indicated Time Points

    Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  7. Change From Baseline in Hematocrit at the Indicated Time Points

    Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  8. Change From Baseline in Hemoglobin at the Indicated Time Points

    Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  9. Change From Baseline in Albumin and Protein at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  10. Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  11. Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in creatinine, urate, and bilirubin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  12. Change From Baseline in BUN/Creatinine at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  13. Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points

    Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in ALT, AP, AST, GGT and LD are summarized. Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

Secondary outcomes

  1. Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points

    SRI response was assessed at Week 16, 32, and 48 during Year 1 to 12 and Week 16 and 32 during Year 13. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. SRI response is defined as:\>=4 point reduction from the Baseline in safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of \<0.30 points from the Baseline) in Physician's Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the Baseline at the time of assessment.

    Time frame: Approximately up to 13 years

  2. Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points

    Anti-double stranded DNA levels in participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.

    Time frame: Approximately up to 13 years

  3. Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points

    Anti-double stranded DNA levels for participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  4. Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points

    Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.

    Time frame: Approximately up to 13 years

  5. Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points

    Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

  6. Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points

    Daily prednisone dose reduction was assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13. Percentage of participants with daily prednisone dose reduced to \<=7.5 mg/day from \>7.5 mg/kg at the Baseline are summarized. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.

    Time frame: Approximately up to 13 years

  7. Absolute Serum Immunoglobulin G Values at Indicated Time Points

    Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.

    Time frame: Approximately up to 13 years

  8. Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points

    Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.

    Time frame: Baseline and approximately up to 13 years

07

Results

Posted Apr 28, 2017

Participant flow

Participants who completed the parent study LBSL02 (NCT00071487) through the 24-week extension period, who received belimumab 1 milligram (mg)/kilogram (kg), 4 mg/kg, 10 mg/kg or placebo in the parent study and achieved a satisfactory response were enrolled in the study.

Participant flow — Overall Study
MilestoneBelimumab 10 mg/kg IV
Started298
Completed96
Not completed202
Withdrew: Adverse event44
Withdrew: Lack of efficacy22
Withdrew: Lost to follow-up4
Withdrew: Non-compliance with study drug28
Withdrew: Pregnancy7
Withdrew: Miscommunication of visit window5
Withdrew: Current site closed7
Withdrew: Subject not dosed in lbsl991
Withdrew: Subject moved out of the country/state2
Withdrew: Missed visits due to staff changes1
Withdrew: Misunderstanding of protocol1
Withdrew: Behavioral problems and non-compliance1
Withdrew: Sponsor request due to missed doses1
Withdrew: Physician decision19
Withdrew: Protocol violation2
Withdrew: Withdrawal by subject57

Outcome measures

PrimaryNumber of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)

An AE is defined as any unfavorable or unintended sign, symptom, or disease that is temporally associated with the use of a study agent but is not necessarily caused by the study agent. This includes worsening (example \[eg\], increase in frequency or severity) of pre-existing conditions. An SAE is defined as an AE resulting in any of the following outcomes: death, is life threatening (that is, an immediate threat to life), inpatient hospitalization, prolongation of an existing hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, and is medically important.

Time frame:
Approximately up to 13 years
Reported as:
Number · Participants
Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)
ParticipantsBelimumab 10 mg/kg IV
AE, Any time post baseline, n=296294
AE, Year 0-1, n=296291
AE, Year 1-2, n=294283
AE, Year 2-3, n=276260
AE, Year 3-4, n=250239
AE, Year 4-5, n=223203
AE, Year 5-6, n=209190
AE, Year 6-7, n=192182
AE, Year 7-8, n=178162
AE, Year 8-9, n=169157
AE, Year 9-10, n=152137
AE, Year 10-11, n=131105
AE, Year 11 plus, n=8845
SAE, Any time post baseline, n=296182
SAE, Year 0-1, n=29641
SAE, Year 1-2, n=29443
SAE, Year 2-3, n=27650
SAE, Year 3-4, n=25030
SAE, Year 4-5, n=22340
SAE, Year 5-6, n=20933
SAE, Year 6-7, n=19235
SAE, Year 7-8, n=17834
SAE, Year 8-9, n=16928
SAE, Year 9-10, n=15225
SAE, Year 10-11, n=13114
SAE, Year 11 plus, n=887
PrimaryAdverse Event (AE) Rates by System Organ Class (SOC) During the Study

AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent AEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365).

Time frame:
Approximately up to 13 years
Reported as:
Number · Events per 100 participant years
Adverse Event (AE) Rates by System Organ Class (SOC) During the Study
Events per 100 participant yearsBelimumab 10 mg/kg IV
Infections and infestations285
Musculoskeletal and connective tissue disorders276
Gastrointestinal disorders257
Skin and subcutaneous tissue disorders256
General disorders, administration site conditions247
Nervous system disorders244
Respiratory, thoracic and mediastinal disorders241
Investigations227
Injury, poisoning and procedural complications221
Psychiatric disorders180
Metabolism and nutrition disorders144
Vascular disorders134
Eye disorders133
Blood and lymphatic system disorders127
Reproductive system and breast disorders114
Renal and urinary disorders109
Immune system disorders101
Neoplasms benign, malignant and unspecified100
Cardiac disorders86
Ear and labyrinth disorders69
Endocrine disorders40
Hepatobiliary disorders27
Social circumstances15
Congenital, familial and genetic disorders7
Pregnancy, puerperium and perinatal conditions5
PrimarySAE Rates by System Organ Class (SOC) During the Study

SAE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatmentemergent SAEs are summarized. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pretreatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate=100\* number of events divided by participant years. Participant years were calculated as sum across all participants (\[last visit of interval day minus first visit of interval day plus 1\] divided by 365).

Time frame:
Approximately up to 13 years
Reported as:
Number · Events per 100 participant years
SAE Rates by System Organ Class (SOC) During the Study
Events per 100 participant yearsBelimumab 10 mg/kg IV
Infections and infestations69
Musculoskeletal and connective tissue disorders44
Gastrointestinal disorders38
Nervous system disorders35
General disorders, administration site conditions31
Injury, poisoning and procedural complications29
Respiratory, thoracic and mediastinal disorders25
Cardiac disorders23
Neoplasms benign, malignant and unspecified23
Renal and urinary disorders20
Vascular disorders19
Reproductive system and breast disorders18
Metabolism and nutrition disorders14
Hepatobiliary disorders10
Blood and lymphatic system disorders8
Skin and subcutaneous tissue disorders8
Investigations7
Psychiatric disorders6
Immune system disorders2
Pregnancy, puerperium and perinatal conditions2
Congenital, familial and genetic disorders1
Eye disorders1
Social circumstances1
PrimaryChange From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points

Hematology parameters were assessed at Baseline, Week 8, 16, 24, 40, and 48 during Year 1 to 8; Week 8, 16, 24, and 40 during Year 9; Week 24 and 40 during Year 10; Week 48 during Year 11; Week 32 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Mean · Seconds
Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points
SecondsBelimumab 10 mg/kg IV
APTT, Year 1, Week 8, n=2740.3 ± 12.60
APTT, Year 1, Week 16, n=276-1.3 ± 7.46
APTT, Year 1, Week 24, n=222-1.6 ± 13.61
APTT, Year 1, Week 32, n=221-1.9 ± 7.24
APTT, Year 1, Week 40, n=219-1.6 ± 7.00
APTT, Year 1, Week 48, n=218-1.0 ± 7.29
APTT, Year 2, Week 8, n=220-0.3 ± 6.73
APTT, Year 2, Week 16, n=214-0.2 ± 8.79
APTT, Year 2, Week 24, n=2120.6 ± 13.81
APTT, Year 2, Week 32, n=351.5 ± 9.20
APTT, Year 2, Week 40, n=282.6 ± 7.53
APTT, Year 2, Week 48, n=213.0 ± 8.69
APTT, Year 3, Week 8, n=252.4 ± 10.70
APTT, Year 3, Week 16, n=232.3 ± 7.77
APTT, Year 3, Week 24, n=231.7 ± 6.30
APTT, Year 3, Week 32, n=225.4 ± 10.01
APTT, Year 3, Week 40, n=182.1 ± 9.62
APTT, Year 3, Week 48, n=183.9 ± 17.23
APTT, Year 4, Week 8, n=142.9 ± 11.42
APTT, Year 4, Week 16, n=163.1 ± 8.97
APTT, Year 4, Week 24, n=101.1 ± 10.29
APTT, Year 4, Week 32, n=182.1 ± 11.37
APTT, Year 4, Week 40, n=13-2.1 ± 10.02
APTT, Year 4, Week 48, n=112.2 ± 11.83
APTT, Year 5, Week 8, n=43.0 ± 14.76
APTT, Year 5, Week 16, n=111.3 ± 5.62
APTT, Year 5, Week 24, n=313.0 ± 11.53
APTT, Year 5, Week 32, n=123.1 ± 6.64
APTT, Year 5, Week 40, n=10-0.5 ± 8.03
APTT, Year 5, Week 48, n=312.3 ± 5.51
APTT, Year 6, Week 8, n=3-2.3 ± 19.50
APTT, Year 6, Week 16, n=39.0 ± 12.12
APTT, Year 6, Week 24, n=314.0 ± 16.52
APTT, Year 6, Week 32, n=26.5 ± 17.68
APTT, Year 6, Week 40, n=89.9 ± 9.11
APTT, Year 6, Week 48, n=418.3 ± 4.99
APTT, Year 7, Week 8, n=127.0 ± NA
APTT, Year 7, Week 16, n=224.5 ± 14.85
APTT, Year 7, Week 24, n=219.5 ± 6.36
APTT, Year 7, Week 32, n=17.0 ± NA
APTT, Year 7, Week 40, n=216.5 ± 16.26
APTT, Year 7, Week 48, n=218.5 ± 2.12
APTT, Year 8, Week 8, n=311.7 ± 18.04
APTT, Year 8, Week 16, n=315.7 ± 10.07
APTT, Year 8, Week 24, n=321.3 ± 22.50
APTT, Year 8, Week 32, n=38.7 ± 14.36
APTT, Year 8, Week 40, n=225.0 ± 5.66
APTT, Year 8, Week 48, n=313.3 ± 15.01
APTT, Year 9, Week 8, n=310.3 ± 9.07
APTT, Year 9, Week 16, n=311.0 ± 9.85
APTT, Year 9, Week 24, n=224.0 ± 25.46
APTT, Year 9, Week 32, n=4-11.0 ± 21.91
APTT, Year 9, Week 40, n=120.0 ± NA
APTT, Year 10, Week 24, n=110.0 ± NA
APTT, Year 10, Week 40, n=1-9 ± NA
APTT, Year 11, Week 48, n=1-27.0 ± NA
APTT, Year 13, Week 32, n=126 ± NA
APTT, Exit, n=102.3 ± 9.66
APTT, 8-Week Follow-up, n=63.8 ± 6.24
APTT, 24-Week Follow-up, n=3-12.3 ± 16.56
PT, Year 1, Week 8, n=278-0.67 ± 12.222
PT, Year 1, Week 16, n=276-0.98 ± 12.134
PT, Year 1, Week 24, n=222-1.00 ± 13.859
PT, Year 1, Week 32, n=223-0.89 ± 13.887
PT, Year 1, Week 40, n=221-0.67 ± 14.262
PT, Year 1, Week 48, n=219-0.95 ± 13.496
PT, Year 2, Week 8, n=221-0.87 ± 13.364
PT, Year 2, Week 16, n=215-0.84 ± 13.682
PT, Year 2, Week 24, n=214-0.66 ± 14.156
PT, Year 2, Week 32, n=350.85 ± 6.887
PT, Year 2, Week 40, n=283.28 ± 11.046
PT, Year 2, Week 48, n=221.75 ± 8.747
PT, Year 3, Week 8, n=251.75 ± 12.409
PT, Year 3, Week 16, n=230.39 ± 5.469
PT, Year 3, Week 24, n=230.98 ± 3.120
PT, Year 3, Week 32, n=224.29 ± 10.640
PT, Year 3, Week 40, n=182.02 ± 8.833
PT, Year 3, Week 48, n=183.23 ± 15.863
PT, Year 4, Week 8, n=144.14 ± 9.948
PT, Year 4, Week 16, n=160.69 ± 8.188
PT, Year 4, Week 24, n=102.10 ± 8.506
PT, Year 4, Week 32, n=181.87 ± 11.251
PT, Year 4, Week 40, n=13-2.70 ± 6.698
PT, Year 4, Week 48, n=110.60 ± 9.651
PT, Year 5, Week 8, n=4-0.43 ± 12.189
PT, Year 5, Week 16, n=112.52 ± 6.118
PT, Year 5, Week 24, n=39.90 ± 8.347
PT, Year 5, Week 32, n=120.67 ± 3.731
PT, Year 5, Week 40, n=10-0.33 ± 5.443
PT, Year 5, Week 48, n=313.23 ± 9.064
PT, Year 6, Week 8, n=3-2.93 ± 7.859
PT, Year 6, Week 16, n=32.10 ± 5.336
PT, Year 6, Week 24, n=37.60 ± 11.623
PT, Year 6, Week 32, n=24.55 ± 21.425
PT, Year 6, Week 40, n=82.30 ± 5.865
PT, Year 6, Week 48, n=46.18 ± 10.637
PT, Year 7, Week 8, n=119.90 ± NA
PT, Year 7, Week 16, n=218.20 ± 14.425
PT, Year 7, Week 24, n=27.35 ± 0.636
PT, Year 7, Week 32, n=14.00 ± NA
PT, Year 7, Week 40, n=211.15 ± 19.587
PT, Year 7, Week 48, n=211.50 ± 4.808
PT, Year 8, Week 8, n=312.47 ± 15.546
PT, Year 8, Week 16, n=37.57 ± 6.799
PT, Year 8, Week 24, n=312.87 ± 13.787
PT, Year 8, Week 32, n=35.63 ± 9.850
PT, Year 8, Week 40, n=226.60 ± 13.435
PT, Year 8, Week 48, n=311.07 ± 9.845
PT, Year 9, Week 8, n=38.23 ± 7.976
PT, Year 9, Week 16, n=34.60 ± 6.773
PT, Year 9, Week 24, n=225.75 ± 36.416
PT, Year 9, Week 32, n=4-10.08 ± 8.139
PT, Year 9, Week 40, n=121.40 ± NA
PT, Year 10, Week 24, n=11.30 ± NA
PT, Year 10, Week 40, n=1-8.00 ± NA
PT, Year 11, Week 48, n=1-22.80 ± NA
PT, Year 13, Week 32, n=114.80 ± NA
PT, Exit, n=100.64 ± 5.559
PT, 8-Week Follow-up, n=6-0.95 ± 4.561
PT, 24-Week Follow-up, n=3-10.23 ± 11.657
PrimaryChange From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points

Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils segmented and platelets is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Mean · 10^9 per liter
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils Segmented and Platelets at the Indicated Time Points
10^9 per literBelimumab 10 mg/kg IV
Basophils, Year 1, Week 8, n=2870.001 ± 0.0163
Basophils, Year 1, Week 16, n=2880.000 ± 0.0181
Basophils, Year 1, Week 24, n=2930.000 ± 0.0171
Basophils, Year 1, Week 32, n=2900.002 ± 0.0166
Basophils, Year 1, Week 40, n=2870.001 ± 0.0159
Basophils, Year 1, Week 48, n=2870.001 ± 0.0178
Basophils, Year 2, Week 8, n=2880.001 ± 0.0164
Basophils, Year 2, Week 16, n=2790.002 ± 0.0172
Basophils, Year 2, Week 24, n=2760.001 ± 0.0168
Basophils, Year 2, Week 32, n=2810.003 ± 0.0179
Basophils, Year 2, Week 40, n=2620.002 ± 0.0162
Basophils, Year 2, Week 48, n=2600.003 ± 0.0174
Basophils, Year 3, Week 8, n=2600.003 ± 0.0167
Basophils, Year 3, Week 16, n=2580.004 ± 0.0177
Basophils, Year 3, Week 24, n=2420.002 ± 0.0160
Basophils, Year 3, Week 32, n=2480.004 ± 0.0204
Basophils, Year 3, Week 40, n=2420.004 ± 0.0178
Basophils, Year 3, Week 48, n=2400.002 ± 0.0172
Basophils, Year 4, Week 8, n=2340.001 ± 0.0189
Basophils, Year 4, Week 16, n=2380.003 ± 0.0183
Basophils, Year 4, Week 24, n=2270.003 ± 0.0160
Basophils, Year 4, Week 32, n=2290.003 ± 0.0174
Basophils, Year 4, Week 40, n=2160.004 ± 0.0174
Basophils, Year 4, Week 48, n=2200.002 ± 0.0181
Basophils, Year 5, Week 8, n=2150.004 ± 0.0173
Basophils, Year 5, Week 16, n=2140.003 ± 0.0182
Basophils, Year 5, Week 24, n=2070.003 ± 0.0174
Basophils, Year 5, Week 32, n=2070.002 ± 0.0159
Basophils, Year 5, Week 40, n=1960.003 ± 0.0184
Basophils, Year 5, Week 48, n=2090.004 ± 0.0177
Basophils, Year 6, Week 8, n=2060.004 ± 0.0183
Basophils, Year 6, Week 16, n=1950.004 ± 0.0203
Basophils, Year 6, Week 24, n=1920.003 ± 0.0212
Basophils, Year 6, Week 32, n=1970.004 ± 0.0177
Basophils, Year 6, Week 40, n=1830.003 ± 0.0157
Basophils, Year 6, Week 48, n=1880.002 ± 0.0174
Basophils, Year 7, Week 8, n=1800.002 ± 0.0194
Basophils, Year 7, Week 16, n=1810.001 ± 0.0186
Basophils, Year 7, Week 24, n=1760.003 ± 0.0178
Basophils, Year 7, Week 32, n=1790.004 ± 0.0173
Basophils, Year 7, Week 40, n=1770.004 ± 0.0172
Basophils, Year 7, Week 48, n=1730.004 ± 0.0171
Basophils, Year 8, Week 8, n=1720.003 ± 0.0184
Basophils, Year 8, Week 16, n=1730.005 ± 0.0167
Basophils, Year 8, Week 24, n=1700.005 ± 0.0160
Basophils, Year 8, Week 32, n=1690.003 ± 0.0165
Basophils, Year 8, Week 40, n=1620.005 ± 0.0177
Basophils, Year 8, Week 48, n=1610.004 ± 0.0187
Basophils, Year 9, Week 8, n=1640.006 ± 0.0227
Basophils, Year 9, Week 16, n=1610.005 ± 0.0194
Basophils, Year 9, Week 24, n=1630.004 ± 0.0170
Basophils, Year 9, Week 32, n=1590.004 ± 0.0167
Basophils, Year 9, Week 40, n=1560.004 ± 0.0180
Basophils, Year 9, Week 48, n=1510.003 ± 0.0153
Basophils, Year 10, Week 8, n=1490.002 ± 0.0183
Basophils, Year 10, Week 16, n=1450.006 ± 0.0205
Basophils, Year 10, Week 24, n=1470.003 ± 0.0186
Basophils, Year 10, Week 32, n=1420.005 ± 0.0214
Basophils, Year 10, Week 40, n=1370.004 ± 0.0192
Basophils, Year 10, Week 48, n=1370.006 ± 0.0185
Basophils, Year 11, Week 8, n=1370.004 ± 0.0200
Basophils, Year 11, Week 16, n=1300.004 ± 0.0188
Basophils, Year 11, Week 24, n=1300.005 ± 0.0176
Basophils, Year 11, Week 32, n=1280.006 ± 0.0187
Basophils, Year 11, Week 40, n=1220.006 ± 0.0232
Basophils, Year 11, Week 48, n=1060.005 ± 0.0189
Basophils, Year 12, Week 8, n=1090.007 ± 0.0209
Basophils, Year 12, Week 16, n=970.004 ± 0.0197
Basophils, Year 12, Week 24, n=860.007 ± 0.0204
Basophils, Year 12, Week 32, n=880.004 ± 0.0213
Basophils, Year 12, Week 40, n=830.007 ± 0.0201
Basophils, Year 12, Week 48, n=720.006 ± 0.0172
Basophils, Year 13, Week 8, n=530.005 ± 0.0173
Basophils, Year 13, Week 16, n=420.006 ± 0.0178
Basophils, Year 13, Week 24, n=200.008 ± 0.0170
Basophils, Year 13, Week 32, n=70.014 ± 0.0151
Basophils, Year 13, Week 40, n=10.020 ± NA
Basophils, Exit, n=2410.005 ± 0.0171
Basophils, 8-Week Follow-up, n=2190.006 ± 0.0205
Basophils, 24-Week Follow-up, n=1980.006 ± 0.0213
Eosinophils, Year 1, Week 8, n=2870.003 ± 0.0999
Eosinophils, Year 1, Week 16, n=2880.007 ± 0.1213
Eosinophils, Year 1, Week 24, n=2930.008 ± 0.1222
Eosinophils, Year 1, Week 32, n=2900.011 ± 0.1219
Eosinophils, Year 1, Week 40, n=2870.007 ± 0.1070
Eosinophils, Year 1, Week 48, n=2870.006 ± 0.1130
Eosinophils, Year 2, Week 8, n=2880.003 ± 0.1135
Eosinophils, Year 2, Week 16, n=2790.034 ± 0.1312
Eosinophils, Year 2, Week 24, n=2760.023 ± 0.1375
Eosinophils, Year 2, Week 32, n=2810.028 ± 0.1423
Eosinophils, Year 2, Week 40, n=2620.028 ± 0.1280
Eosinophils, Year 2, Week 48, n=2600.042 ± 0.1635
Eosinophils, Year 3, Week 8, n=2600.033 ± 0.1353
Eosinophils, Year 3, Week 16, n=2580.038 ± 0.1391
Eosinophils, Year 3, Week 24, n=2420.038 ± 0.1610
Eosinophils, Year 3, Week 32, n=2480.029 ± 0.1427
Eosinophils, Year 3, Week 40, n=2420.035 ± 0.1539
Eosinophils, Year 3, Week 48, n=2400.033 ± 0.1369
Eosinophils, Year 4, Week 8, n=2340.035 ± 0.1331
Eosinophils, Year 4, Week 16, n=2380.034 ± 0.1273
Eosinophils, Year 4, Week 24, n=2270.033 ± 0.1384
Eosinophils, Year 4, Week 32, n=2290.039 ± 0.1381
Eosinophils, Year 4, Week 40, n=2160.038 ± 0.1284
Eosinophils, Year 4, Week 48, n=2200.030 ± 0.1261
Eosinophils, Year 5, Week 8, n=2150.035 ± 0.1242
Eosinophils, Year 5, Week 16, n=2140.019 ± 0.1294
Eosinophils, Year 5, Week 24, n=2070.023 ± 0.1078
Eosinophils, Year 5, Week 32, n=2070.027 ± 0.1201
Eosinophils, Year 5, Week 40, n=1960.019 ± 0.1224
Eosinophils, Year 5, Week 48, n=2090.022 ± 0.1224
Eosinophils, Year 6, Week 8, n=2060.020 ± 0.1288
Eosinophils, Year 6, Week 16, n=1950.021 ± 0.1103
Eosinophils, Year 6, Week 24, n=1920.034 ± 0.1335
Eosinophils, Year 6, Week 32, n=1970.026 ± 0.1171
Eosinophils, Year 6, Week 40, n=1830.044 ± 0.1580
Eosinophils, Year 6, Week 48, n=1880.026 ± 0.1299
Eosinophils, Year 7, Week 8, n=1800.021 ± 0.1317
Eosinophils, Year 7, Week 16, n=1810.015 ± 0.1170
Eosinophils, Year 7, Week 24, n=1760.014 ± 0.1239
Eosinophils, Year 7, Week 32, n=1790.010 ± 0.1149
Eosinophils, Year 7, Week 40, n=1770.009 ± 0.1167
Eosinophils, Year 7, Week 48, n=173-0.008 ± 0.1176
Eosinophils, Year 8, Week 8, n=172-0.003 ± 0.1389
Eosinophils, Year 8, Week 16, n=173-0.009 ± 0.1234
Eosinophils, Year 8, Week 24, n=170-0.007 ± 0.1309
Eosinophils, Year 8, Week 32, n=169-0.023 ± 0.1136
Eosinophils, Year 8, Week 40, n=162-0.009 ± 0.1263
Eosinophils, Year 8, Week 48, n=161-0.011 ± 0.1341
Eosinophils, Year 9, Week 8, n=164-0.004 ± 0.1373
Eosinophils, Year 9, Week 16, n=161-0.020 ± 0.1204
Eosinophils, Year 9, Week 24, n=163-0.020 ± 0.1134
Eosinophils, Year 9, Week 32, n=159-0.012 ± 0.1154
Eosinophils, Year 9, Week 40, n=156-0.029 ± 0.1200
Eosinophils, Year 9, Week 48, n=151-0.018 ± 0.1307
Eosinophils, Year 10, Week 8, n=149-0.020 ± 0.1343
Eosinophils, Year 10, Week 16, n=145-0.010 ± 0.1438
Eosinophils, Year 10, Week 24, n=147-0.019 ± 0.1237
Eosinophils, Year 10, Week 32, n=142-0.002 ± 0.1332
Eosinophils, Year 10, Week 40, n=137-0.021 ± 0.1184
Eosinophils, Year 10, Week 48, n=137-0.021 ± 0.1274
Eosinophils, Year 11, Week 8, n=137-0.018 ± 0.1167
Eosinophils, Year 11, Week 16, n=130-0.004 ± 0.1336
Eosinophils, Year 11, Week 24, n=1300.004 ± 0.1445
Eosinophils, Year 11, Week 32, n=1280.003 ± 0.1360
Eosinophils, Year 11, Week 40, n=122-0.013 ± 0.1298
Eosinophils, Year 11, Week 48, n=106-0.021 ± 0.1435
Eosinophils, Year 12, Week 8, n=109-0.021 ± 0.1242
Eosinophils, Year 12, Week 16, n=97-0.020 ± 0.1349
Eosinophils, Year 12, Week 24, n=86-0.000 ± 0.1535
Eosinophils, Year 12, Week 32, n=88-0.008 ± 0.1356
Eosinophils, Year 12, Week 40, n=83-0.020 ± 0.1242
Eosinophils, Year 12, Week 48, n=72-0.016 ± 0.1319
Eosinophils, Year 13, Week 8, n=53-0.001 ± 0.1436
Eosinophils, Year 13, Week 16, n=42-0.009 ± 0.1244
Eosinophils, Year 13, Week 24, n=200.035 ± 0.1810
Eosinophils, Year 13, Week 32, n=70.081 ± 0.0722
Eosinophils, Year 13, Week 40, n=10.080 ± NA
Eosinophils, Exit, n=2410.006 ± 0.1430
Eosinophils, 8-Week Follow-up, n=219-0.002 ± 0.1436
Eosinophils, 24-Week Follow-up, n=1980.013 ± 0.2255
Lymphocytes, Year 1, Week 8, n=2870.006 ± 0.4143
Lymphocytes, Year 1, Week 16, n=288-0.046 ± 0.4612
Lymphocytes, Year 1, Week 24, n=293-0.035 ± 0.4725
Lymphocytes, Year 1, Week 32, n=290-0.057 ± 0.4425
Lymphocytes, Year 1, Week 40, n=287-0.074 ± 0.5084
Lymphocytes, Year 1, Week 48, n=287-0.075 ± 0.4832
Lymphocytes, Year 2, Week 8, n=288-0.049 ± 0.4324
Lymphocytes, Year 2, Week 16, n=279-0.025 ± 0.4774
Lymphocytes, Year 2, Week 24, n=276-0.053 ± 0.4949
Lymphocytes, Year 2, Week 32, n=281-0.038 ± 0.5080
Lymphocytes, Year 2, Week 40, n=262-0.025 ± 0.5046
Lymphocytes, Year 2, Week 48, n=2600.006 ± 0.4874
Lymphocytes, Year 3, Week 8, n=260-0.037 ± 0.5202
Lymphocytes, Year 3, Week 16, n=258-0.019 ± 0.5004
Lymphocytes, Year 3, Week 24, n=242-0.045 ± 0.5131
Lymphocytes, Year 3, Week 32, n=248-0.008 ± 0.4702
Lymphocytes, Year 3, Week 40, n=242-0.015 ± 0.5407
Lymphocytes, Year 3, Week 48, n=240-0.016 ± 0.5858
Lymphocytes, Year 4, Week 8, n=234-0.041 ± 0.4933
Lymphocytes, Year 4, Week 16, n=238-0.012 ± 0.4974
Lymphocytes, Year 4, Week 24, n=2270.034 ± 0.5406
Lymphocytes, Year 4, Week 32, n=2290.017 ± 0.5270
Lymphocytes, Year 4, Week 40, n=2160.003 ± 0.4347
Lymphocytes, Year 4, Week 48, n=2200.017 ± 0.4826
Lymphocytes, Year 5, Week 8, n=2150.012 ± 0.4654
Lymphocytes, Year 5, Week 16, n=2140.050 ± 0.5205
Lymphocytes, Year 5, Week 24, n=2070.052 ± 0.5355
Lymphocytes, Year 5, Week 32, n=2070.031 ± 0.5323
Lymphocytes, Year 5, Week 40, n=1960.057 ± 0.5482
Lymphocytes, Year 5, Week 48, n=2090.031 ± 0.5125
Lymphocytes, Year 6, Week 8, n=2060.059 ± 0.5734
Lymphocytes, Year 6, Week 16, n=1950.045 ± 0.5931
Lymphocytes, Year 6, Week 24, n=1920.087 ± 0.5757
Lymphocytes, Year 6, Week 32, n=1970.066 ± 0.5970
Lymphocytes, Year 6, Week 40, n=1830.075 ± 0.5984
Lymphocytes, Year 6, Week 48, n=1880.043 ± 0.5839
Lymphocytes, Year 7, Week 8, n=1800.110 ± 0.6114
Lymphocytes, Year 7, Week 16, n=1810.077 ± 0.6114
Lymphocytes, Year 7, Week 24, n=1760.091 ± 0.5944
Lymphocytes, Year 7, Week 32, n=1790.104 ± 0.5944
Lymphocytes, Year 7, Week 40, n=1770.075 ± 0.5385
Lymphocytes, Year 7, Week 48, n=1730.060 ± 0.6039
Lymphocytes, Year 8, Week 8, n=1720.036 ± 0.5942
Lymphocytes, Year 8, Week 16, n=173-0.005 ± 0.5480
Lymphocytes, Year 8, Week 24, n=1700.030 ± 0.6126
Lymphocytes, Year 8, Week 32, n=169-0.020 ± 0.5269
Lymphocytes, Year 8, Week 40, n=1620.065 ± 0.6260
Lymphocytes, Year 8, Week 48, n=1610.087 ± 0.7204
Lymphocytes, Year 9, Week 8, n=1640.090 ± 0.6612
Lymphocytes, Year 9, Week 16, n=1610.022 ± 0.5664
Lymphocytes, Year 9, Week 24, n=1630.062 ± 0.5704
Lymphocytes, Year 9, Week 32, n=1590.017 ± 0.5326
Lymphocytes, Year 9, Week 40, n=1560.069 ± 0.6410
Lymphocytes, Year 9, Week 48, n=1510.064 ± 0.5979
Lymphocytes, Year 10, Week 8, n=1490.046 ± 0.5547
Lymphocytes, Year 10, Week 16, n=1450.089 ± 0.6336
Lymphocytes, Year 10, Week 24, n=1470.033 ± 0.5811
Lymphocytes, Year 10, Week 32, n=1420.076 ± 0.5914
Lymphocytes, Year 10, Week 40, n=1370.071 ± 0.5621
Lymphocytes, Year 10, Week 48, n=1370.073 ± 0.5807
Lymphocytes, Year 11, Week 8, n=1370.112 ± 0.5764
Lymphocytes, Year 11, Week 16, n=1300.112 ± 0.6926
Lymphocytes, Year 11, Week 24, n=1300.129 ± 0.7026
Lymphocytes, Year 11, Week 32, n=1280.139 ± 0.6249
Lymphocytes, Year 11, Week 40, n=1220.143 ± 0.6927
Lymphocytes, Year 11, Week 48, n=1060.133 ± 0.5942
Lymphocytes, Year 12, Week 8, n=1090.145 ± 0.5976
Lymphocytes, Year 12, Week 16, n=970.179 ± 0.5839
Lymphocytes, Year 12, Week 24, n=860.150 ± 0.5857
Lymphocytes, Year 12, Week 32, n=880.135 ± 0.6319
Lymphocytes, Year 12, Week 40, n=830.150 ± 0.6512
Lymphocytes, Year 12, Week 48, n=720.106 ± 0.5855
Lymphocytes, Year 13, Week 8, n=530.133 ± 0.6269
Lymphocytes, Year 13, Week 16, n=420.078 ± 0.6783
Lymphocytes, Year 13, Week 24, n=200.131 ± 0.6760
Lymphocytes, Year 13, Week 32, n=70.293 ± 0.8019
Lymphocytes, Year 13, Week 40, n=10.160 ± NA
Lymphocytes, Exit, n=2410.088 ± 0.6208
Lymphocytes, 8-Week Follow-up, n=2190.119 ± 0.6554
Lymphocytes, 24-Week Follow-up, n=1980.054 ± 0.6847
Monocytes, Year 1, Week 8, n=2870.014 ± 0.1795
Monocytes, Year 1, Week 16, n=2880.018 ± 0.1903
Monocytes, Year 1, Week 24, n=2930.007 ± 0.1834
Monocytes, Year 1, Week 32, n=2900.016 ± 0.1666
Monocytes, Year 1, Week 40, n=2870.020 ± 0.1750
Monocytes, Year 1, Week 48, n=2870.018 ± 0.1739
Monocytes, Year 2, Week 8, n=2880.009 ± 0.1718
Monocytes, Year 2, Week 16, n=2790.016 ± 0.1783
Monocytes, Year 2, Week 24, n=2760.029 ± 0.1764
Monocytes, Year 2, Week 32, n=2810.018 ± 0.1842
Monocytes, Year 2, Week 40, n=2620.014 ± 0.1848
Monocytes, Year 2, Week 48, n=2600.030 ± 0.1594
Monocytes, Year 3, Week 8, n=2600.024 ± 0.1677
Monocytes, Year 3, Week 16, n=2580.038 ± 0.1705
Monocytes, Year 3, Week 24, n=2420.034 ± 0.1632
Monocytes, Year 3, Week 32, n=2480.022 ± 0.1776
Monocytes, Year 3, Week 40, n=2420.044 ± 0.1650
Monocytes, Year 3, Week 48, n=2400.039 ± 0.1855
Monocytes, Year 4, Week 8, n=2340.035 ± 0.1687
Monocytes, Year 4, Week 16, n=2380.039 ± 0.1665
Monocytes, Year 4, Week 24, n=2270.032 ± 0.1667
Monocytes, Year 4, Week 32, n=2290.027 ± 0.1566
Monocytes, Year 4, Week 40, n=2160.035 ± 0.1688
Monocytes, Year 4, Week 48, n=2200.015 ± 0.1771
Monocytes, Year 5, Week 8, n=2150.018 ± 0.1824
Monocytes, Year 5, Week 16, n=2140.036 ± 0.1527
Monocytes, Year 5, Week 24, n=2070.041 ± 0.1632
Monocytes, Year 5, Week 32, n=2070.039 ± 0.1625
Monocytes, Year 5, Week 40, n=1960.049 ± 0.1510
Monocytes, Year 5, Week 48, n=2090.050 ± 0.1628
Monocytes, Year 6, Week 8, n=2060.045 ± 0.1670
Monocytes, Year 6, Week 16, n=1950.033 ± 0.1700
Monocytes, Year 6, Week 24, n=1920.030 ± 0.1556
Monocytes, Year 6, Week 32, n=1970.048 ± 0.1635
Monocytes, Year 6, Week 40, n=1830.051 ± 0.1342
Monocytes, Year 6, Week 48, n=1880.038 ± 0.1665
Monocytes, Year 7, Week 8, n=1800.028 ± 0.1507
Monocytes, Year 7, Week 16, n=1810.030 ± 0.1482
Monocytes, Year 7, Week 24, n=1760.033 ± 0.1583
Monocytes, Year 7, Week 32, n=1790.039 ± 0.1534
Monocytes, Year 7, Week 40, n=1770.047 ± 0.1391
Monocytes, Year 7, Week 48, n=1730.055 ± 0.1508
Monocytes, Year 8, Week 8, n=1720.071 ± 0.1536
Monocytes, Year 8, Week 16, n=1730.072 ± 0.1464
Monocytes, Year 8, Week 24, n=1700.075 ± 0.1545
Monocytes, Year 8, Week 32, n=1690.049 ± 0.1414
Monocytes, Year 8, Week 40, n=1620.070 ± 0.1480
Monocytes, Year 8, Week 48, n=1610.072 ± 0.1744
Monocytes, Year 9, Week 8, n=1640.069 ± 0.1513
Monocytes, Year 9, Week 16, n=1610.063 ± 0.1462
Monocytes, Year 9, Week 24, n=1630.077 ± 0.1603
Monocytes, Year 9, Week 32, n=1590.074 ± 0.1393
Monocytes, Year 9, Week 40, n=1560.075 ± 0.1440
Monocytes, Year 9, Week 48, n=1510.063 ± 0.1576
Monocytes, Year 10, Week 8, n=1490.084 ± 0.1511
Monocytes, Year 10, Week 16, n=1450.083 ± 0.1439
Monocytes, Year 10, Week 24, n=1470.087 ± 0.1874
Monocytes, Year 10, Week 32, n=1420.077 ± 0.1517
Monocytes, Year 10, Week 40, n=1370.064 ± 0.1522
Monocytes, Year 10, Week 48, n=1370.070 ± 0.1454
Monocytes, Year 11, Week 8, n=1370.077 ± 0.1622
Monocytes, Year 11, Week 16, n=1300.077 ± 0.1484
Monocytes, Year 11, Week 24, n=1300.079 ± 0.1775
Monocytes, Year 11, Week 32, n=1280.080 ± 0.1849
Monocytes, Year 11, Week 40, n=1220.075 ± 0.1435
Monocytes, Year 11, Week 48, n=1060.075 ± 0.1854
Monocytes, Year 12, Week 8, n=1090.088 ± 0.2166
Monocytes, Year 12, Week 16, n=970.104 ± 0.1829
Monocytes, Year 12, Week 24, n=860.073 ± 0.1616
Monocytes, Year 12, Week 32, n=880.065 ± 0.1682
Monocytes, Year 12, Week 40, n=830.078 ± 0.1734
Monocytes, Year 12, Week 48, n=720.060 ± 0.1635
Monocytes, Year 13, Week 8, n=530.013 ± 0.1453
Monocytes, Year 13, Week 16, n=420.061 ± 0.1882
Monocytes, Year 13, Week 24, n=200.074 ± 0.1471
Monocytes, Year 13, Week 32, n=70.097 ± 0.1452
Monocytes, Year 13, Week 40, n=10.120 ± NA
Monocytes, Exit, n=2410.062 ± 0.1813
Monocytes, 8-Week Follow-up, n=2190.061 ± 0.2153
Monocytes, 24-Week Follow-up , n=1980.049 ± 0.2118
Neutrophils segmented, Year 1, Week 8, n=2870.003 ± 1.7881
Neutrophils segmented, Year 1, Week 16, n=288-0.107 ± 1.7909
Neutrophils segmented, Year 1, Week 24, n=293-0.166 ± 1.9241
Neutrophils segmented, Year 1, Week 32, n=290-0.129 ± 2.0814
Neutrophils segmented, Year 1, Week 40, n=287-0.140 ± 1.7884
Neutrophils segmented, Year 1, Week 48, n=287-0.223 ± 1.7187
Neutrophils segmented, Year 2, Week 8, n=288-0.301 ± 2.0434
Neutrophils segmented, Year 2, Week 16, n=279-0.392 ± 2.0076
Neutrophils segmented, Year 2, Week 24, n=276-0.250 ± 2.2163
Neutrophils segmented, Year 2, Week 32, n=281-0.129 ± 2.1622
Neutrophils segmented, Year 2, Week 40, n=262-0.236 ± 2.1413
Neutrophils segmented, Year 2, Week 48, n=260-0.148 ± 2.1176
Neutrophils segmented, Year 3, Week 8, n=260-0.333 ± 2.1308
Neutrophils segmented, Year 3, Week 16, n=258-0.308 ± 2.2022
Neutrophils segmented, Year 3, Week 24, n=242-0.129 ± 1.9829
Neutrophils segmented, Year 3, Week 32, n=248-0.211 ± 2.2333
Neutrophils segmented, Year 3, Week 40, n=242-0.161 ± 1.9939
Neutrophils segmented, Year 3, Week 48, n=240-0.159 ± 2.1315
Neutrophils segmented, Year 4, Week 8, n=234-0.119 ± 2.0635
Neutrophils segmented, Year 4, Week 16, n=238-0.177 ± 2.1063
Neutrophils segmented, Year 4, Week 24, n=227-0.136 ± 1.9402
Neutrophils segmented, Year 4, Week 32, n=229-0.123 ± 2.2231
Neutrophils segmented, Year 4, Week 40, n=216-0.119 ± 1.9639
Neutrophils segmented, Year 4, Week 48, n=220-0.024 ± 2.2228
Neutrophils segmented, Year 5, Week 8, n=215-0.169 ± 2.2107
Neutrophils segmented, Year 5, Week 16, n=214-0.189 ± 2.0362
Neutrophils segmented, Year 5, Week 24, n=207-0.120 ± 2.0997
Neutrophils segmented, Year 5, Week 32, n=207-0.088 ± 2.1895
Neutrophils segmented, Year 5, Week 40, n=196-0.064 ± 2.1536
Neutrophils segmented, Year 5, Week 48, n=2090.014 ± 2.0473
Neutrophils segmented, Year 6, Week 8, n=206-0.097 ± 1.9542
Neutrophils segmented, Year 6, Week 16, n=195-0.218 ± 2.2682
Neutrophils segmented, Year 6, Week 24, n=192-0.226 ± 2.1749
Neutrophils segmented, Year 6, Week 32, n=197-0.144 ± 2.0689
Neutrophils segmented, Year 6, Week 40, n=183-0.359 ± 2.2241
Neutrophils segmented, Year 6, Week 48, n=188-0.306 ± 2.1609
Neutrophils segmented, Year 7, Week 8, n=180-0.371 ± 2.1016
Neutrophils segmented, Year 7, Week 16, n=181-0.410 ± 2.0287
Neutrophils segmented, Year 7, Week 24, n=176-0.363 ± 2.2018
Neutrophils segmented, Year 7, Week 32, n=179-0.214 ± 2.2148
Neutrophils segmented, Year 7, Week 40, n=177-0.360 ± 2.2393
Neutrophils segmented, Year 7, Week 48, n=173-0.423 ± 2.1389
Neutrophils segmented, Year 8, Week 8, n=172-0.387 ± 2.1621
Neutrophils segmented, Year 8, Week 16, n=173-0.310 ± 2.1373
Neutrophils segmented, Year 8, Week 24, n=170-0.152 ± 2.3134
Neutrophils segmented, Year 8, Week 32, n=169-0.218 ± 2.1233
Neutrophils segmented, Year 8, Week 40, n=162-0.281 ± 2.2042
Neutrophils segmented, Year 8, Week 48, n=161-0.407 ± 2.2558
Neutrophils segmented, Year 9, Week 8, n=164-0.161 ± 2.1968
Neutrophils segmented, Year 9, Week 16, n=161-0.332 ± 2.0436
Neutrophils segmented, Year 9, Week 24, n=163-0.240 ± 2.1439
Neutrophils segmented, Year 9, Week 32, n=159-0.114 ± 2.3286
Neutrophils segmented, Year 9, Week 40, n=156-0.252 ± 2.2301
Neutrophils segmented, Year 9, Week 48, n=151-0.268 ± 2.4153
Neutrophils segmented, Year 10, Week 8, n=1490.049 ± 2.4409
Neutrophils segmented, Year 10, Week 16, n=1450.008 ± 2.7611
Neutrophils segmented, Year 10, Week 24, n=147-0.166 ± 2.2970
Neutrophils segmented, Year 10, Week 32, n=142-0.299 ± 2.1597
Neutrophils segmented, Year 10, Week 40, n=137-0.051 ± 2.1023
Neutrophils segmented, Year 10, Week 48, n=137-0.176 ± 2.0628
Neutrophils segmented, Year 11, Week 8, n=137-0.077 ± 2.4456
Neutrophils segmented, Year 11, Week 16, n=130-0.035 ± 2.3922
Neutrophils segmented, Year 11, Week 24, n=130-0.031 ± 2.2826
Neutrophils segmented, Year 11, Week 32, n=1280.145 ± 2.4689
Neutrophils segmented, Year 11, Week 40, n=122-0.043 ± 2.2994
Neutrophils segmented, Year 11, Week 48, n=106-0.004 ± 2.5913
Neutrophils segmented, Year 12, Week 8, n=109-0.011 ± 2.5216
Neutrophils segmented, Year 12, Week 16, n=97-0.032 ± 2.6750
Neutrophils segmented, Year 12, Week 24, n=86-0.126 ± 2.2583
Neutrophils segmented, Year 12, Week 32, n=88-0.081 ± 2.5744
Neutrophils segmented, Year 12, Week 40, n=83-0.293 ± 2.2448
Neutrophils segmented, Year 12, Week 48, n=72-0.126 ± 2.9212
Neutrophils segmented, Year 13, Week 8, n=53-0.747 ± 2.7599
Neutrophils segmented, Year 13, Week 16, n=420.169 ± 2.5731
Neutrophils segmented, Year 13, Week 24, n=20-0.121 ± 2.8499
Neutrophils segmented, Year 13, Week 32, n=7-0.927 ± 2.9565
Neutrophils segmented, Year 13, Week 40, n=1-0.680 ± NA
Neutrophils segmented, Exit, n=2410.436 ± 2.6133
Neutrophils segmented, 8-Week Follow-up, n=2190.514 ± 3.6918
Neutrophils segmented, 24-Week Follow-up, n=1980.369 ± 2.6988
Platelets, Year 1, Week ,8 n=2793.7 ± 34.73
Platelets, Year 1, Week 16, n=2794.5 ± 34.48
Platelets, Year 1, Week 24, n=2867.9 ± 36.76
Platelets, Year 1, Week 32, n=28510.3 ± 41.03
Platelets, Year 1, Week 40, n=28313.1 ± 39.75
Platelets, Year 1, Week 48, n=28213.2 ± 46.13
Platelets, Year 2, Week 8, n=28018.1 ± 48.14
Platelets, Year 2, Week 16, n=27615.4 ± 45.99
Platelets, Year 2, Week 24, n=27316.7 ± 49.67
Platelets, Year 2, Week 32, n=27724.0 ± 50.04
Platelets, Year 2, Week 40, n=25921.9 ± 46.95
Platelets, Year 2, Week 48, n=25521.2 ± 50.63
Platelets, Year 3, Week 8, n=25622.0 ± 53.16
Platelets, Year 3, Week 16, n=25322.7 ± 55.76
Platelets, Year 3, Week 24, n=23918.4 ± 50.97
Platelets, Year 3, Week 32, n=24314.1 ± 50.03
Platelets, Year 3, Week 40, n=24014.3 ± 55.47
Platelets, Year 3, Week 48, n=23512.6 ± 56.20
Platelets, Year 4, Week 8, n=23011.5 ± 48.78
Platelets, Year 4, Week 16, n=23411.7 ± 54.46
Platelets, Year 4, Week 24, n=22611.7 ± 51.12
Platelets, Year 4, Week 32, n=2209.6 ± 55.85
Platelets, Year 4, Week 40, n=2145.6 ± 54.44
Platelets, Year 4, Week 48, n=2166.7 ± 56.74
Platelets, Year 5, Week 8, n=2114.6 ± 62.04
Platelets, Year 5, Week 16, n=212-2.1 ± 54.06
Platelets, Year 5, Week 24, n=206-3.0 ± 52.05
Platelets, Year 5, Week 32, n=203-4.8 ± 53.16
Platelets, Year 5, Week 40, n=194-7.7 ± 51.97
Platelets, Year 5, Week 48, n=206-3.4 ± 54.93
Platelets, Year 6, Week 8, n=203-10.8 ± 56.67
Platelets, Year 6, Week 16, n=193-12.7 ± 56.99
Platelets, Year 6, Week 24, n=190-15.6 ± 51.76
Platelets, Year 6, Week 32, n=194-12.2 ± 52.69
Platelets, Year 6, Week 40, n=182-15.8 ± 56.24
Platelets, Year 6, Week 48, n=186-19.5 ± 52.68
Platelets, Year 7, Week 8, n=179-17.3 ± 53.81
Platelets, Year 7, Week 16, n=179-24.2 ± 49.52
Platelets, Year 7, Week 24, n=175-22.0 ± 52.19
Platelets, Year 7, Week 32, n=178-19.4 ± 59.77
Platelets, Year 7, Week 40, n=176-16.6 ± 63.50
Platelets, Year 7, Week 48, n=171-14.3 ± 60.69
Platelets, Year 8, Week 8, n=168-11.5 ± 54.16
Platelets, Year 8, Week 16, n=172-15.0 ± 58.24
Platelets, Year 8, Week 24, n=169-11.0 ± 56.12
Platelets, Year 8, Week 32, n=168-13.9 ± 55.53
Platelets, Year 8, Week 40, n=161-12.0 ± 62.73
Platelets, Year 8, Week 48, n=161-8.9 ± 80.44
Platelets, Year 9, Week 8, n=162-8.4 ± 64.02
Platelets, Year 9, Week 16, n=160-11.7 ± 68.06
Platelets, Year 9, Week 24, n=162-13.6 ± 60.20
Platelets, Year 9, Week 32, n=158-16.8 ± 62.14
Platelets, Year 9, Week 40, n=156-13.4 ± 63.09
Platelets, Year 9, Week 48, n=150-13.0 ± 65.20
Platelets, Year 10, Week 8, n=149-10.9 ± 60.24
Platelets, Year 10, Week 16, n=144-9.7 ± 62.61
Platelets, Year 10, Week 24, n=146-9.7 ± 60.67
Platelets, Year 10, Week 32, n=141-10.6 ± 62.35
Platelets, Year 10, Week 40, n=136-9.5 ± 61.80
Platelets, Year 10, Week 48, n=136-11.7 ± 61.81
Platelets, Year 11, Week 8, n=136-8.4 ± 69.58
Platelets, Year 11, Week 16, n=129-6.4 ± 63.81
Platelets, Year 11, Week 24, n=129-6.7 ± 61.75
Platelets, Year 11, Week 32, n=127-3.0 ± 65.54
Platelets, Year 11, Week 40, n=121-5.8 ± 68.01
Platelets, Year 11, Week 48, n=105-7.8 ± 62.13
Platelets, Year 12, Week 8, n=108-4.1 ± 73.02
Platelets, Year 12, Week 16, n=96-10.6 ± 68.02
Platelets, Year 12, Week 24, n=84-11.5 ± 60.94
Platelets, Year 12, Week 32, n=87-5.7 ± 70.98
Platelets, Year 12, Week 40, n=82-10.7 ± 67.51
Platelets, Year 12, Week 48, n=72-8.7 ± 80.99
Platelets, Year 13, Week 8, n=53-8.6 ± 70.53
Platelets, Year 13, Week 16, n=41-6.2 ± 61.57
Platelets, Year 13, Week 24, n=20-7.1 ± 47.37
Platelets, Year 13, Week 32, n=7-6.7 ± 51.61
Platelets, Year 13, Week 40, n=1-29.0 ± NA
Platelets, Exit, n=2368.4 ± 77.24
Platelets, 8-Week Follow-up, n=2178.2 ± 71.32
Platelets, 24-Week Follow-up, n=1944.0 ± 67.29
PrimaryChange From Baseline in Erythrocytes at the Indicated Time Points

Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Mean · 10^12 per liter
Change From Baseline in Erythrocytes at the Indicated Time Points
10^12 per literBelimumab 10 mg/kg IV
Erythrocytes, Year 1, Week 8, n=2870.01 ± 0.313
Erythrocytes, Year 1, Week 16, n=2880.04 ± 0.361
Erythrocytes, Year 1, Week 24, n=2930.05 ± 0.309
Erythrocytes, Year 1, Week 32, n=2910.07 ± 0.301
Erythrocytes, Year 1, Week 40, n=2870.10 ± 0.321
Erythrocytes, Year 1, Week 48, n=2870.11 ± 0.338
Erythrocytes, Year 2, Week 8, n=2880.07 ± 0.339
Erythrocytes, Year 2, Week 16, n=2800.09 ± 0.320
Erythrocytes, Year 2, Week 24, n=2780.12 ± 0.331
Erythrocytes, Year 2, Week 32, n=2810.15 ± 0.331
Erythrocytes, Year 2, Week 40, n=2620.17 ± 0.330
Erythrocytes, Year 2, Week 48, n=2600.19 ± 0.336
Erythrocytes, Year 3, Week 8, n=2600.18 ± 0.331
Erythrocytes, Year 3, Week 16, n=2580.19 ± 0.347
Erythrocytes, Year 3, Week 24, n=2420.17 ± 0.384
Erythrocytes, Year 3, Week 32, n=2480.16 ± 0.356
Erythrocytes, Year 3, Week 40, n=2430.17 ± 0.369
Erythrocytes, Year 3, Week 48, n=2400.15 ± 0.368
Erythrocytes, Year 4, Week 8, n=2350.15 ± 0.392
Erythrocytes, Year 4, Week 16, n=2380.15 ± 0.367
Erythrocytes, Year 4, Week 24, n=2270.12 ± 0.363
Erythrocytes, Year 4, Week 32, n=2290.14 ± 0.394
Erythrocytes, Year 4, Week 40, n=2160.14 ± 0.383
Erythrocytes, Year 4, Week 48, n=2200.14 ± 0.420
Erythrocytes, Year 5, Week 8, n=2150.13 ± 0.435
Erythrocytes, Year 5, Week 16, n=2140.15 ± 0.432
Erythrocytes, Year 5, Week 24, n=2070.13 ± 0.426
Erythrocytes, Year 5, Week 32, n=2070.12 ± 0.430
Erythrocytes, Year 5, Week 40, n=1960.15 ± 0.417
Erythrocytes, Year 5, Week 48, n=2090.15 ± 0.420
Erythrocytes, Year 6, Week 8, n=2060.13 ± 0.441
Erythrocytes, Year 6, Week 16, n=1950.10 ± 0.448
Erythrocytes, Year 6, Week 24, n=1920.13 ± 0.380
Erythrocytes, Year 6, Week 32, n=1970.14 ± 0.420
Erythrocytes, Year 6, Week 40, n=1840.15 ± 0.430
Erythrocytes, Year 6, Week 48, n=1880.13 ± 0.401
Erythrocytes, Year 7, Week 8, n=1800.12 ± 0.397
Erythrocytes, Year 7, Week 16, n=1810.09 ± 0.407
Erythrocytes, Year 7, Week 24, n=1760.11 ± 0.390
Erythrocytes, Year 7, Week 32, n=1790.14 ± 0.395
Erythrocytes, Year 7, Week 40, n=1770.09 ± 0.391
Erythrocytes, Year 7, Week 48, n=1730.09 ± 0.394
Erythrocytes, Year 8, Week 8, n=1720.09 ± 0.378
Erythrocytes, Year 8, Week 16, n=1730.08 ± 0.368
Erythrocytes, Year 8, Week 24, n=1700.10 ± 0.388
Erythrocytes, Year 8, Week 32, n=1690.11 ± 0.373
Erythrocytes, Year 8, Week 40, n=1620.10 ± 0.415
Erythrocytes, Year 8, Week 48, n=1610.12 ± 0.411
Erythrocytes, Year 9, Week 8, n=1640.11 ± 0.402
Erythrocytes, Year 9, Week 16, n=1610.09 ± 0.396
Erythrocytes, Year 9, Week 24, n=1630.08 ± 0.387
Erythrocytes, Year 9, Week 32, n=1600.11 ± 0.409
Erythrocytes, Year 9, Week 40, n=1560.09 ± 0.407
Erythrocytes, Year 9, Week 48, n=1510.11 ± 0.431
Erythrocytes, Year 10, Week 8, n=1500.16 ± 0.442
Erythrocytes, Year 10, Week 16, n=1450.17 ± 0.411
Erythrocytes, Year 10, Week 24, n=1470.21 ± 0.427
Erythrocytes, Year 10, Week 32, n=1420.18 ± 0.419
Erythrocytes, Year 10, Week 40, n=1370.20 ± 0.417
Erythrocytes, Year 10, Week 48, n=1370.19 ± 0.429
Erythrocytes, Year 11, Week 8, n=1370.20 ± 0.430
Erythrocytes, Year 11, Week 16, n=1300.24 ± 0.422
Erythrocytes, Year 11, Week 24, n=1300.25 ± 0.436
Erythrocytes, Year 11, Week 32, n=1280.27 ± 0.410
Erythrocytes, Year 11, Week 40, n=1220.27 ± 0.426
Erythrocytes, Year 11, Week 48, n=1060.25 ± 0.426
Erythrocytes, Year 12, Week 8, n=1090.29 ± 0.422
Erythrocytes, Year 12, Week 16, n=970.28 ± 0.435
Erythrocytes, Year 12, Week 24, n=860.33 ± 0.483
Erythrocytes, Year 12, Week 32, n=880.26 ± 0.512
Erythrocytes, Year 12, Week 40, n=830.31 ± 0.428
Erythrocytes, Year 12, Week 48, n=720.32 ± 0.467
Erythrocytes, Year 13, Week 8, n=530.35 ± 0.400
Erythrocytes, Year 13, Week 16, n=420.34 ± 0.387
Erythrocytes, Year 13, Week 24, n=200.30 ± 0.407
Erythrocytes, Year 13, Week 32, n=70.20 ± 0.379
Erythrocytes, Year 13, Week 40, n=10.30 ± NA
Erythrocytes, Exit, n=2410.27 ± 0.473
Erythrocytes, 8-Week Follow-up, n=2200.28 ± 0.478
Erythrocytes, 24-Week Follow-up , n=1980.33 ± 0.539
PrimaryChange From Baseline in Hematocrit at the Indicated Time Points

Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Mean · Percentage of blood by volume
Change From Baseline in Hematocrit at the Indicated Time Points
Percentage of blood by volumeBelimumab 10 mg/kg IV
Hematocrit, Year 1, Week 8, n=2870.11 ± 2.908
Hematocrit, Year 1, Week 16, n=2880.23 ± 3.109
Hematocrit, Year 1, Week 24, n=2930.28 ± 2.917
Hematocrit, Year 1, Week 32, n=2910.44 ± 2.973
Hematocrit, Year 1, Week 40, n=2870.60 ± 3.199
Hematocrit, Year 1, Week 48, n=2870.84 ± 3.431
Hematocrit, Year 2, Week 8, n=2880.67 ± 3.415
Hematocrit, Year 2, Week 16, n=2800.93 ± 3.332
Hematocrit, Year 2, Week 24, n=2780.96 ± 3.435
Hematocrit, Year 2, Week 32, n=2811.34 ± 3.496
Hematocrit, Year 2, Week 40, n=2621.43 ± 3.476
Hematocrit, Year 2, Week 48, n=2601.65 ± 3.444
Hematocrit, Year 3, Week 8, n=2601.54 ± 3.453
Hematocrit, Year 3, Week 16, n=2581.76 ± 3.508
Hematocrit, Year 3, Week 24, n=2421.68 ± 3.709
Hematocrit, Year 3, Week 32, n=2481.55 ± 3.676
Hematocrit, Year 3, Week 40, n=2431.55 ± 3.703
Hematocrit, Year 3, Week 48, n=2401.26 ± 3.726
Hematocrit, Year 4, Week 8, n=2351.33 ± 3.908
Hematocrit, Year 4, Week 16, n=2381.37 ± 3.759
Hematocrit, Year 4, Week 24, n=2271.27 ± 3.680
Hematocrit, Year 4, Week 32, n=2291.34 ± 3.955
Hematocrit, Year 4, Week 40, n=2161.39 ± 3.779
Hematocrit, Year 4, Week 48, n=2201.37 ± 4.033
Hematocrit, Year 5, Week 8, n=2151.27 ± 4.031
Hematocrit, Year 5, Week 16, n=2141.58 ± 3.917
Hematocrit, Year 5, Week 24, n=2071.45 ± 3.905
Hematocrit, Year 5, Week 32, n=2071.39 ± 3.979
Hematocrit, Year 5, Week 40, n=1961.59 ± 4.031
Hematocrit, Year 5, Week 48, n=2091.35 ± 3.929
Hematocrit, Year 6, Week 8, n=2061.24 ± 4.128
Hematocrit, Year 6, Week 16, n=1951.07 ± 4.114
Hematocrit, Year 6, Week 24, n=1921.43 ± 3.648
Hematocrit, Year 6, Week 32, n=1971.77 ± 3.822
Hematocrit, Year 6, Week 40, n=1842.07 ± 4.089
Hematocrit, Year 6, Week 48, n=1882.02 ± 3.961
Hematocrit, Year 7, Week 8, n=1801.80 ± 3.808
Hematocrit, Year 7, Week 16, n=1811.50 ± 3.883
Hematocrit, Year 7, Week 24, n=1761.88 ± 3.840
Hematocrit, Year 7, Week 32, n=1792.25 ± 3.824
Hematocrit, Year 7, Week 40, n=1772.07 ± 3.907
Hematocrit, Year 7, Week 48, n=1731.97 ± 3.958
Hematocrit, Year 8, Week 8, n=1721.89 ± 3.909
Hematocrit, Year 8, Week 16, n=1731.87 ± 3.729
Hematocrit, Year 8, Week 24, n=1702.12 ± 4.065
Hematocrit, Year 8, Week 32, n=1692.20 ± 3.954
Hematocrit, Year 8, Week 40, n=1622.10 ± 4.122
Hematocrit, Year 8, Week 48, n=1612.18 ± 4.029
Hematocrit, Year 9, Week 8, n=1641.99 ± 3.995
Hematocrit, Year 9, Week 16, n=1611.76 ± 4.114
Hematocrit, Year 9, Week 24, n=1631.70 ± 4.020
Hematocrit, Year 9, Week 32, n=1601.95 ± 4.171
Hematocrit, Year 9, Week 40, n=1561.88 ± 4.302
Hematocrit, Year 9, Week 48, n=1512.32 ± 4.174
Hematocrit, Year 10, Week 8, n=1502.87 ± 4.087
Hematocrit, Year 10, Week 16, n=1452.80 ± 4.050
Hematocrit, Year 10, Week 24, n=1472.94 ± 4.046
Hematocrit, Year 10, Week 32, n=1422.78 ± 4.046
Hematocrit, Year 10, Week 40, n=1372.95 ± 3.884
Hematocrit, Year 10, Week 48, n=1373.00 ± 4.245
Hematocrit, Year 11, Week 8, n=1373.04 ± 4.176
Hematocrit, Year 11, Week 16, n=1303.20 ± 4.155
Hematocrit, Year 11, Week 24, n=1302.93 ± 4.331
Hematocrit, Year 11, Week 32, n=1283.06 ± 3.976
Hematocrit, Year 11, Week 40, n=1223.15 ± 4.098
Hematocrit, Year 11, Week 48, n=1062.93 ± 4.356
Hematocrit, Year 12, Week 8, n=1093.12 ± 4.223
Hematocrit, Year 12, Week 16, n=973.43 ± 4.321
Hematocrit, Year 12, Week 24, n=863.74 ± 4.867
Hematocrit, Year 12, Week 32, n=882.99 ± 4.826
Hematocrit, Year 12, Week 40, n=833.57 ± 4.377
Hematocrit, Year 12, Week 48, n=723.88 ± 4.439
Hematocrit, Year 13, Week 8, n=534.20 ± 3.776
Hematocrit, Year 13, Week 16, n=424.26 ± 3.803
Hematocrit, Year 13, Week 24, n=203.81 ± 3.930
Hematocrit, Year 13, Week 32, n=73.26 ± 4.547
Hematocrit, Year 13, Week 40, n=12.20 ± NA
Hematocrit, Exit, n=2413.35 ± 4.596
Hematocrit, 8-Week Follow-up, n=2203.46 ± 4.690
Hematocrit, 24-Week Follow-up , n=1983.51 ± 4.627
PrimaryChange From Baseline in Hemoglobin at the Indicated Time Points

Hematology parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Mean · grams per liter
Change From Baseline in Hemoglobin at the Indicated Time Points
grams per literBelimumab 10 mg/kg IV
Hemoglobin, Year 1, Week 8, n=2870.1 ± 9.42
Hemoglobin, Year 1, Week 16, n=2880.6 ± 10.60
Hemoglobin, Year 1, Week 24, n=2931.5 ± 9.86
Hemoglobin, Year 1, Week 32, n=2912.2 ± 10.37
Hemoglobin, Year 1, Week 40, n=2872.8 ± 10.84
Hemoglobin, Year 1, Week 48, n=2872.9 ± 11.39
Hemoglobin, Year 2, Week 8, n=2882.2 ± 11.62
Hemoglobin, Year 2, Week 16, n=2802.8 ± 11.54
Hemoglobin, Year 2, Week 24, n=2783.2 ± 12.20
Hemoglobin, Year 2, Week 32, n=2814.5 ± 12.19
Hemoglobin, Year 2, Week 40, n=2624.9 ± 12.15
Hemoglobin, Year 2, Week 48, n=2605.6 ± 12.10
Hemoglobin, Year 3, Week 8, n=2604.8 ± 12.01
Hemoglobin, Year 3, Week 16, n=2585.2 ± 12.15
Hemoglobin, Year 3, Week 24, n=2425.4 ± 12.47
Hemoglobin, Year 3, Week 32, n=2485.6 ± 12.59
Hemoglobin, Year 3, Week 40, n=2435.9 ± 12.90
Hemoglobin, Year 3, Week 48, n=2405.1 ± 12.97
Hemoglobin, Year 4, Week 8, n=2355.2 ± 13.49
Hemoglobin, Year 4, Week 16, n=2385.2 ± 13.11
Hemoglobin, Year 4, Week 24, n=2274.1 ± 13.05
Hemoglobin, Year 4, Week 32, n=2294.9 ± 13.64
Hemoglobin, Year 4, Week 40, n=2164.9 ± 13.25
Hemoglobin, Year 4, Week 48, n=2205.3 ± 13.94
Hemoglobin, Year 5, Week 8, n=2155.1 ± 14.20
Hemoglobin, Year 5, Week 16, n=2145.5 ± 13.44
Hemoglobin, Year 5, Week 24, n=2074.4 ± 13.73
Hemoglobin, Year 5, Week 32, n=2074.1 ± 13.39
Hemoglobin, Year 5, Week 40, n=1965.2 ± 14.31
Hemoglobin, Year 5, Week 48, n=2095.4 ± 14.20
Hemoglobin, Year 6, Week 8, n=2065.5 ± 14.72
Hemoglobin, Year 6, Week 16, n=1954.8 ± 14.82
Hemoglobin, Year 6, Week 24, n=1925.6 ± 12.80
Hemoglobin, Year 6, Week 32, n=1975.9 ± 13.12
Hemoglobin, Year 6, Week 40, n=1846.6 ± 13.96
Hemoglobin, Year 6, Week 48, n=1886.4 ± 13.78
Hemoglobin, Year 7, Week 8, n=1806.3 ± 13.58
Hemoglobin, Year 7, Week 16, n=1815.5 ± 13.83
Hemoglobin, Year 7, Week 24, n=1766.0 ± 13.51
Hemoglobin, Year 7, Week 32, n=1797.0 ± 13.37
Hemoglobin, Year 7, Week 40, n=1776.4 ± 13.61
Hemoglobin, Year 7, Week 48, n=1735.6 ± 13.91
Hemoglobin, Year 8, Week 8, n=1725.7 ± 13.69
Hemoglobin, Year 8, Week 16, n=1735.3 ± 13.09
Hemoglobin, Year 8, Week 24, n=1706.1 ± 14.13
Hemoglobin, Year 8, Week 32, n=1695.8 ± 13.33
Hemoglobin, Year 8, Week 40, n=1624.9 ± 13.93
Hemoglobin, Year 8, Week 48, n=1615.5 ± 13.95
Hemoglobin, Year 9, Week 8, n=1645.5 ± 13.79
Hemoglobin, Year 9, Week 16, n=1614.9 ± 14.60
Hemoglobin, Year 9, Week 24, n=1634.6 ± 14.32
Hemoglobin, Year 9, Week 32, n=1605.2 ± 14.39
Hemoglobin, Year 9, Week 40, n=1563.9 ± 15.20
Hemoglobin, Year 9, Week 48, n=1514.8 ± 14.50
Hemoglobin, Year 10, Week 8, n=1506.5 ± 14.46
Hemoglobin, Year 10, Week 16, n=1456.5 ± 14.05
Hemoglobin, Year 10, Week 24, n=1476.5 ± 14.20
Hemoglobin, Year 10, Week 32, n=1425.9 ± 14.02
Hemoglobin, Year 10, Week 40, n=1376.0 ± 13.29
Hemoglobin, Year 10, Week 48, n=1375.7 ± 14.86
Hemoglobin, Year 11, Week 8, n=1375.9 ± 14.40
Hemoglobin, Year 11, Week 16, n=1306.4 ± 14.50
Hemoglobin, Year 11, Week 24, n=1305.9 ± 15.02
Hemoglobin, Year 11, Week 32, n=1286.3 ± 13.79
Hemoglobin, Year 11, Week 40, n=1226.7 ± 14.03
Hemoglobin, Year 11, Week 48, n=1066.2 ± 14.95
Hemoglobin, Year 12, Week 8, n=1096.8 ± 14.55
Hemoglobin, Year 12, Week 16, n=978.1 ± 15.12
Hemoglobin, Year 12, Week 24, n=868.9 ± 16.83
Hemoglobin, Year 12, Week 32, n=886.6 ± 17.18
Hemoglobin, Year 12, Week 40, n=837.0 ± 15.41
Hemoglobin, Year 12, Week 48, n=728.3 ± 14.80
Hemoglobin, Year 13, Week 8, n=538.4 ± 12.37
Hemoglobin, Year 13, Week 16, n=428.0 ± 12.81
Hemoglobin, Year 13, Week 24, n=206.3 ± 12.01
Hemoglobin, Year 13, Week 32, n=75.4 ± 14.27
Hemoglobin, Year 13, Week 40, n=13.0 ± NA
Hemoglobin, Exit, n=2417.4 ± 15.11
Hemoglobin, 8-Week Follow-up, n=2206.7 ± 15.46
Hemoglobin, 24-Week Follow-up , n=1986.8 ± 14.91
PrimaryChange From Baseline in Albumin and Protein at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Mean · grams/liter
Change From Baseline in Albumin and Protein at the Indicated Time Points
grams/literBelimumab 10 mg/kg IV
Albumin, Year 1, Week 8, n=2840.1 ± 2.36
Albumin, Year 1, Week 16, n=286-0.2 ± 2.68
Albumin, Year 1, Week 24, n=2920.2 ± 2.74
Albumin, Year 1, Week 32, n=2870.1 ± 2.91
Albumin, Year 1, Week 40, n=2840.2 ± 3.06
Albumin, Year 1, Week 48, n=2870.3 ± 3.21
Albumin, Year 2, Week 8, n=2880.4 ± 2.84
Albumin, Year 2, Week 16, n=2780.4 ± 2.95
Albumin, Year 2, Week 24, n=2730.1 ± 3.17
Albumin, Year 2, Week 32, n=2840.7 ± 3.08
Albumin, Year 2, Week 40, n=2640.8 ± 2.92
Albumin, Year 2, Week 48, n=2691.1 ± 3.25
Albumin, Year 3, Week 8, n=2650.7 ± 3.39
Albumin, Year 3, Week 16, n=2601.0 ± 3.05
Albumin, Year 3, Week 24, n=2441.2 ± 3.23
Albumin, Year 3, Week 32, n=2491.3 ± 3.13
Albumin, Year 3, Week 40, n=2451.4 ± 3.11
Albumin, Year 3, Week 48, n=2441.5 ± 3.12
Albumin, Year 4, Week 8, n=2391.4 ± 3.36
Albumin, Year 4, Week 16, n=2381.3 ± 3.21
Albumin, Year 4, Week 24, n=2271.2 ± 3.15
Albumin, Year 4, Week 32, n=2331.3 ± 3.31
Albumin, Year 4, Week 40, n=2201.2 ± 3.29
Albumin, Year 4, Week 48, n=2181.6 ± 3.57
Albumin, Year 5, Week 8, n=2181.6 ± 3.37
Albumin, Year 5, Week 16, n=2141.5 ± 3.07
Albumin, Year 5, Week 24, n=2111.5 ± 3.36
Albumin, Year 5, Week 32, n=2111.9 ± 3.34
Albumin, Year 5, Week 40, n=1981.8 ± 3.40
Albumin, Year 5, Week 48, n=2071.7 ± 3.41
Albumin, Year 6, Week 8, n=2061.8 ± 3.27
Albumin, Year 6, Week 16, n=1981.5 ± 3.72
Albumin, Year 6, Week 24, n=1901.6 ± 3.32
Albumin, Year 6, Week 32, n=1932.0 ± 3.71
Albumin, Year 6, Week 40, n=1851.9 ± 3.52
Albumin, Year 6, Week 48, n=1861.9 ± 3.64
Albumin, Year 7, Week 8, n=1791.9 ± 3.36
Albumin, Year 7, Week 16, n=1791.7 ± 3.57
Albumin, Year 7, Week 24, n=1731.7 ± 3.88
Albumin, Year 7, Week 32, n=1801.9 ± 3.53
Albumin, Year 7, Week 40, n=1751.6 ± 3.41
Albumin, Year 7, Week 48, n=1751.6 ± 3.60
Albumin, Year 8, Week 8, n=1711.7 ± 3.61
Albumin, Year 8, Week 16, n=1701.5 ± 3.31
Albumin, Year 8, Week 24, n=1681.6 ± 3.47
Albumin, Year 8, Week 32, n=1681.7 ± 3.25
Albumin, Year 8, Week 40, n=1621.3 ± 3.46
Albumin, Year 8, Week 48, n=1591.7 ± 3.56
Albumin, Year 9, Week 8, n=1642.0 ± 3.97
Albumin, Year 9, Week 16, n=1621.9 ± 3.58
Albumin, Year 9, Week 24, n=1611.6 ± 3.38
Albumin, Year 9, Week 32, n=1631.9 ± 3.27
Albumin, Year 9, Week 40, n=1561.6 ± 3.54
Albumin, Year 9, Week 48, n=1511.9 ± 3.55
Albumin, Year 10, Week 8, n=1521.9 ± 3.64
Albumin, Year 10, Week 16, n=1432.1 ± 3.55
Albumin, Year 10, Week 24, n=1452.0 ± 3.85
Albumin, Year 10, Week 32, n=1422.1 ± 4.05
Albumin, Year 10, Week 40, n=1381.8 ± 3.78
Albumin, Year 10, Week 48, n=1352.0 ± 3.52
Albumin, Year 11, Week 8, n=1382.0 ± 3.74
Albumin, Year 11, Week 16, n=1282.2 ± 3.58
Albumin, Year 11, Week 24, n=1302.1 ± 3.87
Albumin, Year 11, Week 32, n=1251.8 ± 3.89
Albumin, Year 11, Week 40, n=1241.7 ± 3.69
Albumin, Year 11, Week 48, n=1081.8 ± 3.91
Albumin, Year 12, Week 8, n=1101.8 ± 3.43
Albumin, Year 12, Week 16, n=971.9 ± 3.68
Albumin, Year 12, Week 24, n=872.5 ± 4.01
Albumin, Year 12, Week 32, n=841.9 ± 4.01
Albumin, Year 12, Week 40, n=821.7 ± 3.76
Albumin, Year 12, Week 48, n=722.1 ± 3.67
Albumin, Year 13, Week 8, n=532.8 ± 3.68
Albumin, Year 13, Week 16, n=422.3 ± 3.61
Albumin, Year 13, Week 24, n=202.5 ± 3.30
Albumin, Year 13, Week 32, n=71.1 ± 2.67
Albumin, Year 13, Week 40, n=15.0 ± NA
Albumin, Exit, n=2482.0 ± 4.02
Albumin, 8-Week Follow-up, n=2201.6 ± 3.92
Albumin, 24-Week Follow-up , n=2002.2 ± 4.24
Protein, Year 1, Week 8, n=284-1.3 ± 4.31
Protein, Year 1, Week 16, n=286-1.8 ± 4.63
Protein, Year 1, Week 24, n=292-1.5 ± 4.76
Protein, Year 1, Week 32, n=287-1.7 ± 4.69
Protein, Year 1, Week 40, n=284-1.6 ± 5.0
Protein, Year 1, Week 48, n=287-2.0 ± 5.01
Protein, Year 2, Week 8, n=288-2.1 ± 4.74
Protein, Year 2, Week 16, n=278-2.5 ± 4.66
Protein, Year 2, Week 24, n=273-2.9 ± 5.07
Protein, Year 2, Week 32, n=284-2.4 ± 5.13
Protein, Year 2, Week 40, n=264-2.4 ± 4.87
Protein, Year 2, Week 48, n=269-1.5 ± 5.18
Protein, Year 3, Week 8, n=265-2.2 ± 5.49
Protein, Year 3, Week 16, n=260-2.0 ± 5.19
Protein, Year 3, Week 24, n=244-1.9 ± 5.63
Protein, Year 3, Week 32, n=249-1.8 ± 5.19
Protein, Year 3, Week 40, n=245-1.6 ± 5.34
Protein, Year 3, Week 48, n=244-1.8 ± 5.16
Protein, Year 4, Week 8, n=239-2.1 ± 5.27
Protein, Year 4, Week 16, n=238-1.8 ± 4.93
Protein, Year 4, Week 24, n=227-2.5 ± 5.06
Protein, Year 4, Week 32, n=233-2.3 ± 5.02
Protein, Year 4, Week 40, n=220-2.8 ± 4.97
Protein, Year 4, Week 48, n=218-2.2 ± 5.44
Protein, Year 5, Week 8, n=218-2.5 ± 5.34
Protein, Year 5, Week 16, n=214-2.6 ± 5.09
Protein, Year 5, Week 24, n=211-3.2 ± 5.22
Protein, Year 5, Week 32, n=211-2.5 ± 5.05
Protein, Year 5, Week 40, n=198-2.9 ± 5.47
Protein, Year 5, Week 48, n=207-2.8 ± 5.67
Protein, Year 6, Week 8, n=206-3.1 ± 5.39
Protein, Year 6, Week 16, n=198-3.4 ± 5.75
Protein, Year 6, Week 24, n=190-3.5 ± 5.6
Protein, Year 6, Week 32, n=193-3.0 ± 5.77
Protein, Year 6, Week 40, n=185-3.4 ± 5.84
Protein, Year 6, Week 48, n=186-3.5 ± 6.0
Protein, Year 7, Week 8, n=179-3.6 ± 5.52
Protein, Year 7, Week 16, n=179-4.1 ± 5.87
Protein, Year 7, Week 24, n=173-3.9 ± 5.96
Protein, Year 7, Week 32, n=180-3.7 ± 5.68
Protein, Year 7, Week 40, n=175-4.2 ± 5.39
Protein, Year 7, Week 48, n=175-4.5 ± 5.6
Protein, Year 8, Week 8, n=171-4.6 ± 5.75
Protein, Year 8, Week 16, n=170-4.7 ± 5.37
Protein, Year 8, Week 24, n=168-4.7 ± 5.54
Protein, Year 8, Week 32, n=168-4.5 ± 5.46
Protein, Year 8, Week 40, n=162-5.2 ± 5.36
Protein, Year 8, Week 48, n=159-4.5 ± 5.3
Protein, Year 9, Week 8, n=164-4.5 ± 5.75
Protein, Year 9, Week 16, n=162-4.8 ± 5.34
Protein, Year 9, Week 24, n=161-5.0 ± 5.32
Protein, Year 9, Week 32, n=163-4.8 ± 5.18
Protein, Year 9, Week 40, n=156-5.4 ± 5.51
Protein, Year 9, Week 48, n=151-5.1 ± 5.6
Protein, Year 10, Week 8, n=152-5.2 ± 5.86
Protein, Year 10, Week 16, n=143-5.0 ± 5.79
Protein, Year 10, Week 24, n=145-5.2 ± 5.88
Protein, Year 10, Week 32, n=142-5.1 ± 5.98
Protein, Year 10, Week 40, n=138-5.4 ± 5.98
Protein, Year 10, Week 48, n=135-5.4 ± 5.62
Protein, Year 11, Week 8, n=138-5.4 ± 6.15
Protein, Year 11, Week 16, n=128-5.1 ± 5.51
Protein, Year 11, Week 24, n=130-5.1 ± 6.15
Protein, Year 11, Week 32, n=125-5.6 ± 6.12
Protein, Year 11, Week 40, n=124-5.6 ± 5.81
Protein, Year 11, Week 48, n=108-5.4 ± 6.42
Protein, Year 12, Week 8, n=110-5.0 ± 5.65
Protein, Year 12, Week 16, n=97-5.1 ± 5.86
Protein, Year 12, Week 24, n=87-4.6 ± 6.26
Protein, Year 12, Week 32, n=84-5.1 ± 5.82
Protein, Year 12, Week 40, n=82-5.7 ± 5.35
Protein, Year 12, Week 48, n=72-5.0 ± 5.86
Protein, Year 13, Week 8, n=53-4.8 ± 6.0
Protein, Year 13, Week 16, n=42-5.6 ± 6.04
Protein, Year 13, Week 24, n=20-4.4 ± 6.3
Protein, Year 13, Week 32, n=7-8.9 ± 5.08
Protein, Year 13, Week 40, n=11.0 ± NA
Protein, Exit, n=248-3.2 ± 6.12
Protein, 8-Week Follow-up, n=220-3.7 ± 6.39
Protein, 24-Week Follow-up , n=200-2.6 ± 6.72
PrimaryChange From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Mean · millimoles per liter
Change From Baseline in Blood Urea Nitrogen (BUN), Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points
millimoles per literBelimumab 10 mg/kg IV
BUN, Year 1, Week 8, n=2840.0189 ± 1.4412
BUN, Year 1, Week 16, n=286-0.0836 ± 1.4928
BUN, Year 1, Week 24, n=292-0.0281 ± 1.5612
BUN, Year 1, Week 32, n=287-0.0199 ± 1.4020
BUN, Year 1, Week 40, n=284-0.1823 ± 1.3626
BUN, Year 1, Week 48, n=2870.0224 ± 1.6607
BUN, Year 2, Week 8, n=288-0.0607 ± 1.5714
BUN, Year 2, Week 16, n=278-0.0796 ± 1.6220
BUN, Year 2, Week 24, n=273-0.0850 ± 1.6900
BUN, Year 2, Week 32, n=284-0.0779 ± 1.8263
BUN, Year 2, Week 40, n=264-0.1136 ± 1.7293
BUN, Year 2, Week 48, n=269-0.0571 ± 1.7035
BUN, Year 3, Week 8, n=265-0.0620 ± 1.6580
BUN, Year 3, Week 16, n=260-0.0357 ± 1.7963
BUN, Year 3, Week 24, n=2440.0775 ± 1.9949
BUN, Year 3, Week 32, n=2490.0129 ± 1.8758
BUN, Year 3, Week 40, n=2450.0903 ± 1.9922
BUN, Year 3, Week 48, n=2440.1346 ± 2.1131
BUN, Year 4, Week 8, n=2390.1658 ± 1.9076
BUN, Year 4, Week 16, n=2380.0900 ± 1.7799
BUN, Year 4, Week 24, n=2270.1258 ± 2.0386
BUN, Year 4, Week 32, n=2330.0812 ± 1.8611
BUN, Year 4, Week 40, n=2200.0325 ± 2.0164
BUN, Year 4, Week 48, n=2180.2948 ± 2.3008
BUN, Year 5, Week 8, n=2180.2047 ± 2.0007
BUN, Year 5, Week 16, n=2140.2669 ± 1.8316
BUN, Year 5, Week 24, n=2110.2064 ± 2.0558
BUN, Year 5, Week 32, n=2110.0558 ± 1.7962
BUN, Year 5, Week 40, n=1980.2632 ± 2.0944
BUN, Year 5, Week 48, n=2070.1794 ± 2.0505
BUN, Year 6, Week 8, n=2060.2773 ± 1.8758
BUN, Year 6, Week 16, n=1980.2632 ± 1.8983
BUN, Year 6, Week 24, n=1900.1447 ± 2.0291
BUN, Year 6, Week 32, n=1930.2960 ± 2.1213
BUN, Year 6, Week 40, n=1850.3184 ± 2.1795
BUN, Year 6, Week 48, n=1860.3647 ± 1.9359
BUN, Year 7, Week 8, n=1790.2852 ± 2.1528
BUN, Year 7, Week 16, n=1790.3191 ± 2.0398
BUN, Year 7, Week 24, n=1730.2683 ± 2.5539
BUN, Year 7, Week 32, n=1800.1686 ± 2.1547
BUN, Year 7, Week 40, n=1750.2285 ± 1.9007
BUN, Year 7, Week 48, n=1750.2326 ± 2.3098
BUN, Year 8, Week 8, n=1710.2234 ± 2.3330
BUN, Year 8, Week 16, n=1700.1932 ± 2.1219
BUN, Year 8, Week 24, n=1680.2189 ± 2.0413
BUN, Year 8, Week 32, n=1680.0680 ± 2.0995
BUN, Year 8, Week 40, n=1620.1234 ± 2.0504
BUN, Year 8, Week 48, n=1590.2560 ± 1.8494
BUN, Year 9, Week 8, n=1640.1197 ± 1.6667
BUN, Year 9, Week 16, n=1620.1719 ± 1.8226
BUN, Year 9, Week 24, n=1610.1397 ± 1.9255
BUN, Year 9, Week 32, n=1630.2979 ± 1.9020
BUN, Year 9, Week 40, n=1560.1304 ± 1.8027
BUN, Year 9, Week 48, n=1510.0804 ± 1.9432
BUN, Year 10, Week 8, n=1520.1973 ± 2.1517
BUN, Year 10, Week 16, n=1430.1098 ± 1.8916
BUN, Year 10, Week 24, n=1450.1847 ± 1.8330
BUN, Year 10, Week 32, n=1420.1911 ± 1.8808
BUN, Year 10, Week 40, n=138-0.0440 ± 1.8103
BUN, Year 10, Week 48, n=1350.0926 ± 1.8219
BUN, Year 11, Week 8, n=1380.1837 ± 2.0925
BUN, Year 11, Week 16, n=1280.1060 ± 1.9866
BUN, Year 11, Week 24, n=1300.1291 ± 1.8654
BUN, Year 11, Week 32, n=1250.0029 ± 1.7563
BUN, Year 11, Week 40, n=1240.0576 ± 1.9364
BUN, Year 11, Week 48, n=108-0.0926 ± 1.8134
BUN, Year 12, Week 8, n=1100.1266 ± 2.0325
BUN, Year 12, Week 16, n=970.2687 ± 1.9561
BUN, Year 12, Week 24, n=870.0780 ± 1.8996
BUN, Year 12, Week 32, n=84-0.2167 ± 1.6336
BUN, Year 12, Week 40, n=82-0.1741 ± 1.8725
BUN, Year 12, Week 48, n=72-0.0992 ± 1.8146
BUN, Year 13, Week 8, n=530.0808 ± 1.7244
BUN, Year 13, Week 16, n=420.5695 ± 1.6690
BUN, Year 13, Week 24, n=200.1964 ± 1.0708
BUN, Year 13, Week 32, n=7-0.4590 ± 1.6961
BUN, Year 13, Week 40, n=1-1.7850 ± NA
BUN, Exit, n=2480.2519 ± 2.3492
BUN, 8-Week Follow-up, n=2200.0471 ± 2.3709
BUN, 24-Week Follow-up , n=200-0.0268 ± 2.1652
Glucose, Year 1, Week 8, n=284-0.0264 ± 1.4683
Glucose, Year 1, Week 16, n=2860.0314 ± 1.5221
Glucose, Year 1, Week 24, n=292-0.0375 ± 1.6213
Glucose, Year 1, Week 32, n=287-0.0265 ± 1.6241
Glucose, Year 1, Week 40, n=2840.0031 ± 1.4590
Glucose, Year 1, Week 48, n=2870.0232 ± 1.8176
Glucose, Year 2, Week 8, n=2880.0168 ± 1.6196
Glucose, Year 2, Week 16, n=2780.0327 ± 1.6027
Glucose, Year 2, Week 24, n=2730.1194 ± 1.6450
Glucose, Year 2, Week 32, n=2840.0510 ± 1.4905
Glucose, Year 2, Week 40, n=2640.0639 ± 1.5995
Glucose, Year 2, Week 48, n=2690.0017 ± 1.6178
Glucose, Year 3, Week 8, n=265-0.0161 ± 1.3878
Glucose, Year 3, Week 16, n=260-0.1223 ± 1.5965
Glucose, Year 3, Week 24, n=2440.0348 ± 1.9713
Glucose, Year 3, Week 32, n=249-0.0887 ± 1.7057
Glucose, Year 3, Week 40, n=245-0.0242 ± 1.3532
Glucose, Year 3, Week 48, n=244-0.0271 ± 2.1535
Glucose, Year 4, Week 8, n=239-0.0451 ± 1.6912
Glucose, Year 4, Week 16, n=238-0.1199 ± 1.7495
Glucose, Year 4, Week 24, n=227-0.1142 ± 1.8087
Glucose, Year 4, Week 32, n=2330.0741 ± 1.7592
Glucose, Year 4, Week 40, n=2200.1204 ± 2.0200
Glucose, Year 4, Week 48, n=218-0.0410 ± 1.9212
Glucose, Year 5, Week 8, n=2180.1350 ± 1.8331
Glucose, Year 5, Week 16, n=2140.0999 ± 1.9373
Glucose, Year 5, Week 24, n=2110.2402 ± 1.7548
Glucose, Year 5, Week 32, n=211-0.0873 ± 1.5258
Glucose, Year 5, Week 40, n=1980.0535 ± 1.7957
Glucose, Year 5, Week 48, n=207-0.0107 ± 1.3758
Glucose, Year 6, Week 8, n=2060.0385 ± 2.0336
Glucose, Year 6, Week 16, n=1980.0112 ± 1.6676
Glucose, Year 6, Week 24, n=1900.0894 ± 2.1875
Glucose, Year 6, Week 32, n=1930.0380 ± 1.9025
Glucose, Year 6, Week 40, n=1850.0939 ± 1.9242
Glucose, Year 6, Week 48, n=186-0.0176 ± 1.7507
Glucose, Year 7, Week 8, n=1790.1098 ± 1.9999
Glucose, Year 7, Week 16, n=1790.0558 ± 2.0164
Glucose, Year 7, Week 24, n=1730.2118 ± 2.3731
Glucose, Year 7, Week 32, n=1800.1588 ± 1.6939
Glucose, Year 7, Week 40, n=1750.1380 ± 2.1777
Glucose, Year 7, Week 48, n=1750.0698 ± 1.9178
Glucose, Year 8, Week 8, n=1710.0217 ± 2.0227
Glucose, Year 8, Week 16, n=1700.0307 ± 1.9951
Glucose, Year 8, Week 24, n=1680.0430 ± 1.5670
Glucose, Year 8, Week 32, n=1680.2029 ± 2.1886
Glucose, Year 8, Week 40, n=1620.3481 ± 1.8895
Glucose, Year 8, Week 48, n=1590.2821 ± 2.3294
Glucose, Year 9, Week 8, n=1640.2065 ± 2.3063
Glucose, Year 9, Week 16, n=1620.2457 ± 2.2362
Glucose, Year 9, Week 24, n=1610.2065 ± 2.3096
Glucose, Year 9, Week 32, n=1630.1437 ± 1.7266
Glucose, Year 9, Week 40, n=1560.2619 ± 2.4664
Glucose, Year 9, Week 48, n=1510.3110 ± 1.7497
Glucose, Year 10, Week 8, n=1520.2184 ± 2.5367
Glucose, Year 10, Week 16, n=1430.2713 ± 2.2189
Glucose, Year 10, Week 24, n=1450.2695 ± 1.9119
Glucose, Year 10, Week 32, n=1420.0192 ± 2.0309
Glucose, Year 10, Week 40, n=1380.2277 ± 1.8718
Glucose, Year 10, Week 48, n=1350.2919 ± 2.2420
Glucose, Year 11, Week 8, n=1380.3524 ± 2.4257
Glucose, Year 11, Week 16, n=1280.1778 ± 2.4430
Glucose, Year 11, Week 24, n=1300.2818 ± 1.9155
Glucose, Year 11, Week 32, n=1250.2203 ± 2.2945
Glucose, Year 11, Week 40, n=1240.0877 ± 2.0564
Glucose, Year 11, Week 48, n=1080.1778 ± 2.2984
Glucose, Year 12, Week 8, n=1100.2861 ± 2.5700
Glucose, Year 12, Week 16, n=970.0830 ± 2.1347
Glucose, Year 12, Week 24, n=870.1448 ± 1.8433
Glucose, Year 12, Week 32, n=84-0.0886 ± 2.2813
Glucose, Year 12, Week 40, n=820.3209 ± 1.4176
Glucose, Year 12, Week 48, n=720.3870 ± 1.4519
Glucose, Year 13, Week 8, n=530.3561 ± 1.1963
Glucose, Year 13, Week 16, n=420.2498 ± 1.2196
Glucose, Year 13, Week 24, n=200.4663 ± 1.6396
Glucose, Year 13, Week 32, n=70.3727 ± 0.8144
Glucose, Year 13, Week 40, n=1-0.8326 ± NA
Glucose, Exit, n=2480.1744 ± 1.9656
Glucose, 8-Week Follow-up, n=2200.2707 ± 1.5879
Glucose, 24-Week Follow-up , n=2000.3295 ± 2.1561
Calcium, Year 1, Week 8, n=281-0.0033 ± 0.1012
Calcium, Year 1, Week 16, n=283-0.0025 ± 0.1175
Calcium, Year 1, Week 24, n=2870.0156 ± 0.1036
Calcium, Year 1, Week 32, n=2830.0159 ± 0.1067
Calcium, Year 1, Week 40, n=2820.0203 ± 0.1102
Calcium, Year 1, Week 48, n=2840.0011 ± 0.1193
Calcium, Year 2, Week 8, n=2880.0010 ± 0.1093
Calcium, Year 2, Week 16, n=276-0.0080 ± 0.1104
Calcium, Year 2, Week 24, n=269-0.0180 ± 0.1171
Calcium, Year 2, Week 32, n=284-0.0131 ± 0.1120
Calcium, Year 2, Week 40, n=261-0.0071 ± 0.1091
Calcium, Year 2, Week 48, n=267-0.0081 ± 0.1158
Calcium, Year 3, Week 8, n=262-0.0273 ± 0.1291
Calcium, Year 3, Week 16, n=258-0.0189 ± 0.1102
Calcium, Year 3, Week 24, n=241-0.0205 ± 0.1165
Calcium, Year 3, Week 32, n=245-0.0205 ± 0.1044
Calcium, Year 3, Week 40, n=242-0.0121 ± 0.1122
Calcium, Year 3, Week 48, n=239-0.0156 ± 0.1112
Calcium, Year 4, Week 8, n=237-0.0183 ± 0.1147
Calcium, Year 4, Week 16, n=235-0.0264 ± 0.1118
Calcium, Year 4, Week 24, n=225-0.0250 ± 0.1140
Calcium, Year 4, Week 32, n=230-0.0221 ± 0.1074
Calcium, Year 4, Week 40, n=218-0.0220 ± 0.1105
Calcium, Year 4, Week 48, n=214-0.0192 ± 0.1162
Calcium, Year 5, Week 8, n=217-0.0297 ± 0.1112
Calcium, Year 5, Week 16, n=213-0.0274 ± 0.1149
Calcium, Year 5, Week 24, n=206-0.0292 ± 0.1179
Calcium, Year 5, Week 32, n=211-0.0104 ± 0.1132
Calcium, Year 5, Week 40, n=196-0.0140 ± 0.1166
Calcium, Year 5, Week 48, n=207-0.0036 ± 0.1133
Calcium, Year 6, Week 8, n=205-0.0127 ± 0.1086
Calcium, Year 6, Week 16, n=198-0.0263 ± 0.1269
Calcium, Year 6, Week 24, n=189-0.0037 ± 0.1155
Calcium, Year 6, Week 32, n=192-0.0044 ± 0.1150
Calcium, Year 6, Week 40, n=181-0.0123 ± 0.1068
Calcium, Year 6, Week 48, n=186-0.0025 ± 0.1107
Calcium, Year 7, Week 8, n=177-0.0162 ± 0.1076
Calcium, Year 7, Week 16, n=178-0.0175 ± 0.1217
Calcium, Year 7, Week 24, n=171-0.0163 ± 0.1169
Calcium, Year 7, Week 32, n=179-0.0114 ± 0.1097
Calcium, Year 7, Week 40, n=172-0.0144 ± 0.1111
Calcium, Year 7, Week 48, n=175-0.0234 ± 0.1058
Calcium, Year 8, Week 8, n=170-0.0203 ± 0.1144
Calcium, Year 8, Week 16, n=169-0.0176 ± 0.1099
Calcium, Year 8, Week 24, n=167-0.0121 ± 0.1047
Calcium, Year 8, Week 32, n=166-0.0153 ± 0.1015
Calcium, Year 8, Week 40, n=161-0.0254 ± 0.1111
Calcium, Year 8, Week 48, n=159-0.0210 ± 0.1138
Calcium, Year 9, Week 8, n=163-0.0167 ± 0.1283
Calcium, Year 9, Week 16, n=160-0.0198 ± 0.1181
Calcium, Year 9, Week 24, n=160-0.0253 ± 0.1231
Calcium, Year 9, Week 32, n=162-0.0205 ± 0.1150
Calcium, Year 9, Week 40, n=156-0.0157 ± 0.1246
Calcium, Year 9, Week 48, n=150-0.0075 ± 0.1116
Calcium, Year 10, Week 8, n=151-0.0114 ± 0.1050
Calcium, Year 10, Week 16, n=1430.0026 ± 0.1015
Calcium, Year 10, Week 24, n=145-0.0067 ± 0.1115
Calcium, Year 10, Week 32, n=140-0.0066 ± 0.1109
Calcium, Year 10, Week 40, n=137-0.0067 ± 0.1157
Calcium, Year 10, Week 48, n=135-0.0033 ± 0.1268
Calcium, Year 11, Week 8, n=138-0.0043 ± 0.1185
Calcium, Year 11, Week 16, n=128-0.0033 ± 0.1078
Calcium, Year 11, Week 24, n=129-0.0116 ± 0.1304
Calcium, Year 11, Week 32, n=124-0.0131 ± 0.1131
Calcium, Year 11, Week 40, n=124-0.0093 ± 0.1157
Calcium, Year 11, Week 48, n=107-0.0061 ± 0.1238
Calcium, Year 12, Week 8, n=109-0.0153 ± 0.1214
Calcium, Year 12, Week 16, n=97-0.0005 ± 0.1189
Calcium, Year 12, Week 24, n=850.0220 ± 0.1251
Calcium, Year 12, Week 32, n=840.0009 ± 0.1265
Calcium, Year 12, Week 40, n=82-0.0103 ± 0.1247
Calcium, Year 12, Week 48, n=72-0.0028 ± 0.1206
Calcium, Year 13, Week 8, n=53-0.0151 ± 0.1402
Calcium, Year 13, Week 16, n=42-0.0154 ± 0.1595
Calcium, Year 13, Week 24, n=200.0037 ± 0.1435
Calcium, Year 13, Week 32, n=7-0.0784 ± 0.1234
Calcium, Year 13, Week 40, n=10.0000 ± NA
Calcium, Exit, n=2480.0141 ± 0.1239
Calcium, 8-Week Follow-up, n=2200.0082 ± 0.1152
Calcium, 24-Week Follow-up , n=2000.0181 ± 0.1211
Carbon dioxide, Year 1, Week 8, n=2810.2 ± 2.54
Carbon dioxide, Year 1, Week 16, n=2830.7 ± 2.73
Carbon dioxide, Year 1, Week 24, n=2870.9 ± 2.78
Carbon dioxide, Year 1, Week 32, n=2831.0 ± 2.51
Carbon dioxide, Year 1, Week 40, n=2821.0 ± 2.75
Carbon dioxide, Year 1, Week 48, n=2841.3 ± 2.71
Carbon dioxide, Year 2, Week 8, n=2881.0 ± 2.74
Carbon dioxide, Year 2, Week 16, n=2751.2 ± 2.74
Carbon dioxide, Year 2, Week 24, n=2691.2 ± 2.96
Carbon dioxide, Year 2, Week 32, n=2841.3 ± 2.77
Carbon dioxide, Year 2, Week 40, n=2611.1 ± 2.72
Carbon dioxide, Year 2, Week 48, n=2671.7 ± 3.02
Carbon dioxide, Year 3, Week 8, n=2621.3 ± 2.83
Carbon dioxide, Year 3, Week 16, n=2581.5 ± 2.95
Carbon dioxide, Year 3, Week 24, n=2411.0 ± 2.81
Carbon dioxide, Year 3, Week 32, n=2451.1 ± 2.96
Carbon dioxide, Year 3, Week 40, n=2421.0 ± 2.94
Carbon dioxide, Year 3, Week 48, n=2391.3 ± 3.29
Carbon dioxide, Year 4, Week 8, n=2371.1 ± 2.81
Carbon dioxide, Year 4, Week 16, n=2351.3 ± 3.04
Carbon dioxide, Year 4, Week 24, n=2251.0 ± 2.84
Carbon dioxide, Year 4, Week 32, n=2301.1 ± 2.90
Carbon dioxide, Year 4, Week 40, n=2181.2 ± 3.11
Carbon dioxide, Year 4, Week 48, n=2141.6 ± 3.17
Carbon dioxide, Year 5, Week 8, n=2171.4 ± 2.93
Carbon dioxide, Year 5, Week 16, n=2131.7 ± 2.93
Carbon dioxide, Year 5, Week 24, n=2061.4 ± 2.82
Carbon dioxide, Year 5, Week 32, n=2111.5 ± 2.98
Carbon dioxide, Year 5, Week 40, n=1961.5 ± 2.91
Carbon dioxide, Year 5, Week 48, n=2071.7 ± 2.82
Carbon dioxide, Year 6, Week 8, n=2051.8 ± 3.10
Carbon dioxide, Year 6, Week 16, n=1981.8 ± 2.94
Carbon dioxide, Year 6, Week 24, n=1891.7 ± 2.77
Carbon dioxide, Year 6, Week 32, n=1921.7 ± 2.82
Carbon dioxide, Year 6, Week 40, n=1811.8 ± 3.07
Carbon dioxide, Year 6, Week 48, n=1861.9 ± 2.97
Carbon dioxide, Year 7, Week 8, n=1771.8 ± 3.12
Carbon dioxide, Year 7, Week 16, n=1781.6 ± 3.11
Carbon dioxide, Year 7, Week 24, n=1711.6 ± 3.08
Carbon dioxide, Year 7, Week 32, n=1791.6 ± 3.10
Carbon dioxide, Year 7, Week 40, n=1721.6 ± 2.83
Carbon dioxide, Year 7, Week 48, n=1751.6 ± 2.97
Carbon dioxide, Year 8, Week 8, n=1701.5 ± 3.00
Carbon dioxide, Year 8, Week 16, n=1691.5 ± 3.17
Carbon dioxide, Year 8, Week 24, n=1671.5 ± 3.08
Carbon dioxide, Year 8, Week 32, n=1661.5 ± 3.27
Carbon dioxide, Year 8, Week 40, n=1611.6 ± 3.32
Carbon dioxide, Year 8, Week 48, n=1591.5 ± 3.25
Carbon dioxide, Year 9, Week 8, n=1631.1 ± 3.26
Carbon dioxide, Year 9, Week 16, n=1601.4 ± 3.08
Carbon dioxide, Year 9, Week 24, n=1601.1 ± 2.93
Carbon dioxide, Year 9, Week 32, n=1621.4 ± 3.13
Carbon dioxide, Year 9, Week 40, n=1561.0 ± 3.30
Carbon dioxide, Year 9, Week 48, n=1501.0 ± 3.16
Carbon dioxide, Year 10, Week 8, n=1511.1 ± 2.95
Carbon dioxide, Year 10, Week 16, n=1431.2 ± 3.14
Carbon dioxide, Year 10, Week 24, n=1451.0 ± 3.14
Carbon dioxide, Year 10, Week 32, n=1401.5 ± 3.12
Carbon dioxide, Year 10, Week 40, n=1371.5 ± 3.21
Carbon dioxide, Year 10, Week 48, n=1351.3 ± 3.03
Carbon dioxide, Year 11, Week 8, n=1381.0 ± 3.13
Carbon dioxide, Year 11, Week 16, n=1281.5 ± 3.04
Carbon dioxide, Year 11, Week 24, n=1291.5 ± 3.13
Carbon dioxide, Year 11, Week 32, n=1241.6 ± 2.99
Carbon dioxide, Year 11, Week 40, n=1241.7 ± 3.03
Carbon dioxide, Year 11, Week 48, n=1071.7 ± 3.10
Carbon dioxide, Year 12, Week 8, n=1091.1 ± 3.12
Carbon dioxide, Year 12, Week 16, n=972.1 ± 3.05
Carbon dioxide, Year 12, Week 24, n=852.0 ± 3.12
Carbon dioxide, Year 12, Week 32, n=842.3 ± 3.58
Carbon dioxide, Year 12, Week 40, n=822.0 ± 3.26
Carbon dioxide, Year 12, Week 48, n=721.7 ± 3.39
Carbon dioxide, Year 13, Week 8, n=531.6 ± 2.90
Carbon dioxide, Year 13, Week 16, n=422.0 ± 2.76
Carbon dioxide, Year 13, Week 24, n=202.5 ± 3.19
Carbon dioxide, Year 13, Week 32, n=71.3 ± 3.59
Carbon dioxide, Year 13, Week 40, n=14.0 ± NA
Carbon dioxide, Exit, n=2481.8 ± 2.93
Carbon dioxide, 8-Week Follow-up, n=2201.8 ± 3.26
Carbon dioxide, 24-Week Follow-up , n=2001.8 ± 3.25
Chloride, Year 1, Week 8, n=2840.1 ± 2.52
Chloride, Year 1, Week 16, n=2860.4 ± 2.76
Chloride, Year 1, Week 24, n=2920.0 ± 2.64
Chloride, Year 1, Week 32, n=2870.0 ± 2.66
Chloride, Year 1, Week 40, n=2840.0 ± 2.74
Chloride, Year 1, Week 48, n=2870.4 ± 2.90
Chloride, Year 2, Week 8, n=2880.2 ± 2.77
Chloride, Year 2, Week 16, n=2780.4 ± 2.95
Chloride, Year 2, Week 24, n=2730.6 ± 2.82
Chloride, Year 2, Week 32, n=2840.4 ± 2.80
Chloride, Year 2, Week 40, n=2640.3 ± 3.05
Chloride, Year 2, Week 48, n=2690.2 ± 2.94
Chloride, Year 3, Week 8, n=2650.3 ± 3.07
Chloride, Year 3, Week 16, n=2600.0 ± 2.91
Chloride, Year 3, Week 24, n=2440.1 ± 2.93
Chloride, Year 3, Week 32, n=249-0.1 ± 2.99
Chloride, Year 3, Week 40, n=245-0.2 ± 2.87
Chloride, Year 3, Week 48, n=244-0.3 ± 3.29
Chloride, Year 4, Week 8, n=239-0.2 ± 2.93
Chloride, Year 4, Week 16, n=238-0.2 ± 3.16
Chloride, Year 4, Week 24, n=2270.1 ± 2.85
Chloride, Year 4, Week 32, n=233-0.3 ± 3.12
Chloride, Year 4, Week 40, n=220-0.4 ± 2.94
Chloride, Year 4, Week 48, n=218-0.3 ± 3.15
Chloride, Year 5, Week 8, n=218-0.1 ± 3.20
Chloride, Year 5, Week 16, n=2140.1 ± 2.80
Chloride, Year 5, Week 24, n=2110.2 ± 3.05
Chloride, Year 5, Week 32, n=211-0.2 ± 3.08
Chloride, Year 5, Week 40, n=1980.1 ± 2.97
Chloride, Year 5, Week 48, n=207-0.3 ± 3.00
Chloride, Year 6, Week 8, n=206-0.2 ± 3.11
Chloride, Year 6, Week 16, n=198-0.2 ± 3.23
Chloride, Year 6, Week 24, n=190-0.2 ± 3.11
Chloride, Year 6, Week 32, n=193-0.4 ± 3.31
Chloride, Year 6, Week 40, n=185-0.3 ± 3.25
Chloride, Year 6, Week 48, n=186-0.4 ± 3.07
Chloride, Year 7, Week 8, n=179-0.3 ± 2.95
Chloride, Year 7, Week 16, n=179-0.3 ± 3.10
Chloride, Year 7, Week 24, n=173-0.2 ± 3.18
Chloride, Year 7, Week 32, n=180-0.3 ± 4.06
Chloride, Year 7, Week 40, n=175-0.4 ± 3.32
Chloride, Year 7, Week 48, n=175-0.4 ± 3.24
Chloride, Year 8, Week 8, n=171-0.3 ± 3.46
Chloride, Year 8, Week 16, n=170-0.5 ± 3.75
Chloride, Year 8, Week 24, n=168-0.5 ± 3.37
Chloride, Year 8, Week 32, n=168-0.6 ± 3.30
Chloride, Year 8, Week 40, n=162-0.4 ± 3.26
Chloride, Year 8, Week 48, n=159-0.4 ± 3.49
Chloride, Year 9, Week 8, n=164-0.7 ± 3.36
Chloride, Year 9, Week 16, n=162-0.7 ± 3.26
Chloride, Year 9, Week 24, n=161-0.3 ± 3.21
Chloride, Year 9, Week 32, n=163-0.6 ± 3.43
Chloride, Year 9, Week 40, n=156-0.3 ± 3.72
Chloride, Year 9, Week 48, n=151-0.6 ± 3.76
Chloride, Year 10, Week 8, n=152-0.6 ± 3.61
Chloride, Year 10, Week 16, n=143-0.7 ± 3.59
Chloride, Year 10, Week 24, n=145-0.3 ± 3.87
Chloride, Year 10, Week 32, n=142-0.3 ± 3.72
Chloride, Year 10, Week 40, n=138-0.2 ± 3.18
Chloride, Year 10, Week 48, n=135-0.2 ± 3.48
Chloride, Year 11, Week 8, n=138-0.1 ± 3.28
Chloride, Year 11, Week 16, n=128-0.4 ± 3.41
Chloride, Year 11, Week 24, n=130-0.5 ± 3.39
Chloride, Year 11, Week 32, n=125-0.7 ± 3.69
Chloride, Year 11, Week 40, n=124-0.4 ± 3.22
Chloride, Year 11, Week 48, n=108-0.4 ± 3.33
Chloride, Year 12, Week 8, n=110-0.3 ± 3.51
Chloride, Year 12, Week 16, n=97-0.6 ± 3.23
Chloride, Year 12, Week 24, n=87-0.3 ± 3.18
Chloride, Year 12, Week 32, n=84-0.4 ± 3.01
Chloride, Year 12, Week 40, n=82-0.4 ± 3.32
Chloride, Year 12, Week 48, n=72-1.3 ± 3.09
Chloride, Year 13, Week 8, n=53-0.8 ± 3.31
Chloride, Year 13, Week 16, n=42-0.8 ± 3.00
Chloride, Year 13, Week 24, n=200.0 ± 3.03
Chloride, Year 13, Week 32, n=71.1 ± 3.13
Chloride, Year 13, Week 40, n=10.0 ± NA
Chloride, Exit, n=248-0.8 ± 3.38
Chloride, 8-Week Follow-up, n=220-0.8 ± 3.33
Chloride, 24-Week Follow-up, n=200-0.8 ± 3.52
Magnesium, Year 1, Week 8, n=284-0.003 ± 0.0646
Magnesium, Year 1, Week 16, n=286-0.006 ± 0.0707
Magnesium, Year 1, Week 24, n=292-0.002 ± 0.0660
Magnesium, Year 1, Week 32, n=287-0.007 ± 0.0680
Magnesium, Year 1, Week 40, n=284-0.007 ± 0.0657
Magnesium, Year 1, Week 48, n=287-0.017 ± 0.0724
Magnesium, Year 2, Week 8, n=288-0.016 ± 0.0694
Magnesium, Year 2, Week 16, n=278-0.015 ± 0.0723
Magnesium, Year 2, Week 24, n=273-0.020 ± 0.0704
Magnesium, Year 2, Week 32, n=284-0.018 ± 0.0642
Magnesium, Year 2, Week 40, n=264-0.018 ± 0.0699
Magnesium, Year 2, Week 48, n=269-0.021 ± 0.0720
Magnesium, Year 3, Week 8, n=265-0.029 ± 0.0709
Magnesium, Year 3, Week 16, n=260-0.027 ± 0.0672
Magnesium, Year 3, Week 24, n=244-0.040 ± 0.0646
Magnesium, Year 3, Week 32, n=249-0.042 ± 0.0742
Magnesium, Year 3, Week 40, n=245-0.054 ± 0.0712
Magnesium, Year 3, Week 48, n=244-0.051 ± 0.0724
Magnesium, Year 4, Week 8, n=239-0.052 ± 0.0692
Magnesium, Year 4, Week 16, n=238-0.049 ± 0.0764
Magnesium, Year 4, Week 24, n=227-0.046 ± 0.0720
Magnesium, Year 4, Week 32, n=233-0.049 ± 0.0709
Magnesium, Year 4, Week 40, n=220-0.053 ± 0.0702
Magnesium, Year 4, Week 48, n=218-0.050 ± 0.0757
Magnesium, Year 5, Week 8, n=218-0.052 ± 0.0676
Magnesium, Year 5, Week 16, n=214-0.054 ± 0.0633
Magnesium, Year 5, Week 24, n=211-0.062 ± 0.0648
Magnesium, Year 5, Week 32, n=211-0.068 ± 0.0700
Magnesium, Year 5, Week 40, n=198-0.063 ± 0.0709
Magnesium, Year 5, Week 48, n=207-0.067 ± 0.0754
Magnesium, Year 6, Week 8, n=206-0.059 ± 0.0724
Magnesium, Year 6, Week 16, n=198-0.067 ± 0.0786
Magnesium, Year 6, Week 24, n=190-0.065 ± 0.0724
Magnesium, Year 6, Week 32, n=193-0.063 ± 0.0712
Magnesium, Year 6, Week 40, n=185-0.060 ± 0.0750
Magnesium, Year 6, Week 48, n=186-0.068 ± 0.0721
Magnesium, Year 7, Week 8, n=179-0.052 ± 0.0746
Magnesium, Year 7, Week 16, n=179-0.058 ± 0.0711
Magnesium, Year 7, Week 24, n=173-0.056 ± 0.0712
Magnesium, Year 7, Week 32, n=180-0.054 ± 0.0747
Magnesium, Year 7, Week 40, n=175-0.050 ± 0.0826
Magnesium, Year 7, Week 48, n=175-0.057 ± 0.0772
Magnesium, Year 8, Week 8, n=171-0.052 ± 0.0761
Magnesium, Year 8, Week 16, n=170-0.060 ± 0.0748
Magnesium, Year 8, Week 24, n=168-0.051 ± 0.0739
Magnesium, Year 8, Week 32, n=168-0.055 ± 0.0777
Magnesium, Year 8, Week 40, n=162-0.050 ± 0.0737
Magnesium, Year 8, Week 48, n=159-0.047 ± 0.0788
Magnesium, Year 9, Week 8, n=164-0.049 ± 0.0793
Magnesium, Year 9, Week 16, n=162-0.047 ± 0.0776
Magnesium, Year 9, Week 24, n=161-0.052 ± 0.0825
Magnesium, Year 9, Week 32, n=163-0.052 ± 0.0771
Magnesium, Year 9, Week 40, n=156-0.048 ± 0.0840
Magnesium, Year 9, Week 48, n=151-0.056 ± 0.0771
Magnesium, Year 10, Week 8, n=152-0.050 ± 0.0795
Magnesium, Year 10, Week 16, n=143-0.054 ± 0.0772
Magnesium, Year 10, Week 24, n=145-0.055 ± 0.0770
Magnesium, Year 10, Week 32, n=142-0.050 ± 0.0750
Magnesium, Year 10, Week 40, n=138-0.055 ± 0.0798
Magnesium, Year 10, Week 48, n=135-0.055 ± 0.0825
Magnesium, Year 11, Week 8, n=138-0.057 ± 0.0823
Magnesium, Year 11, Week 16, n=128-0.055 ± 0.0809
Magnesium, Year 11, Week 24, n=130-0.055 ± 0.0810
Magnesium, Year 11, Week 32, n=125-0.055 ± 0.0889
Magnesium, Year 11, Week 40, n=124-0.044 ± 0.0842
Magnesium, Year 11, Week 48, n=108-0.057 ± 0.0800
Magnesium, Year 12, Week 8, n=110-0.041 ± 0.0855
Magnesium, Year 12, Week 16, n=97-0.047 ± 0.0797
Magnesium, Year 12, Week 24, n=87-0.040 ± 0.0846
Magnesium, Year 12, Week 32, n=84-0.056 ± 0.0808
Magnesium, Year 12, Week 40, n=82-0.049 ± 0.0909
Magnesium, Year 12, Week 48, n=72-0.047 ± 0.0809
Magnesium, Year 13, Week 8, n=53-0.045 ± 0.0834
Magnesium, Year 13, Week 16, n=42-0.046 ± 0.0752
Magnesium, Year 13, Week 24, n=20-0.055 ± 0.0776
Magnesium, Year 13, Week 32, n=7-0.050 ± 0.0500
Magnesium, Year 13, Week 40, n=10.050 ± NA
Magnesium, Exit, n=248-0.037 ± 0.0793
Magnesium, 8-Week Follow-up, n=220-0.037 ± 0.0794
Magnesium, 24-Week Follow-up , n=200-0.040 ± 0.0790
Phosphate, Year 1, Week 8, n=284-0.0259 ± 0.1980
Phosphate, Year 1, Week 16, n=286-0.0215 ± 0.1849
Phosphate, Year 1, Week 24, n=292-0.0001 ± 0.2023
Phosphate, Year 1, Week 32, n=287-0.0154 ± 0.1983
Phosphate, Year 1, Week 40, n=284-0.0024 ± 0.1913
Phosphate, Year 1, Week 48, n=287-0.0234 ± 0.1926
Phosphate, Year 2, Week 8, n=288-0.0185 ± 0.1959
Phosphate, Year 2, Week 16, n=278-0.0194 ± 0.2003
Phosphate, Year 2, Week 24, n=273-0.0209 ± 0.1991
Phosphate, Year 2, Week 32, n=284-0.0318 ± 0.2122
Phosphate, Year 2, Week 40, n=264-0.0297 ± 0.2103
Phosphate, Year 2, Week 48, n=269-0.0116 ± 0.2050
Phosphate, Year 3, Week 8, n=265-0.04112 ± 0.2073
Phosphate, Year 3, Week 16, n=260-0.0451 ± 0.2059
Phosphate, Year 3, Week 24, n=244-0.0639 ± 0.2068
Phosphate, Year 3, Week 32, n=249-0.0484 ± 0.2139
Phosphate, Year 3, Week 40, n=245-0.0583 ± 0.2190
Phosphate, Year 3, Week 48, n=244-0.0658 ± 0.2179
Phosphate, Year 4, Week 8, n=239-0.0621 ± 0.2103
Phosphate, Year 4, Week 16, n=238-0.0532 ± 0.2217
Phosphate, Year 4, Week 24, n=227-0.0700 ± 0.2106
Phosphate, Year 4, Week 32, n=233-0.0601 ± 0.2034
Phosphate, Year 4, Week 40, n=220-0.0710 ± 0.2098
Phosphate, Year 4, Week 48, n=218-0.0400 ± 0.2213
Phosphate, Year 5, Week 8, n=218-0.0529 ± 0.2222
Phosphate, Year 5, Week 16, n=214-0.0429 ± 0.2240
Phosphate, Year 5, Week 24, n=211-0.0502 ± 0.1996
Phosphate, Year 5, Week 32, n=211-0.0435 ± 0.2313
Phosphate, Year 5, Week 40, n=198-0.0452 ± 0.2147
Phosphate, Year 5, Week 48, n=207-0.0323 ± 0.2167
Phosphate, Year 6, Week 8, n=206-0.0417 ± 0.2246
Phosphate, Year 6, Week 16, n=198-0.0354 ± 0.2253
Phosphate, Year 6, Week 24, n=190-0.0262 ± 0.2326
Phosphate, Year 6, Week 32, n=193-0.0341 ± 0.2154
Phosphate, Year 6, Week 40, n=185-0.0086 ± 0.2179
Phosphate, Year 6, Week 48, n=186-0.0085 ± 0.2256
Phosphate, Year 7, Week 8, n=179-0.0316 ± 0.2254
Phosphate, Year 7, Week 16, n=179-0.0372 ± 0.1999
Phosphate, Year 7, Week 24, n=173-0.0390 ± 0.2099
Phosphate, Year 7, Week 32, n=180-0.0321 ± 0.2099
Phosphate, Year 7, Week 40, n=175-0.0138 ± 0.2146
Phosphate, Year 7, Week 48, n=175-0.0400 ± 0.2031
Phosphate, Year 8, Week 8, n=171-0.0453 ± 0.2135
Phosphate, Year 8, Week 16, n=170-0.0319 ± 0.2088
Phosphate, Year 8, Week 24, n=168-0.0450 ± 0.2136
Phosphate, Year 8, Week 32, n=168-0.0530 ± 0.2073
Phosphate, Year 8, Week 40, n=162-0.0429 ± 0.2341
Phosphate, Year 8, Week 48, n=159-0.0266 ± 0.2158
Phosphate, Year 9, Week 8, n=164-0.0329 ± 0.2133
Phosphate, Year 9, Week 16, n=162-0.0255 ± 0.2140
Phosphate, Year 9, Week 24, n=161-0.0327 ± 0.2372
Phosphate, Year 9, Week 32, n=163-0.0487 ± 0.2039
Phosphate, Year 9, Week 40, n=156-0.0230 ± 0.2123
Phosphate, Year 9, Week 48, n=151-0.0385 ± 0.2170
Phosphate, Year 10, Week 8, n=152-0.0310 ± 0.2136
Phosphate, Year 10, Week 16, n=143-0.0458 ± 0.2087
Phosphate, Year 10, Week 24, n=145-0.0307 ± 0.2130
Phosphate, Year 10, Week 32, n=142-0.0241 ± 0.2227
Phosphate, Year 10, Week 40, n=138-0.0459 ± 0.2184
Phosphate, Year 10, Week 48, n=135-0.0335 ± 0.2158
Phosphate, Year 11, Week 8, n=138-0.0314 ± 0.2311
Phosphate, Year 11, Week 16, n=128-0.0560 ± 0.2327
Phosphate, Year 11, Week 24, n=130-0.0365 ± 0.2371
Phosphate, Year 11, Week 32, n=125-0.0302 ± 0.2140
Phosphate, Year 11, Week 40, n=124-0.0370 ± 0.2215
Phosphate, Year 11, Week 48, n=108-0.0287 ± 0.2361
Phosphate, Year 12, Week 8, n=110-0.0470 ± 0.2230
Phosphate, Year 12, Week 16, n=97-0.0333 ± 0.2264
Phosphate, Year 12, Week 24, n=87-0.0238 ± 0.2169
Phosphate, Year 12, Week 32, n=84-0.0488 ± 0.2235
Phosphate, Year 12, Week 40, n=82-0.0555 ± 0.2188
Phosphate, Year 12, Week 48, n=72-0.0341 ± 0.2213
Phosphate, Year 13, Week 8, n=53-0.0804 ± 0.2002
Phosphate, Year 13, Week 16, n=42-0.0461 ± 0.2669
Phosphate, Year 13, Week 24, n=200.0533 ± 0.1881
Phosphate, Year 13, Week 32, n=70.0784 ± 0.2075
Phosphate, Year 13, Week 40, n=1-0.1615 ± NA
Phosphate, Exit, n=248-0.0328 ± 0.2385
Phosphate, 8-Week Follow-up, n=220-0.0631 ± 0.2221
Phosphate, 24-Week Follow-up , n=200-0.0375 ± 0.2183
Potassium, Year 1, Week 8, n=281-0.01 ± 0.354
Potassium, Year 1, Week 16, n=2830.04 ± 0.394
Potassium, Year 1, Week 24, n=2870.04 ± 0.406
Potassium, Year 1, Week 32, n=2830.01 ± 0.381
Potassium, Year 1, Week 40, n=2820.03 ± 0.378
Potassium, Year 1, Week 48, n=2840.00 ± 0.406
Potassium, Year 2, Week 8, n=2880.00 ± 0.370
Potassium, Year 2, Week 16, n=2750.03 ± 0.385
Potassium, Year 2, Week 24, n=2690.02 ± 0.398
Potassium, Year 2, Week 32, n=2840.00 ± 0.397
Potassium, Year 2, Week 40, n=2610.04 ± 0.378
Potassium, Year 2, Week 48, n=2670.01 ± 0.386
Potassium, Year 3, Week 8, n=2620.00 ± 0.415
Potassium, Year 3, Week 16, n=2580.02 ± 0.413
Potassium, Year 3, Week 24, n=2410.02 ± 0.407
Potassium, Year 3, Week 32, n=245-0.02 ± 0.406
Potassium, Year 3, Week 40, n=2420.02 ± 0.428
Potassium, Year 3, Week 48, n=2390.00 ± 0.400
Potassium, Year 4, Week 8, n=2370.03 ± 0.414
Potassium, Year 4, Week 16, n=2360.00 ± 0.423
Potassium, Year 4, Week 24, n=2250.03 ± 0.400
Potassium, Year 4, Week 32, n=2300.02 ± 0.383
Potassium, Year 4, Week 40, n=218-0.02 ± 0.396
Potassium, Year 4, Week 48, n=2140.02 ± 0.391
Potassium, Year 5, Week 8, n=2170.01 ± 0.413
Potassium, Year 5, Week 16, n=2130.00 ± 0.390
Potassium, Year 5, Week 24, n=2060.03 ± 0.420
Potassium, Year 5, Week 32, n=211-0.01 ± 0.393
Potassium, Year 5, Week 40, n=1960.03 ± 0.416
Potassium, Year 5, Week 48, n=207-0.01 ± 0.375
Potassium, Year 6, Week 8, n=205-0.02 ± 0.424
Potassium, Year 6, Week 16, n=198-0.04 ± 0.429
Potassium, Year 6, Week 24, n=1890.00 ± 0.411
Potassium, Year 6, Week 32, n=192-0.02 ± 0.395
Potassium, Year 6, Week 40, n=1810.03 ± 0.435
Potassium, Year 6, Week 48, n=186-0.01 ± 0.388
Potassium,Year 7, Week 8, n=1770.00 ± 0.424
Potassium, Year 7, Week 16, n=178-0.02 ± 0.412
Potassium, Year 7, Week 24, n=1710.03 ± 0.388
Potassium, Year 7, Week 32, n=1790.02 ± 0.406
Potassium, Year 7, Week 40, n=1720.03 ± 0.453
Potassium, Year 7, Week 48, n=175-0.03 ± 0.403
Potassium, Year 8, Week 8, n=170-0.05 ± 0.426
Potassium, Year 8, Week 16, n=169-0.05 ± 0.455
Potassium, Year 8, Week 24, n=1670.00 ± 0.386
Potassium, Year 8, Week 32, n=166-0.06 ± 0.382
Potassium, Year 8, Week 40, n=1610.00 ± 0.401
Potassium, Year 8, Week 48, n=159-0.07 ± 0.377
Potassium, Year 9, Week 8, n=163-0.02 ± 0.448
Potassium, Year 9, Week 16, n=160-0.02 ± 0.385
Potassium, Year 9, Week 24, n=160-0.03 ± 0.391
Potassium, Year 9, Week 32, n=162-0.05 ± 0.391
Potassium, Year 9, Week 40, n=156-0.04 ± 0.447
Potassium, Year 9, Week 48, n=150-0.04 ± 0.432
Potassium, Year 10, Week 8, n=151-0.03 ± 0.417
Potassium, Year 10, Week 16, n=143-0.05 ± 0.415
Potassium, Year 10, Week 24, n=1450.00 ± 0.428
Potassium, Year 10, Week 32, n=140-0.03 ± 0.452
Potassium, Year 10, Week 40, n=137-0.02 ± 0.433
Potassium, Year 10, Week 48, n=135-0.02 ± 0.442
Potassium, Year 11, Week 8, n=138-0.03 ± 0.438
Potassium, Year 11, Week 16, n=128-0.04 ± 0.395
Potassium, Year 11, Week 24, n=1290.02 ± 0.433
Potassium, Year 11, Week 32, n=124-0.08 ± 0.399
Potassium, Year 11, Week 40, n=124-0.01 ± 0.383
Potassium, Year 11, Week 48, n=1070.01 ± 0.413
Potassium, Year 12, Week 8, n=1090.01 ± 0.422
Potassium, Year 12, Week 16, n=97-0.02 ± 0.433
Potassium, Year 12, Week 24, n=850.00 ± 0.447
Potassium, Year 12, Week 32, n=84-0.06 ± 0.443
Potassium, Year 12, Week 40, n=82-0.02 ± 0.411
Potassium, Year 12, Week 48, n=72-0.06 ± 0.527
Potassium, Year 13, Week 8, n=53-0.14 ± 0.401
Potassium, Year 13, Week 16, n=42-0.09 ± 0.416
Potassium, Year 13, Week 24, n=200.01 ± 0.525
Potassium, Year 13, Week 32, n=7-0.19 ± 0.389
Potassium, Year 13, Week 40, n=10.60 ± NA
Potassium, Exit, n=2480.03 ± 0.409
Potassium, 8-Week Follow-up, n=2200.01 ± 0.415
Potassium, 24-Week Follow-up , n=2000.02 ± 0.411
Sodium, Year 1, Week 8, n=2840.1 ± 2.76
Sodium, Year 1, Week 16, n=2860.2 ± 2.91
Sodium, ,Year 1, Week 24, n=2920.0 ± 2.78
Sodium, Year 1, Week 32, n=2870.0 ± 2.83
Sodium, Year 1, Week 40, n=284-0.2 ± 2.64
Sodium, Year 1, Week 48, n=287-0.1 ± 2.75
Sodium, Year 2, Week 8, n=2880.0 ± 2.64
Sodium, Year 2, Week 16, n=2780.1 ± 2.74
Sodium, Year 2, Week 24, n=2730.1 ± 2.72
Sodium, Year 2, Week 32, n=284-0.3 ± 2.79
Sodium, Year 2, Week 40, n=264-0.2 ± 2.67
Sodium, Year 2, Week 48, n=269-0.1 ± 2.86
Sodium, Year 3, Week 8, n=265-0.3 ± 2.81
Sodium, Year 3, Week 16, n=260-0.3 ± 2.90
Sodium, Year 3, Week 24, n=244-0.2 ± 2.76
Sodium, Year 3, Week 32, n=249-0.2 ± 2.74
Sodium, Year 3, Week 40, n=245-0.2 ± 2.77
Sodium, Year 3, Week 48, n=244-0.3 ± 2.91
Sodium, Year 4, Week 8, n=239-0.2 ± 2.72
Sodium, Year 4, Week 16, n=238-0.2 ± 2.71
Sodium, Year 4, Week 24, n=227-0.1 ± 2.64
Sodium, Year 4, Week 32, n=233-0.2 ± 2.57
Sodium, Year 4, Week 40, n=220-0.1 ± 2.55
Sodium, Year 4, Week 48, n=218-0.1 ± 2.64
Sodium, Year 5, Week 8, n=218-0.1 ± 2.85
Sodium, Year 5, Week 16, n=214-0.1 ± 2.60
Sodium, Year 5, Week 24, n=2110.0 ± 2.92
Sodium, Year 5, Week 32, n=211-0.1 ± 2.74
Sodium, Year 5, Week 40, n=1980.1 ± 3.04
Sodium, Year 5, Week 48, n=207-0.3 ± 2.90
Sodium, Year 6, Week 8, n=206-0.1 ± 2.96
Sodium, Year 6, Week 16, n=198-0.3 ± 2.85
Sodium, Year 6, Week 24, n=190-0.3 ± 2.90
Sodium, Year 6, Week 32, n=193-0.3 ± 2.90
Sodium, Year 6, Week 40, n=185-0.3 ± 2.91
Sodium, Year 6, Week 48, n=186-0.4 ± 2.77
Sodium,Year 7, Week 8, n=179-0.4 ± 2.90
Sodium, Year 7, Week 16, n=179-0.5 ± 2.86
Sodium, Year 7, Week 24, n=173-0.5 ± 2.86
Sodium, Year 7, Week 32, n=180-0.4 ± 4.24
Sodium, Year 7, Week 40, n=175-0.2 ± 2.98
Sodium, Year 7, Week 48, n=175-0.5 ± 3.01
Sodium, Year 8, Week 8, n=171-0.2 ± 2.96
Sodium, Year 8, Week 16, n=170-0.3 ± 3.22
Sodium, Year 8, Week 24, n=168-0.3 ± 2.79
Sodium, Year 8, Week 32, n=168-0.5 ± 3.01
Sodium, Year 8, Week 40, n=162-0.3 ± 2.94
Sodium, Year 8, Week 48, n=159-0.3 ± 2.88
Sodium, Year 9, Week 8, n=164-0.4 ± 2.94
Sodium, Year 9, Week 16, n=162-0.4 ± 3.14
Sodium, Year 9, Week 24, n=161-0.3 ± 3.05
Sodium, Year 9, Week 32, n=163-0.7 ± 2.94
Sodium, Year 9, Week 40, n=156-0.4 ± 3.13
Sodium, Year 9, Week 48, n=151-0.6 ± 3.22
Sodium, Year 10, Week 8, n=152-0.5 ± 3.25
Sodium, Year 10, Week 16, n=143-0.3 ± 3.31
Sodium, Year 10, Week 24, n=145-0.4 ± 3.56
Sodium, Year 10, Week 32, n=142-0.2 ± 3.15
Sodium, Year 10, Week 40, n=138-0.1 ± 2.80
Sodium, Year 10, Week 48, n=135-0.4 ± 3.26
Sodium, Year 11, Week 8, n=138-0.2 ± 3.21
Sodium, Year 11, Week 16, n=128-0.5 ± 3.30
Sodium, Year 11, Week 24, n=130-0.4 ± 3.27
Sodium, Year 11, Week 32, n=125-0.6 ± 3.19
Sodium, Year 11, Week 40, n=124-0.5 ± 3.25
Sodium, Year 11, Week 48, n=108-0.7 ± 3.16
Sodium, Year 12, Week 8, n=110-0.9 ± 3.07
Sodium, Year 12, Week 16, n=97-0.7 ± 3.12
Sodium, Year 12, Week 24, n=87-0.1 ± 3.26
Sodium, Year 12, Week 32, n=84-0.3 ± 2.91
Sodium, Year 12, Week 40, n=82-0.5 ± 3.18
Sodium, Year 12, Week 48, n=72-1.1 ± 2.98
Sodium, Year 13, Week 8, n=53-0.3 ± 3.04
Sodium, Year 13, Week 16, n=42-0.3 ± 2.68
Sodium, Year 13, Week 24, n=200.2 ± 3.47
Sodium, Year 13, Week 32, n=70.0 ± 3.21
Sodium, Year 13, Week 40, n=12.0 ± NA
Sodium, Exit, n=248-0.7 ± 2.96
Sodium, 8-Week Follow-up, n=220-0.5 ± 3.06
Sodium, 24-Week Follow-up , n=200-0.3 ± 3.16
PrimaryChange From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in creatinine, urate, and bilirubin is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Mean · micromoles per liter
Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points
micromoles per literBelimumab 10 mg/kg IV
Creatinine, Year 1, Week 8, n=2840.436 ± 11.3838
Creatinine, Year 1, Week 16, n=2860.464 ± 12.4820
Creatinine, Year 1, Week 24, n=2921.211 ± 12.9503
Creatinine, Year 1, Week 32, n=2871.047 ± 12.5885
Creatinine, Year 1, Week 40, n=2840.965 ± 12.0245
Creatinine, Year 1, Week 48, n=2870.955 ± 12.4760
Creatinine, Year 2, Week 8, n=2880.583 ± 11.9874
Creatinine, Year 2, Week 16, n=2781.558 ± 11.7857
Creatinine, Year 2, Week 24, n=2731.036 ± 13.7310
Creatinine, Year 2, Week 32, n=2840.716 ± 14.1894
Creatinine, Year 2, Week 40, n=2641.976 ± 15.7590
Creatinine, Year 2, Week 48, n=2691.413 ± 13.7896
Creatinine, Year 3, Week 8, n=265-1.268 ± 14.8256
Creatinine, Year 3, Week 16, n=260-2.006 ± 14.6735
Creatinine, Year 3, Week 24, n=244-2.464 ± 15.3328
Creatinine, Year 3, Week 32, n=249-3.089 ± 14.8793
Creatinine, Year 3, Week 40, n=245-3.320 ± 18.5589
Creatinine, Year 3, Week 48, n=244-3.297 ± 17.3222
Creatinine, Year 4, Week 8, n=239-3.440 ± 14.6181
Creatinine, Year 4, Week 16, n=238-3.417 ± 17.3832
Creatinine, Year 4, Week 24, n=227-3.271 ± 15.7446
Creatinine, Year 4, Week 32, n=233-2.238 ± 15.9372
Creatinine, Year 4, Week 40, n=220-2.331 ± 15.0967
Creatinine, Year 4, Week 48, n=218-1.987 ± 18.0028
Creatinine, Year 5, Week 8, n=218-2.514 ± 16.1511
Creatinine, Year 5, Week 16, n=214-2.602 ± 16.0764
Creatinine, Year 5, Week 24, n=211-1.843 ± 16.8703
Creatinine, Year 5, Week 32, n=211-1.634 ± 17.1000
Creatinine, Year 5, Week 40, n=198-2.456 ± 17.8333
Creatinine, Year 5, Week 48, n=207-3.203 ± 17.3533
Creatinine, Year 6, Week 8, n=206-3.562 ± 16.8131
Creatinine, Year 6, Week 16, n=198-2.634 ± 26.0097
Creatinine, Year 6, Week 24, n=190-4.373 ± 15.1824
Creatinine, Year 6, Week 32, n=193-3.527 ± 18.6685
Creatinine, Year 6, Week 40, n=185-3.488 ± 19.8547
Creatinine, Year 6, Week 48, n=186-3.565 ± 18.7328
Creatinine, Year 7, Week 8, n=179-4.198 ± 19.0041
Creatinine, Year 7, Week 16, n=179-5.185 ± 20.4159
Creatinine, Year 7, Week 24, n=173-6.438 ± 20.9087
Creatinine, Year 7, Week 32, n=180-7.907 ± 19.4999
Creatinine, Year 7, Week 40, n=175-8.486 ± 15.0558
Creatinine, Year 7, Week 48, n=175-8.789 ± 17.9447
Creatinine, Year 8, Week 8, n=171-9.202 ± 17.7671
Creatinine, Year 8, Week 16, n=170-8.008 ± 19.5492
Creatinine, Year 8, Week 24, n=168-8.630 ± 19.0791
Creatinine, Year 8, Week 32, n=168-8.682 ± 19.2383
Creatinine, Year 8, Week 40, n=162-8.349 ± 21.3658
Creatinine, Year 8, Week 48, n=159-8.228 ± 18.9524
Creatinine, Year 9, Week 8, n=164-8.517 ± 14.5862
Creatinine, Year 9, Week 16, n=162-7.585 ± 20.0682
Creatinine, Year 9, Week 24, n=161-8.291 ± 21.4197
Creatinine, Year 9, Week 32, n=163-7.593 ± 18.2143
Creatinine, Year 9, Week 40, n=156-7.763 ± 18.4432
Creatinine, Year 9, Week 48, n=151-8.430 ± 15.7255
Creatinine, Year 10, Week 8, n=152-8.258 ± 19.3747
Creatinine, Year 10, Week 16, n=143-9.273 ± 14.3973
Creatinine, Year 10, Week 24, n=145-7.986 ± 17.3492
Creatinine, Year 10, Week 32, n=142-8.217 ± 17.1597
Creatinine, Year 10, Week 40, n=138-9.417 ± 16.4848
Creatinine, Year 10, Week 48, n=135-8.120 ± 15.7637
Creatinine, Year 11, Week 8, n=138-8.584 ± 16.5792
Creatinine, Year 11, Week 16, n=128-9.254 ± 16.0322
Creatinine, Year 11, Week 24, n=130-8.500 ± 16.4151
Creatinine, Year 11, Week 32, n=125-8.699 ± 15.1035
Creatinine, Year 11, Week 40, n=124-7.058 ± 19.1292
Creatinine, Year 11, Week 48, n=108-7.858 ± 15.6339
Creatinine, Year 12, Week 8, n=110-7.715 ± 14.5236
Creatinine, Year 12, Week 16, n=97-6.744 ± 13.1845
Creatinine, Year 12, Week 24, n=87-7.316 ± 13.4273
Creatinine, Year 12, Week 32, n=84-7.998 ± 14.5624
Creatinine, Year 12, Week 40, n=82-7.331 ± 14.9482
Creatinine, Year 12, Week 48, n=72-8.103 ± 14.0558
Creatinine, Year 13, Week 8, n=53-7.672 ± 12.1403
Creatinine, Year 13, Week 16, n=42-6.104 ± 9.8570
Creatinine, Year 13, Week 24, n=20-9.282 ± 9.7155
Creatinine, Year 13, Week 32, n=7-3.789 ± 15.1893
Creatinine, Year 13, Week 40, n=1-8.840 ± NA
Creatinine, Exit, n=248-3.707 ± 21.7147
Creatinine, 8-Week Follow-up, n=220-4.058 ± 21.6587
Creatinine, 24-Week Follow-up , n=200-5.216 ± 19.0936
Urate, Year 1, Week 8, n=2841.8849 ± 44.3384
Urate, Year 1, Week 16, n=286-2.8076 ± 47.4812
Urate, Year 1, Week 24, n=292-2.6888 ± 47.8723
Urate, Year 1, Week 32, n=287-4.9739 ± 51.9503
Urate, Year 1, Week 40, n=284-10.2415 ± 52.6846
Urate, Year 1, Week 48, n=287-9.6785 ± 52.9454
Urate, Year 2, Week 8, n=288-5.8034 ± 54.3409
Urate, Year 2, Week 16, n=278-2.2679 ± 55.1544
Urate, Year 2, Week 24, n=273-2.5709 ± 59.5925
Urate, Year 2, Week 32, n=284-2.1153 ± 62.2559
Urate, Year 2, Week 40, n=2640.8111 ± 59.7227
Urate, Year 2, Week 48, n=2692.1448 ± 60.1246
Urate, Year 3, Week 8, n=2652.1772 ± 66.2923
Urate, Year 3, Week 16, n=2608.6246 ± 60.1972
Urate, Year 3, Week 24, n=24417.1614 ± 64.9072
Urate, Year 3, Week 32, n=24920.6627 ± 69.7507
Urate, Year 3, Week 40, n=24515.5862 ± 64.9204
Urate, Year 3, Week 48, n=24417.2346 ± 69.9632
Urate, Year 4, Week 8, n=23918.8644 ± 69.2770
Urate, Year 4, Week 16, n=23817.0443 ± 65.9764
Urate, Year 4, Week 24, n=22722.1150 ± 73.0409
Urate, Year 4, Week 32, n=23327.1872 ± 67.0773
Urate, Year 4, Week 40, n=22020.6017 ± 77.3509
Urate, Year 4, Week 48, n=21827.3663 ± 74.9898
Urate, Year 5, Week 8, n=21826.3294 ± 73.0884
Urate, Year 5, Week 16, n=21426.4325 ± 75.1583
Urate, Year 5, Week 24, n=21125.6525 ± 73.5651
Urate, Year 5, Week 32, n=21132.0515 ± 75.9635
Urate, Year 5, Week 40, n=19826.8862 ± 77.2803
Urate, Year 5, Week 48, n=20724.9126 ± 79.1890
Urate, Year 6, Week 8, n=20626.3329 ± 80.0258
Urate, Year 6, Week 16, n=19827.2166 ± 79.2525
Urate, Year 6, Week 24, n=19032.5888 ± 81.4485
Urate, Year 6, Week 32, n=19332.3904 ± 81.4550
Urate, Year 6, Week 40, n=18534.4019 ± 75.0211
Urate, Year 6, Week 48, n=18639.1737 ± 75.6743
Urate, Year 7, Week 8, n=17934.0930 ± 75.0241
Urate, Year 7, Week 16, n=17935.0566 ± 77.2918
Urate, Year 7, Week 24, n=17334.7941 ± 80.7184
Urate, Year 7, Week 32, n=18032.8792 ± 75.6337
Urate, Year 7, Week 40, n=17531.7453 ± 81.9889
Urate, Year 7, Week 48, n=17531.9832 ± 78.3131
Urate, Year 8, Week 8, n=17126.6790 ± 79.7678
Urate, Year 8, Week 16, n=17030.7197 ± 83.1681
Urate, Year 8, Week 24, n=16825.4560 ± 83.0349
Urate, Year 8, Week 32, n=16830.0940 ± 81.9997
Urate, Year 8, Week 40, n=16229.4096 ± 76.1203
Urate, Year 8, Week 48, n=15929.9270 ± 82.9390
Urate, Year 9, Week 8, n=16437.6828 ± 78.7998
Urate, Year 9, Week 16, n=16227.2066 ± 79.3972
Urate, Year 9, Week 24, n=16125.9717 ± 78.7793
Urate, Year 9, Week 32, n=16326.1639 ± 78.0704
Urate, Year 9, Week 40, n=15624.7833 ± 81.4956
Urate, Year 9, Week 48, n=15121.9012 ± 82.0174
Urate, Year 10, Week 8, n=15224.8486 ± 75.5325
Urate, Year 10, Week 16, n=14317.5528 ± 82.4129
Urate, Year 10, Week 24, n=14517.6389 ± 88.8154
Urate, Year 10, Week 32, n=14216.9644 ± 84.0128
Urate, Year 10, Week 40, n=13816.0768 ± 88.6943
Urate, Year 10, Week 48, n=13520.9722 ± 92.2400
Urate, Year 11, Week 8, n=13816.3354 ± 88.7370
Urate, Year 11, Week 16, n=12819.0057 ± 80.9138
Urate, Year 11, Week 24, n=12913.8326 ± 91.9844
Urate, Year 11, Week 32, n=12514.4180 ± 81.6362
Urate, Year 11, Week 40, n=12417.8920 ± 97.1467
Urate, Year 11, Week 48, n=10815.9164 ± 86.7371
Urate, Year 12, Week 8, n=11018.3307 ± 92.3013
Urate, Year 12, Week 16, n=9715.3912 ± 85.1873
Urate, Year 12, Week 24, n=8715.3828 ± 87.1985
Urate, Year 12, Week 32, n=8416.7817 ± 89.8376
Urate, Year 12, Week 40, n=8212.2587 ± 83.5304
Urate, Year 12, Week 48, n=729.9133 ± 85.1185
Urate, Year 13, Week 8, n=5332.4334 ± 79.1035
Urate, Year 13, Week 16, n=4242.6273 ± 74.2314
Urate, Year 13, Week 24, n=2025.5764 ± 56.8583
Urate, Year 13, Week 32, n=764.5783 ± 59.0251
Urate, Year 13, Week 40, n=153.5320 ± NA
Urate, Exit, n=24818.5635 ± 89.4280
Urate, 8-Week Follow-up, n=22019.6014 ± 89.9097
Urate, 24-Week Follow-up , n=20017.5763 ± 82.1420
Bilirubin, Year 1, Week 8, n=2830.145 ± 2.2995
Bilirubin, Year 1, Week 16, n=2850.168 ± 2.3476
Bilirubin, Year 1, Week 24, n=2920.287 ± 2.4529
Bilirubin, Year 1, Week 32, n=2870.346 ± 2.6100
Bilirubin, Year 1, Week 40, n=2830.236 ± 2.3829
Bilirubin, Year 1, Week 48, n=2860.293 ± 2.5315
Bilirubin, Year 2, Week 8, n=2880.243 ± 2.6498
Bilirubin, Year 2, Week 16, n=2770.019 ± 2.5896
Bilirubin, Year 2, Week 24, n=2720.176 ± 2.5041
Bilirubin, Year 2, Week 32, n=2840.331 ± 2.6475
Bilirubin, Year 2, Week 40, n=2620.398 ± 2.9233
Bilirubin, Year 2, Week 48, n=2690.464 ± 2.5138
Bilirubin, Year 3, Week 8, n=2640.343 ± 2.6599
Bilirubin, Year 3, Week 16, n=2580.252 ± 2.8788
Bilirubin, Year 3, Week 24, n=2430.274 ± 3.0754
Bilirubin, Year 3, Week 32, n=2490.494 ± 2.5860
Bilirubin, Year 3, Week 40, n=2440.182 ± 2.8589
Bilirubin, Year 3, Week 48, n=2430.267 ± 3.0780
Bilirubin, Year 4, Week 8, n=2390.336 ± 2.7639
Bilirubin, Year 4, Week 16, n=2380.481 ± 2.8625
Bilirubin, Year 4, Week 24, n=2270.309 ± 2.8038
Bilirubin, Year 4, Week 32, n=2310.326 ± 2.9524
Bilirubin, Year 4, Week 40, n=220-0.023 ± 2.5236
Bilirubin, Year 4, Week 48, n=2180.157 ± 2.8815
Bilirubin, Year 5, Week 8, n=2180.329 ± 2.4013
Bilirubin, Year 5, Week 16, n=2140.304 ± 2.6180
Bilirubin, Year 5, Week 24, n=2110.259 ± 2.5450
Bilirubin, Year 5, Week 32, n=2110.575 ± 2.6520
Bilirubin, Year 5, Week 40, n=1980.544 ± 2.6496
Bilirubin, Year 5, Week 48, n=2070.322 ± 2.5320
Bilirubin, Year 6, Week 8, n=2060.282 ± 2.5233
Bilirubin, Year 6, Week 16, n=1980.138 ± 2.6093
Bilirubin, Year 6, Week 24, n=1900.099 ± 2.7600
Bilirubin, Year 6, Week 32, n=1930.284 ± 2.6431
Bilirubin, Year 6, Week 40, n=1850.296 ± 2.8314
Bilirubin, Year 6, Week 48, n=1860.248 ± 3.0097
Bilirubin, Year 7, Week 8, n=1790.258 ± 2.6974
Bilirubin, Year 7, Week 16, n=1790.143 ± 2.6134
Bilirubin, Year 7, Week 24, n=1730.287 ± 2.6082
Bilirubin, Year 7, Week 32, n=1800.313 ± 2.9727
Bilirubin, Year 7, Week 40, n=1750.137 ± 2.7527
Bilirubin, Year 7, Week 48, n=1750.156 ± 2.9747
Bilirubin, Year 8, Week 8, n=1710.020 ± 2.9559
Bilirubin, Year 8, Week 16, n=170-0.050 ± 2.6856
Bilirubin, Year 8, Week 24, n=1680.010 ± 2.4720
Bilirubin, Year 8, Week 32, n=168-0.336 ± 2.5471
Bilirubin, Year 8, Week 40, n=162-0.032 ± 2.8934
Bilirubin, Year 8, Week 48, n=159-0.097 ± 3.2550
Bilirubin, Year 9, Week 8, n=164-0.125 ± 2.7616
Bilirubin, Year 9, Week 16, n=162-0.095 ± 2.9603
Bilirubin, Year 9, Week 24, n=161-0.234 ± 3.1385
Bilirubin, Year 9, Week 32, n=163-0.126 ± 2.7175
Bilirubin, Year 9, Week 40, n=156-0.296 ± 3.3709
Bilirubin, Year 9, Week 48, n=1510.057 ± 2.8231
Bilirubin, Year 10, Week 8, n=152-0.158 ± 3.0763
Bilirubin, Year 10, Week 16, n=143-0.179 ± 3.1616
Bilirubin, Year 10, Week 24, n=145-0.024 ± 2.8853
Bilirubin, Year 10, Week 32, n=1420.120 ± 3.3068
Bilirubin, Year 10, Week 40, n=138-0.248 ± 3.0684
Bilirubin, Year 10, Week 48, n=1350.190 ± 3.0751
Bilirubin, Year 11, Week 8, n=1380.050 ± 2.9936
Bilirubin, Year 11, Week 16, n=1280.281 ± 2.9640
Bilirubin, Year 11, Week 24, n=1300.026 ± 2.8004
Bilirubin, Year 11, Week 32, n=1250.192 ± 2.5160
Bilirubin, Year 11, Week 40, n=1240.193 ± 3.2650
Bilirubin, Year 11, Week 48, n=1080.538 ± 2.9261
Bilirubin, Year 12, Week 8, n=1100.311 ± 2.8762
Bilirubin, Year 12, Week 16, n=970.776 ± 3.0231
Bilirubin, Year 12, Week 24, n=870.511 ± 3.4508
Bilirubin, Year 12, Week 32, n=841.282 ± 3.3563
Bilirubin, Year 12, Week 40, n=820.542 ± 3.2454
Bilirubin, Year 12, Week 48, n=720.570 ± 3.8398
Bilirubin, Year 13, Week 8, n=530.129 ± 2.8623
Bilirubin, Year 13, Week 16, n=42-0.244 ± 3.1046
Bilirubin, Year 13, Week 24, n=20-0.513 ± 2.0080
Bilirubin, Year 13, Week 32, n=7-0.244 ± 2.5032
Bilirubin, Year 13, Week 40, n=10.000 ± NA
Bilirubin, Exit, n=2480.510 ± 3.0619
Bilirubin, 8-Week Follow-up, n=2200.389 ± 2.7311
Bilirubin, 24-Week Follow-up , n=2000.650 ± 3.3222
PrimaryChange From Baseline in BUN/Creatinine at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Mean · Ratio
Change From Baseline in BUN/Creatinine at the Indicated Time Points
RatioBelimumab 10 mg/kg IV
BUN/Creatinine, Year 1, Week 8, n=284-0.1 ± 4.13
BUN/Creatinine, Year 1, Week 16, n=286-0.4 ± 4.31
BUN/Creatinine, Year 1, Week 24, n=292-0.4 ± 4.67
BUN/Creatinine, Year 1, Week 32, n=287-0.4 ± 4.07
BUN/Creatinine, Year 1, Week 40, n=284-0.8 ± 4.26
BUN/Creatinine, Year 1, Week 48, n=287-0.3 ± 4.80
BUN/Creatinine, Year 2, Week 8, n=288-0.4 ± 4.91
BUN/Creatinine, Year 2, Week 16, n=278-0.6 ± 4.95
BUN/Creatinine, Year 2, Week 24, n=273-0.6 ± 5.00
BUN/Creatinine, Year 2, Week 32, n=284-0.4 ± 4.82
BUN/Creatinine, Year 2, Week 40, n=264-0.8 ± 4.80
BUN/Creatinine, Year 2, Week 48, n=269-0.5 ± 4.90
BUN/Creatinine, Year 3, Week 8, n=2650.2 ± 4.81
BUN/Creatinine, Year 3, Week 16, n=2600.2 ± 4.95
BUN/Creatinine, Year 3, Week 24, n=2440.6 ± 4.93
BUN/Creatinine, Year 3, Week 32, n=2490.5 ± 5.16
BUN/Creatinine, Year 3, Week 40, n=2450.9 ± 4.83
BUN/Creatinine, Year 3, Week 48, n=2440.8 ± 4.99
BUN/Creatinine, Year 4, Week 8, n=2391.1 ± 4.99
BUN/Creatinine, Year 4, Week 16, n=2380.8 ± 4.86
BUN/Creatinine, Year 4, Week 24, n=2270.9 ± 5.15
BUN/Creatinine, Year 4, Week 32, n=2330.5 ± 4.93
BUN/Creatinine, Year 4, Week 40, n=2200.3 ± 4.81
BUN/Creatinine, Year 4, Week 48, n=2181.1 ± 5.35
BUN/Creatinine, Year 5, Week 8, n=2180.8 ± 5.34
BUN/Creatinine, Year 5, Week 16, n=2141.2 ± 5.03
BUN/Creatinine, Year 5, Week 24, n=2110.8 ± 5.01
BUN/Creatinine, Year 5, Week 32, n=2110.3 ± 4.93
BUN/Creatinine, Year 5, Week 40, n=1981.2 ± 5.04
BUN/Creatinine, Year 5, Week 48, n=2070.9 ± 5.11
BUN/Creatinine, Year 6, Week 8, n=2061.4 ± 5.04
BUN/Creatinine, Year 6, Week 16, n=1981.3 ± 5.03
BUN/Creatinine, Year 6, Week 24, n=1901.2 ± 5.37
BUN/Creatinine, Year 6, Week 32, n=1931.6 ± 5.76
BUN/Creatinine, Year 6, Week 40, n=1851.5 ± 4.73
BUN/Creatinine, Year 6, Week 48, n=1861.8 ± 5.08
BUN/Creatinine, Year 7, Week 8, n=1791.6 ± 5.07
BUN/Creatinine, Year 7, Week 16, n=1792.1 ± 5.04
BUN/Creatinine, Year 7, Week 24, n=1732.1 ± 5.55
BUN/Creatinine, Year 7, Week 32, n=1802.3 ± 5.39
BUN/Creatinine, Year 7, Week 40, n=1752.6 ± 5.19
BUN/Creatinine, Year 7, Week 48, n=1752.6 ± 5.31
BUN/Creatinine, Year 8, Week 8, n=1712.7 ± 5.65
BUN/Creatinine, Year 8, Week 16, n=1702.5 ± 5.54
BUN/Creatinine, Year 8, Week 24, n=1682.6 ± 5.37
BUN/Creatinine, Year 8, Week 32, n=1682.2 ± 5.11
BUN/Creatinine, Year 8, Week 40, n=1622.3 ± 5.36
BUN/Creatinine, Year 8, Week 48, n=1592.9 ± 5.20
BUN/Creatinine, Year 9, Week 8, n=1642.4 ± 5.26
BUN/Creatinine, Year 9, Week 16, n=1622.5 ± 6.15
BUN/Creatinine, Year 9, Week 24, n=1612.4 ± 5.89
BUN/Creatinine, Year 9, Week 32, n=1632.7 ± 5.54
BUN/Creatinine, Year 9, Week 40, n=1562.4 ± 5.90
BUN/Creatinine, Year 9, Week 48, n=1512.2 ± 6.01
BUN/Creatinine, Year 10, Week 8, n=1522.6 ± 5.98
BUN/Creatinine, Year 10, Week 16, n=1432.6 ± 6.13
BUN/Creatinine, Year 10, Week 24, n=1452.5 ± 5.72
BUN/Creatinine, Year 10, Week 32, n=1422.8 ± 6.03
BUN/Creatinine, Year 10, Week 40, n=1382.0 ± 5.87
BUN/Creatinine, Year 10, Week 48, n=1352.4 ± 6.07
BUN/Creatinine, Year 11, Week 8, n=1382.7 ± 6.13
BUN/Creatinine, Year 11, Week 16, n=1282.6 ± 6.28
BUN/Creatinine, Year 11, Week 24, n=1302.8 ± 6.12
BUN/Creatinine, Year 11, Week 32, n=1252.2 ± 6.10
BUN/Creatinine, Year 11, Week 40, n=1242.3 ± 6.68
BUN/Creatinine, Year 11, Week 48, n=1081.7 ± 5.65
BUN/Creatinine, Year 12, Week 8, n=1102.4 ± 6.36
BUN/Creatinine, Year 12, Week 16, n=972.4 ± 6.38
BUN/Creatinine, Year 12, Week 24, n=872.2 ± 6.62
BUN/Creatinine, Year 12, Week 32, n=841.5 ± 5.75
BUN/Creatinine, Year 12, Week 40, n=821.4 ± 6.50
BUN/Creatinine, Year 12, Week 48, n=721.6 ± 6.42
BUN/Creatinine, Year 13, Week 8, n=532.1 ± 5.44
BUN/Creatinine, Year 13, Week 16, n=423.5 ± 6.22
BUN/Creatinine, Year 13, Week 24, n=203.6 ± 4.36
BUN/Creatinine, Year 13, Week 32, n=70.3 ± 2.93
BUN/Creatinine, Year 13, Week 40, n=1-6.0 ± NA
BUN/Creatinine, Exit, n=2481.6 ± 5.66
BUN/Creatinine, 8-Week Follow-up, n=2201.1 ± 5.88
BUN/Creatinine, 24-Week Follow-up , n=2001.3 ± 5.53
PrimaryChange From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points

Clinical chemistry parameters were assessed at Baseline, Week 8, 16, 24, 32, 40 and 48 during Year 1 to 12; Week 8, 16, 24, 32, and 40 during Year 13; Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Change from Baseline in ALT, AP, AST, GGT and LD are summarized. Baseline is defined as the Extension Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Mean · International units per liter
Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (AP), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT) and Lactate Dehydrogenase (LD) at the Indicated Time Points
International units per literBelimumab 10 mg/kg IV
ALT, Year 1, Week 8, n=284-0.7 ± 12.05
ALT, Year 1, Week 16, n=2860.2 ± 17.32
ALT, Year 1, Week 24, n=2920.9 ± 17.04
ALT, Year 1, Week 32, n=287-0.6 ± 12.36
ALT, Year 1, Week 40, n=284-0.6 ± 14.15
ALT, Year 1, Week 48, n=287-1.3 ± 11.56
ALT, Year 2, Week 8, n=288-0.7 ± 13.36
ALT, Year 2, Week 16, n=278-1.2 ± 11.44
ALT, Year 2, Week 24, n=2730.3 ± 13.35
ALT, Year 2, Week 32, n=2840.1 ± 15.85
ALT, Year 2, Week 40, n=2640.0 ± 14.02
ALT, Year 2, Week 48, n=2690.9 ± 15.65
ALT, Year 3, Week 8, n=2650.5 ± 14.46
ALT, Year 3, Week 16, n=2601.3 ± 21.94
ALT, Year 3, Week 24, n=244-0.1 ± 13.95
ALT, Year 3, Week 32, n=2490.0 ± 12.55
ALT, Year 3, Week 40, n=245-0.3 ± 13.08
ALT, Year 3, Week 48, n=244-0.4 ± 13.62
ALT, Year 4, Week 8, n=239-0.5 ± 10.97
ALT, Year 4, Week 16, n=238-1.3 ± 14.28
ALT, Year 4, Week 24, n=227-1.3 ± 13.29
ALT, Year 4, Week 32, n=233-0.4 ± 13.60
ALT, Year 4, Week 40, n=220-1.6 ± 12.83
ALT, Year 4, Week 48, n=218-1.3 ± 12.45
ALT, Year 5, Week 8, n=2180.1 ± 12.76
ALT, Year 5, Week 16, n=214-0.5 ± 12.67
ALT, Year 5, Week 24, n=211-0.9 ± 14.68
ALT, Year 5, Week 32, n=211-1.5 ± 13.23
ALT, Year 5, Week 40, n=198-1.3 ± 13.90
ALT, Year 5, Week 48, n=207-0.1 ± 17.16
ALT, Year 6, Week 8, n=206-1.4 ± 12.09
ALT, Year 6, Week 16, n=198-1.4 ± 13.55
ALT, Year 6, Week 24, n=190-1.6 ± 13.87
ALT, Year 6, Week 32, n=193-1.4 ± 13.58
ALT, Year 6, Week 40, n=185-1.4 ± 14.78
ALT, Year 6, Week 48, n=186-0.9 ± 14.98
ALT, Year 7, Week 8, n=179-0.4 ± 14.50
ALT, Year 7, Week 16, n=1790.5 ± 15.78
ALT, Year 7, Week 24, n=1730.1 ± 16.09
ALT, Year 7, Week 32, n=180-0.2 ± 14.71
ALT, Year 7, Week 40, n=175-0.1 ± 16.43
ALT, Year 7, Week 48, n=175-0.4 ± 16.15
ALT, Year 8, Week 8, n=1710.9 ± 16.58
ALT, Year 8, Week 16, n=170-0.2 ± 17.74
ALT, Year 8, Week 24, n=168-0.2 ± 15.62
ALT, Year 8, Week 32, n=168-0.4 ± 14.82
ALT, Year 8, Week 40, n=162-0.7 ± 14.79
ALT, Year 8, Week 48, n=159-0.7 ± 15.14
ALT, Year 9, Week 8, n=1641.5 ± 21.38
ALT, Year 9, Week 16, n=162-0.8 ± 14.31
ALT, Year 9, Week 24, n=161-1.5 ± 14.35
ALT, Year 9, Week 32, n=1630.0 ± 15.62
ALT, Year 9, Week 40, n=156-0.5 ± 14.61
ALT, Year 9, Week 48, n=151-0.2 ± 15.69
ALT, Year 10, Week 8, n=152-0.6 ± 14.25
ALT, Year 10, Week 16, n=143-0.3 ± 13.88
ALT, Year 10, Week 24, n=145-1.1 ± 15.71
ALT, Year 10, Week 32, n=142-0.8 ± 15.97
ALT, Year 10, Week 40, n=138-1.9 ± 15.56
ALT, Year 10, Week 48, n=135-0.7 ± 19.61
ALT, Year 11, Week 8, n=138-1.9 ± 15.75
ALT, Year 11, Week 16, n=128-1.3 ± 16.74
ALT, Year 11, Week 24, n=130-2.5 ± 15.11
ALT, Year 11, Week 32, n=125-3.2 ± 14.71
ALT, Year 11, Week 40, n=124-2.8 ± 15.31
ALT, Year 11, Week 48, n=108-1.7 ± 18.29
ALT, Year 12, Week 8, n=110-1.9 ± 16.30
ALT, Year 12, Week 16, n=97-2.9 ± 12.74
ALT, Year 12, Week 24, n=87-2.0 ± 13.47
ALT, Year 12, Week 32, n=84-2.4 ± 13.39
ALT, Year 12, Week 40, n=82-2.3 ± 14.74
ALT, Year 12, Week 48, n=72-3.6 ± 14.92
ALT, Year 13, Week 8, n=53-5.3 ± 16.58
LT, Year 13, Week 16, n=42-5.7 ± 20.42
ALT, Year 13, Week 24, n=20-1.0 ± 6.55
ALT, Year 13, Week 32, n=7-0.6 ± 9.14
ALT, Year 13, Week 40, n=13.0 ± NA
ALT, Exit, n=248-1.2 ± 13.39
ALT, 8-Week Follow-up, n=220-0.6 ± 15.74
ALT, 24-Week Follow-up , n=2001.5 ± 36.52
AP, Year 1, Week 8, n=284-0.1 ± 11.43
AP, Year 1, Week 16, n=2860.9 ± 14.08
AP, Year 1, Week 24, n=2920.7 ± 13.87
AP, Year 1, Week 32, n=2870.6 ± 14.03
AP, Year 1, Week 40, n=2841.1 ± 14.61
AP, Year 1, Week 48, n=2870.5 ± 16.94
AP, Year 2, Week 8, n=2881.2 ± 17.67
AP, Year 2, Week 16, n=2780.2 ± 15.87
AP, Year 2, Week 24, n=2731.3 ± 16.91
AP, Year 2, Week 32, n=2842.5 ± 17.17
AP, Year 2, Week 40, n=2643.5 ± 19.55
AP, Year 2, Week 48, n=2695.6 ± 23.81
AP, Year 3, Week 8, n=2654.0 ± 18.04
AP, Year 3, Week 16, n=2603.2 ± 19.53
AP, Year 3, Week 24, n=2442.0 ± 19.26
AP, Year 3, Week 32, n=2493.7 ± 21.48
AP, Year 3, Week 40, n=2453.4 ± 18.62
AP, Year 3, Week 48, n=2443.4 ± 19.32
AP, Year 4, Week 8, n=2392.5 ± 19.33
AP, Year 4, Week 16, n=2382.8 ± 17.37
AP, Year 4, Week 24, n=2272.5 ± 21.94
AP, Year 4, Week 32, n=2333.7 ± 21.17
AP, Year 4, Week 40, n=2202.9 ± 20.93
AP, Year 4, Week 48, n=2183.7 ± 22.97
AP, Year 5, Week 8, n=2184.9 ± 24.65
AP, Year 5, Week 16, n=2144.1 ± 23.87
AP, Year 5, Week 24, n=2114.0 ± 20.17
AP, Year 5, Week 32, n=2115.7 ± 20.68
AP, Year 5, Week 40, n=1985.5 ± 21.34
AP, Year 5, Week 48, n=2076.6 ± 21.74
AP, Year 6, Week 8, n=2067.1 ± 23.65
AP, Year 6, Week 16, n=1987.5 ± 21.41
AP, Year 6, Week 24, n=1907.5 ± 22.41
AP, Year 6, Week 32, n=19314.0 ± 67.61
AP, Year 6, Week 40, n=18510.2 ± 24.43
AP, Year 6, Week 48, n=1869.1 ± 22.93
AP, Year 7, Week 8, n=1799.0 ± 24.52
AP, Year 7, Week 16, n=1799.6 ± 25.70
AP, Year 7, Week 24, n=1739.9 ± 25.38
AP, Year 7, Week 32, n=18011.5 ± 27.02
AP, Year 7, Week 40, n=1759.6 ± 25.13
AP, Year 7, Week 48, n=17511.1 ± 24.96
AP, Year 8, Week 8, n=17110.0 ± 23.29
AP, Year 8, Week 16, n=17010.1 ± 27.16
AP, Year 8, Week 24, n=16810.4 ± 26.44
AP, Year 8, Week 32, n=16812.9 ± 27.45
AP, Year 8, Week 40, n=16211.1 ± 25.66
AP, Year 8, Week 48, n=15911.5 ± 30.97
AP, Year 9, Week 8, n=16412.0 ± 25.38
AP, Year 9, Week 16, n=16210.9 ± 25.48
AP, Year 9, Week 24, n=16110.5 ± 22.81
AP, Year 9, Week 32, n=16310.4 ± 24.05
AP, Year 9, Week 40, n=1569.5 ± 24.43
AP, Year 9, Week 48, n=15110.2 ± 22.77
AP, Year 10, Week 8, n=15210.6 ± 24.51
AP, Year 10, Week 16, n=14311.9 ± 29.31
AP, Year 10, Week 24, n=14513.0 ± 22.92
AP, Year 10, Week 32, n=14214.4 ± 24.55
AP, Year 10, Week 40, n=13813.7 ± 23.20
AP, Year 10, Week 48, n=13512.5 ± 23.89
AP, Year 11, Week 8, n=13813.3 ± 26.11
AP, Year 11, Week 16, n=12814.2 ± 26.05
AP, Year 11, Week 24, n=13012.9 ± 23.22
AP, Year 11, Week 32, n=12513.3 ± 23.74
AP, Year 11, Week 40, n=12413.3 ± 23.05
AP, Year 11, Week 48, n=10811.9 ± 25.59
AP, Year 12, Week 8, n=11012.3 ± 25.69
AP, Year 12, Week 16, n=9710.2 ± 22.48
AP, Year 12, Week 24, n=8711.5 ± 20.69
AP, Year 12, Week 32, n=8410.7 ± 19.91
AP, Year 12, Week 40, n=8210.8 ± 21.35
AP, Year 12, Week 48, n=7211.6 ± 21.77
AP, Year 13, Week 8, n=5312.2 ± 19.25
AP, Year 13, Week 16, n=4216.9 ± 37.69
AP, Year 13, Week 24, n=2020.7 ± 23.57
AP, Year 13, Week 32, n=718.1 ± 21.47
AP, Year 13, Week 40, n=115.0 ± NA
AP, Exit, n=2488.3 ± 26.49
AP, 8-Week Follow-up, n=22010.3 ± 42.15
AP, 24-Week Follow-up , n=20010.7 ± 32.86
AST, Year 1, Week 8, n=281-0.3 ± 8.68
AST, Year 1, Week 16, n=2832.0 ± 22.78
AST, Year 1, Week 24, n=2872.3 ± 26.94
AST, Year 1, Week 32, n=2830.5 ± 12.19
AST, Year 1, Week 40, n=282-0.1 ± 9.63
AST, Year 1, Week 48, n=284-1.2 ± 6.98
AST, Year 2, Week 8, n=288-0.8 ± 9.15
AST, Year 2, Week 16, n=275-1.2 ± 8.51
AST, Year 2, Week 24, n=269-0.3 ± 9.04
AST, Year 2, Week 32, n=2840.2 ± 13.80
AST, Year 2, Week 40, n=261-0.2 ± 10.44
AST, Year 2, Week 48, n=2670.7 ± 10.95
AST, Year 3, Week 8, n=2620.3 ± 10.81
AST, Year 3, Week 16, n=2581.0 ± 11.84
AST, Year 3, Week 24, n=2410.4 ± 10.36
AST, Year 3, Week 32, n=2451.3 ± 11.19
AST, Year 3, Week 40, n=2420.2 ± 10.99
AST, Year 3, Week 48, n=2390.6 ± 10.60
AST, Year 4, Week 8, n=2370.5 ± 7.73
AST, Year 4, Week 16, n=235-0.2 ± 12.78
AST, Year 4, Week 24, n=2260.4 ± 11.45
AST, Year 4, Week 32, n=2300.8 ± 9.26
AST, Year 4, Week 40, n=218-0.3 ± 9.44
AST, Year 4, Week 48, n=214-0.2 ± 9.48
AST, Year 5, Week 8, n=2170.3 ± 12.79
AST, Year 5, Week 16, n=2130.8 ± 15.76
AST, Year 5, Week 24, n=206-0.5 ± 11.36
AST, Year 5, Week 32, n=211-0.8 ± 10.64
AST, Year 5, Week 40, n=1970.3 ± 14.39
AST, Year 5, Week 48, n=2070.0 ± 11.58
AST, Year 6, Week 8, n=205-0.4 ± 9.04
AST, Year 6, Week 16, n=198-0.7 ± 9.83
AST, Year 6, Week 24, n=189-0.9 ± 11.35
AST, Year 6, Week 32, n=192-0.6 ± 11.04
AST, Year 6, Week 40, n=181-0.7 ± 10.56
AST, Year 6, Week 48, n=1860.1 ± 12.21
AST, Year 7, Week 8, n=177-0.2 ± 10.76
AST, Year 7, Week 16, n=1781.0 ± 12.91
AST, Year 7, Week 24, n=1711.5 ± 14.44
AST, Year 7, Week 32, n=1790.5 ± 10.56
AST, Year 7, Week 40, n=1720.4 ± 14.51
AST, Year 7, Week 48, n=1750.2 ± 11.15
AST, Year 8, Week 8, n=1701.0 ± 16.78
AST, Year 8, Week 16, n=1691.0 ± 21.12
AST, Year 8, Week 24, n=1670.5 ± 13.61
AST, Year 8, Week 32, n=1660.7 ± 14.74
AST, Year 8, Week 40, n=1611.4 ± 16.28
AST, Year 8, Week 48, n=1590.2 ± 11.00
AST, Year 9, Week 8, n=1631.6 ± 16.09
AST, Year 9, Week 16, n=1600.8 ± 13.55
AST, Year 9, Week 24, n=1600.3 ± 12.60
AST, Year 9, Week 32, n=1621.3 ± 17.39
AST, Year 9, Week 40, n=1561.0 ± 14.17
AST, Year 9, Week 48, n=1501.5 ± 15.79
AST, Year 10, Week 8, n=1510.0 ± 11.05
AST, Year 10, Week 16, n=1430.1 ± 13.75
AST, Year 10, Week 24, n=1450.1 ± 13.80
AST, Year 10, Week 32, n=1400.5 ± 13.90
AST, Year 10, Week 40, n=137-0.4 ± 13.30
AST, Year 10, Week 48, n=1350.9 ± 14.71
AST, Year 11, Week 8, n=138-0.2 ± 12.04
AST, Year 11, Week 16, n=128-0.1 ± 12.72
AST, Year 11, Week 24, n=129-0.3 ± 12.69
AST, Year 11, Week 32, n=124-1.0 ± 10.03
AST, Year 11, Week 40, n=1240.1 ± 14.28
AST, Year 11, Week 48, n=1071.3 ± 17.70
AST, Year 12, Week 8, n=1090.1 ± 16.11
AST, Year 12, Week 16, n=97-0.5 ± 7.74
AST, Year 12, Week 24, n=851.0 ± 13.58
AST, Year 12, Week 32, n=840.5 ± 11.11
AST, Year 12, Week 40, n=820.2 ± 11.60
AST, Year 12, Week 48, n=72-1.0 ± 12.48
AST, Year 13, Week 8, n=53-2.5 ± 10.00
AST, Year 13, Week 16, n=42-3.4 ± 14.32
AST, Year 13, Week 24, n=200.1 ± 7.94
AST, Year 13, Week 32, n=70.3 ± 4.96
AST, Year 13, Week 40, n=11.0 ± NA
AST, Exit, n=248-0.9 ± 10.19
AST, 8-Week Follow-up, n=220-0.3 ± 11.02
AST, 24-Week Follow-up , n=2003.3 ± 52.99
GGT, Year 1, Week 8, n=2840.6 ± 23.57
GGT, Year 1, Week 16, n=2865.0 ± 32.94
GGT, Year 1, Week 24, n=2926.3 ± 48.10
GGT, Year 1, Week 32, n=2874.9 ± 46.96
GGT, Year 1, Week 40, n=2846.7 ± 55.51
GGT, Year 1, Week 48, n=2875.2 ± 58.66
GGT, Year 2, Week 8, n=2884.6 ± 50.82
GGT, Year 2, Week 16, n=2782.9 ± 37.57
GGT, Year 2, Week 24, n=2734.5 ± 42.01
GGT, Year 2, Week 32, n=2843.8 ± 38.55
GGT, Year 2, Week 40, n=2644.2 ± 41.34
GGT, Year 2, Week 48, n=2695.7 ± 48.48
GGT, Year 3, Week 8, n=2653.9 ± 33.83
GGT, Year 3, Week 16, n=2605.3 ± 44.46
GGT, Year 3, Week 24, n=2444.0 ± 51.58
GGT, Year 3, Week 32, n=2496.7 ± 57.32
GGT, Year 3, Week 40, n=2453.7 ± 29.97
GGT, Year 3, Week 48, n=2441.7 ± 39.47
GGT, Year 4, Week 8, n=2393.1 ± 53.57
GGT, Year 4, Week 16, n=2381.2 ± 36.22
GGT, Year 4, Week 24, n=2263.0 ± 55.72
GGT, Year 4, Week 32, n=2333.4 ± 47.24
GGT, Year 4, Week 40, n=2202.0 ± 40.20
GGT, Year 4, Week 48, n=2182.6 ± 39.26
GGT, Year 5, Week 8, n=2184.8 ± 40.08
GGT, Year 5, Week 16, n=2141.6 ± 41.04
GGT, Year 5, Week 24, n=2113.0 ± 39.90
GGT, Year 5, Week 32, n=2111.7 ± 36.58
GGT, Year 5, Week 40, n=1981.4 ± 41.74
GGT, Year 5, Week 48, n=2073.6 ± 46.10
GGT, Year 6, Week 8, n=2061.9 ± 48.45
GGT, Year 6, Week 16, n=1981.8 ± 37.61
GGT, Year 6, Week 24, n=1901.6 ± 43.58
GGT, Year 6, Week 32, n=1935.9 ± 55.25
GGT, Year 6, Week 40, n=1852.0 ± 34.66
GGT, Year 6, Week 48, n=1862.2 ± 38.05
GGT, Year 7, Week 8, n=1792.3 ± 36.39
GGT, Year 7, Week 16, n=1793.8 ± 43.49
GGT, Year 7, Week 24, n=1734.5 ± 33.15
GGT, Year 7, Week 32, n=1804.6 ± 41.12
GGT, Year 7, Week 40, n=1754.9 ± 36.94
GGT, Year 7, Week 48, n=1754.9 ± 40.27
GGT, Year 8, Week 8, n=1717.0 ± 41.53
GGT, Year 8, Week 16, n=1706.8 ± 41.70
GGT, Year 8, Week 24, n=1688.5 ± 48.16
GGT, Year 8, Week 32, n=1688.5 ± 44.76
GGT, Year 8, Week 40, n=1623.5 ± 38.79
GGT, Year 8, Week 48, n=1597.3 ± 37.89
GGT, Year 9, Week 8, n=1647.1 ± 39.19
GGT, Year 9, Week 16, n=1625.0 ± 37.32
GGT, Year 9, Week 24, n=1612.6 ± 33.54
GGT, Year 9, Week 32, n=1632.4 ± 29.43
GGT, Year 9, Week 40, n=1562.9 ± 32.70
GGT, Year 9, Week 48, n=1514.5 ± 33.25
GGT, Year 10, Week 8, n=1522.7 ± 28.57
GGT, Year 10, Week 16, n=1434.5 ± 33.50
GGT, Year 10, Week 24, n=1453.0 ± 31.51
GGT, Year 10, Week 32, n=1424.2 ± 31.74
GGT, Year 10, Week 40, n=1382.9 ± 31.64
GGT, Year 10, Week 48, n=1355.9 ± 29.18
GGT, Year 11, Week 8, n=1383.8 ± 33.68
GGT, Year 11, Week 16, n=1284.8 ± 32.72
GGT, Year 11, Week 24, n=1303.4 ± 26.42
GGT, Year 11, Week 32, n=1252.8 ± 29.33
GGT, Year 11, Week 40, n=1242.5 ± 28.02
GGT, Year 11, Week 48, n=1087.0 ± 37.14
GGT, Year 12, Week 8, n=1107.9 ± 37.22
GGT, Year 12, Week 16, n=972.3 ± 19.42
GGT, Year 12, Week 24, n=875.2 ± 32.26
GGT, Year 12, Week 32, n=844.4 ± 26.44
GGT, Year 12, Week 40, n=822.0 ± 27.54
GGT, Year 12, Week 48, n=721.6 ± 18.01
GGT, Year 13, Week 8, n=532.4 ± 18.65
GGT, Year 13, Week 16, n=428.8 ± 57.73
GGT, Year 13, Week 24, n=2010.5 ± 40.97
GGT, Year 13, Week 32, n=76.1 ± 19.07
GGT, Year 13, Week 40, n=13.0 ± NA
GGT, Exit, n=2481.8 ± 53.15
GGT, 8-Week Follow-up, n=2203.3 ± 24.91
GGT, 24-Week Follow-up , n=2003.1 ± 55.20
LD, Year 1, Week 8, n=281-0.4 ± 23.41
LD, Year 1, Week 16, n=283-0.4 ± 29.97
LD, Year 1, Week 24, n=287-0.8 ± 31.43
LD, Year 1, Week 32, n=283-5.1 ± 26.19
LD, Year 1, Week 40, n=282-3.6 ± 27.97
LD, Year 1, Week 48, n=284-4.5 ± 28.66
LD, Year 2, Week 8, n=288-1.7 ± 28.26
LD, Year 2, Week 16, n=275-0.3 ± 30.16
LD, Year 2, Week 24, n=269-0.4 ± 29.91
LD, Year 2, Week 32, n=284-2.1 ± 34.05
LD, Year 2, Week 40, n=261-4.7 ± 29.69
LD, Year 2, Week 48, n=267-1.9 ± 29.81
LD, Year 3, Week 8, n=262-5.1 ± 29.71
LD, Year 3, Week 16, n=258-2.9 ± 31.27
LD, Year 3, Week 24, n=2411.0 ± 32.12
LD, Year 3, Week 32, n=2450.9 ± 36.26
LD, Year 3, Week 40, n=2421.3 ± 34.00
LD, Year 3, Week 48, n=2394.5 ± 35.46
LD, Year 4, Week 8, n=2373.9 ± 36.59
LD, Year 4, Week 16, n=2354.2 ± 38.16
LD, Year 4, Week 24, n=2253.8 ± 38.59
LD, Year 4, Week 32, n=2306.3 ± 37.05
LD, Year 4, Week 40, n=2182.0 ± 37.75
LD, Year 4, Week 48, n=2148.5 ± 39.80
LD, Year 5, Week 8, n=2176.7 ± 39.42
LD, Year 5, Week 16, n=2137.9 ± 42.94
LD, Year 5, Week 24, n=2067.6 ± 40.54
LD, Year 5, Week 32, n=2117.0 ± 36.84
LD, Year 5, Week 40, n=1965.0 ± 40.29
LD, Year 5, Week 48, n=2076.1 ± 37.15
LD, Year 6, Week 8, n=2058.4 ± 36.82
LD, Year 6, Week 16, n=1986.4 ± 36.98
LD, Year 6, Week 24, n=1895.2 ± 38.41
LD, Year 6, Week 32, n=1926.1 ± 34.07
LD, Year 6, Week 40, n=1816.0 ± 39.60
LD, Year 6, Week 48, n=1862.9 ± 39.20
LD, Year 7, Week 8, n=1774.8 ± 37.46
LD, Year 7, Week 16, n=1783.3 ± 37.02
LD, Year 7, Week 24, n=1718.9 ± 39.81
LD, Year 7, Week 32, n=1794.7 ± 40.87
LD, Year 7, Week 40, n=1726.8 ± 39.49
LD, Year 7, Week 48, n=1753.5 ± 37.36
LD, Year 8, Week 8, n=1703.0 ± 36.88
LD, Year 8, Week 16, n=1692.4 ± 36.06
LD, Year 8, Week 24, n=1672.4 ± 37.06
LD, Year 8, Week 32, n=1667.4 ± 36.86
LD, Year 8, Week 40, n=1612.1 ± 35.04
LD, Year 8, Week 48, n=1596.6 ± 39.01
LD, Year 9, Week 8, n=1634.5 ± 36.82
LD, Year 9, Week 16, n=1601.8 ± 36.46
LD, Year 9, Week 24, n=1603.9 ± 35.65
LD, Year 9, Week 32, n=1623.8 ± 37.69
LD, Year 9, Week 40, n=1567.5 ± 39.97
LD, Year 9, Week 48, n=1505.8 ± 39.05
LD, Year 10, Week 8, n=1514.5 ± 42.02
LD, Year 10, Week 16, n=1432.5 ± 34.44
LD, Year 10, Week 24, n=1452.1 ± 38.80
LD, Year 10, Week 32, n=1405.4 ± 41.37
LD, Year 10, Week 40, n=1377.6 ± 37.07
LD, Year 10, Week 48, n=1355.4 ± 37.12
LD, Year 11, Week 8, n=1386.1 ± 45.90
LD, Year 11, Week 16, n=1282.4 ± 38.69
LD, Year 11, Week 24, n=1295.5 ± 42.10
LD, Year 11, Week 32, n=1240.8 ± 44.21
LD, Year 11, Week 40, n=1242.1 ± 41.89
LD, Year 11, Week 48, n=1078.8 ± 40.94
LD, Year 12, Week 8, n=1095.9 ± 51.46
LD, Year 12, Week 16, n=975.2 ± 45.81
LD, Year 12, Week 24, n=856.6 ± 47.18
LD, Year 12, Week 32, n=842.0 ± 47.59
LD, Year 12, Week 40, n=822.2 ± 47.71
LD, Year 12, Week 48, n=721.9 ± 61.71
LD, Year 13, Week 8, n=53-0.3 ± 31.81
LD, Year 13, Week 16, n=42-6.3 ± 38.99
LD, Year 13, Week 24, n=200.3 ± 51.57
LD, Year 13, Week 32, n=7-27.3 ± 63.45
LD, Year 13, Week 40, n=126.0 ± NA
LD, Exit, n=2486.4 ± 44.59
LD, 8-Week Follow-up, n=2207.7 ± 51.21
LD, 24-Week Follow-up , n=2006.5 ± 49.90
SecondaryPercentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points

SRI response was assessed at Week 16, 32, and 48 during Year 1 to 12 and Week 16 and 32 during Year 13. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. SRI response is defined as:\>=4 point reduction from the Baseline in safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of \<0.30 points from the Baseline) in Physician's Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the Baseline at the time of assessment.

Time frame:
Approximately up to 13 years
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving SLE Responder Index (SRI) Response at Indicated Time Points
Percentage of participantsBelimumab 10 mg/kg IV
Year 1 , Week 16, n=26832.8
Year 1 , Week 32, n=26941.6
Year 1 , Week 48, n=26647.0
Year 2 , Week 16, n=26650.8
Year 2, Week 32, n=26256.5
Year 2, Week 48, n=25157.0
Year 3, Week 16, n=24559.2
Year 3, Week 32, n=23554.5
Year 3, Week 48, n=22557.8
Year 4, Week 16, n=22556.9
Year 4, Week 32, n=21256.6
Year 4, Week 48, n=20659.7
Year 5, Week 16, n=19865.7
Year 5, Week 32, n=19464.4
Year 5, Week 48, n=19262.5
Year 6, Week 16, n=18264.8
Year 6, Week 32, n=18165.7
Year 6, Week 48, n=17663.6
Year 7, Week 16, n=16963.9
Year 7, Week 32, n=17369.4
Year 7, Week 48, n=16269.1
Year 8, Week 16, n=16168.3
Year 8, Week 32, n=15867.7
Year 8, Week 48, n=14962.4
Year 9, Week 16, n=15164.2
Year 9, Week 32, n=14866.2
Year 9, Week 48, n=14266.2
Year 10, Week 16, n=14166.0
Year 10, Week 32, n=13566.7
Year 10, Week 48, n=12665.1
Year 11, Week 16, n=12573.6
Year 11, Week 32, n=12064.2
Year 11, Week 48, n=10965.1
Year 12, Week 16, n=10069.0
Year 12, Week 32, n=9075.6
Year 12, Week 48, n=7171.8
Year 13, Week 16, n=4273.8
Year 13, Week 32, n=757.1
SecondaryObserved Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points

Anti-double stranded DNA levels in participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.

Time frame:
Approximately up to 13 years
Reported as:
Median · International units (IU)/milliliter (mL)
Observed Anti-double Stranded DNA Levels in Participants Positive at Baseline at Indicated Time Points
International units (IU)/milliliter (mL)Belimumab 10 mg/kg IV
Baseline, n=149147.00 (31.0 to 418.0)
Year 1 , Week 16, n=147114.00 (6.0 to 418.0)
Year 1 , Week 32, n=147113.00 (5.0 to 349.0)
Year 1 , Week 48, n=144106.50 (5.0 to 464.0)
Year 2 , Week 16, n=14493.50 (3.0 to 328.0)
Year 2, Week 32, n=14385.00 (5.0 to 271.0)
Year 2, Week 48, n=12883.50 (5.0 to 271.0)
Year 3, Week 16, n=13483.50 (5.0 to 271.0)
Year 3, Week 32, n=12776.00 (5.0 to 271.0)
Year 3, Week 48, n=12573.00 (5.0 to 271.0)
Year 4, Week 16, n=12480.00 (5.0 to 271.0)
Year 4, Week 32, n=12072.00 (5.0 to 271.0)
Year 4, Week 48, n=11666.50 (5.0 to 271.0)
Year 5, Week 16, n=11254.00 (5.0 to 271.0)
Year 5, Week 32, n=11161.00 (5.0 to 271.0)
Year 5, Week 48, n=10849.50 (5.0 to 271.0)
Year 6, Week 16, n=10541.00 (5.0 to 271.0)
Year 6, Week 32, n=10144.00 (5.0 to 271.0)
Year 6, Week 48, n=9936.00 (5.0 to 271.0)
Year 7, Week 16, n=8941.00 (5.0 to 271.0)
Year 7, Week 32, n=9436.50 (5.0 to 271.0)
Year 7, Week 48, n=8938.00 (5.0 to 586.0)
Year 8, Week 16, n=8730.00 (5.0 to 468.0)
Year 8, Week 32, n=8943.00 (5.0 to 890.0)
Year 8, Week 48, n=8027.50 (5.0 to 1826.0)
Year 9, Week 16, n=8532.00 (5.0 to 745.0)
Year 9, Week 32, n=8320.00 (5.0 to 2120.0)
Year 9, Week 48, n=7716.00 (5.0 to 423.0)
Year 10, Week 16, n=7718.00 (5.0 to 593.0)
Year 10, Week 32, n=7522.00 (5.0 to 607.0)
Year 10, Week 48, n=7118.00 (5.0 to 500.0)
Year 11, Week 16, n=6717.00 (5.0 to 445.0)
Year 11, Week 32, n=6615.00 (5.0 to 611.0)
Year 11, Week 48, n=6311.00 (5.0 to 546.0)
Year 12, Week 16, n=5411.00 (5.0 to 330.0)
Year 12, Week 32, n=478.00 (5.0 to 219.0)
Year 12, Week 48, n=3914.00 (5.0 to 402.0)
Year 13, Week 16, n=2013.50 (5.0 to 549.0)
Year 13, Week 32, n=37.00 (5.0 to 8.0)
Exit, n=12431.00 (5.0 to 1073.0)
SecondaryMedian Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points

Anti-double stranded DNA levels for participants positive at Baseline were assessed at Baseline, Week 16, 32, and 48 during Year 1 to 11, Week 16 and 32 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Median · Percent change
Median Percent Change From Baseline in Anti-double Stranded DNA in Participants Positive at Baseline at Indicated Time Points
Percent changeBelimumab 10 mg/kg IV
Year 1 , Week 16, n=147-16.26 (-87.5 to 252.1)
Year 1 , Week 32, n=147-25.57 (-93.8 to 168.8)
Year 1 , Week 48, n=144-30.17 (-93.4 to 177.1)
Year 2 , Week 16, n=144-30.26 (-96.3 to 344.3)
Year 2, Week 32, n=143-31.25 (-90.0 to 224.6)
Year 2, Week 48, n=128-41.63 (-93.8 to 133.6)
Year 3, Week 16, n=134-41.10 (-94.1 to 232.4)
Year 3, Week 32, n=127-44.44 (-94.8 to 208.3)
Year 3, Week 48, n=125-45.29 (-95.4 to 133.6)
Year 4, Week 16, n=124-47.33 (-95.2 to 243.0)
Year 4, Week 32, n=120-48.53 (-95.4 to 243.0)
Year 4, Week 48, n=116-48.45 (-96.7 to 243.0)
Year 5, Week 16, n=112-53.97 (-96.1 to 243.0)
Year 5, Week 32, n=111-47.27 (-96.7 to 411.3)
Year 5, Week 48, n=108-57.76 (-96.7 to 453.1)
Year 6, Week 16, n=105-60.00 (-97.4 to 361.2)
Year 6, Week 32, n=101-65.38 (-96.8 to 411.3)
Year 6, Week 48, n=99-66.42 (-97.7 to 243.0)
Year 7, Week 16, n=89-64.14 (-97.2 to 243.0)
Year 7, Week 32, n=94-68.93 (-96.7 to 243.0)
Year 7, Week 48, n=89-68.63 (-98.1 to 182.3)
Year 8, Week 16, n=87-73.77 (-98.1 to 111.7)
Year 8, Week 32, n=89-71.02 (-98.3 to 249.0)
Year 8, Week 48, n=80-76.62 (-98.1 to 1326.6)
Year 9, Week 16, n=85-75.00 (-97.4 to 1452.1)
Year 9, Week 32, n=83-80.13 (-98.1 to 4316.7)
Year 9, Week 48, n=77-81.38 (-97.7 to 152.1)
Year 10, Week 16, n=77-81.25 (-97.4 to 363.3)
Year 10, Week 32, n=75-78.11 (-98.1 to 175.0)
Year 10, Week 48, n=71-81.13 (-98.4 to 124.2)
Year 11, Week 16, n=67-82.86 (-98.4 to 99.6)
Year 11, Week 32, n=66-85.39 (-97.7 to 377.3)
Year 11, Week 48, n=63-85.29 (-98.4 to 326.6)
Year 12, Week 16, n=54-85.39 (-97.8 to 132.8)
Year 12, Week 32, n=47-88.52 (-98.4 to 71.1)
Year 12, Week 48, n=39-87.76 (-98.4 to 135.2)
Year 13, Week 16, n=20-86.87 (-98.4 to 192.0)
Year 13, Week 32, n=3-91.49 (-98.4 to -86.8)
Exit, n=124-75.68 (-98.4 to 257.7)
SecondaryObserved Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points

Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.

Time frame:
Approximately up to 13 years
Reported as:
Median · grams per liter
Observed Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points
grams per literBelimumab 10 mg/kg IV
C3, Baseline, n=880.77 (0.4 to 0.9)
C3, Year 1, Week 16, n=860.81 (0.5 to 1.3)
C3, Year 1, Week 32, n=880.81 (0.2 to 1.5)
C3, Year 1, Week 48, n=860.82 (0.5 to 1.3)
C3, Year 2, Week 16, n=830.82 (0.6 to 1.4)
C3, Year 2, Week 32, n=830.84 (0.5 to 1.4)
C3, Year 2, Week 48, n=760.88 (0.5 to 1.3)
C3, Year 3, Week 16, n=750.88 (0.3 to 1.3)
C3, Year 3, Week 32, n=750.90 (0.5 to 1.4)
C3, Year 3, Week 48, n=730.90 (0.3 to 1.5)
C3, Year 4, Week 16, n=740.93 (0.5 to 1.4)
C3, Year 4, Week 32, n=720.96 (0.4 to 1.3)
C3, Year 4, Week 48, n=670.93 (0.5 to 1.4)
C3, Year 5, Week 16, n=650.94 (0.4 to 1.5)
C3, Year 5, Week 32, n=650.97 (0.4 to 1.5)
C3, Year 5, Week 48, n=651.01 (0.4 to 1.5)
C3, Year 6, Week 16, n=611.02 (0.4 to 1.4)
C3, Year 6, Week 32, n=591.03 (0.5 to 1.5)
C3, Year 6, Week 48, n=571.00 (0.4 to 1.5)
C3, Year 7, Week 16, n=500.94 (0.5 to 1.6)
C3, Year 7, Week 32, n=540.99 (0.2 to 1.5)
C3, Year 7, Week 48, n=520.98 (0.3 to 1.7)
C3, Year 8, Week 16, n=460.98 (0.3 to 1.6)
C3, Year 8, Week 32, n=481.01 (0.5 to 1.6)
C3, Year 8, Week 48, n=451.01 (0.6 to 2.0)
C3, Year 9, Week 16, n=491.02 (0.5 to 2.1)
C3, Year 9, Week 32, n=460.95 (0.5 to 2.0)
C3, Year 9, Week 48, n=470.98 (0.5 to 1.9)
C3, Year 10, Week 16, n=430.91 (0.4 to 1.6)
C3, Year 10, Week 32, n=450.99 (0.3 to 2.0)
C3, Year 10, Week 48, n=440.90 (0.5 to 1.9)
C3, Year 11, Week 16, n=430.97 (0.4 to 1.7)
C3, Year 11, Week 32, n=420.99 (0.6 to 1.9)
C3, Year 11, Week 48, n=370.88 (0.5 to 1.7)
C3, Year 12, Week 16, n=310.92 (0.5 to 1.9)
C3, Year 12, Week 32, n=280.94 (0.5 to 1.7)
C3, Year 12, Week 48, n=280.84 (0.4 to 1.6)
C3, Year 13, Week 16, n=120.95 (0.6 to 1.6)
C3, Year 13, Week 32, n=20.99 (0.8 to 1.2)
C3, Exit, n=740.98 (0.4 to 1.6)
C4, Baseline, n=1160.10 (0.0 to 0.2)
C4, Year 1, Week 16, n=1120.12 (0.0 to 0.4)
C4, Year 1, Week 32, n=1130.13 (0.0 to 0.3)
C4, Year 1, Week 48, n=1120.14 (0.0 to 0.3)
C4, Year 2, Week 16, n=1100.15 (0.0 to 0.3)
C4, Year 2, Week 32, n=1100.15 (0.0 to 0.3)
C4, Year 2, Week 48, n=1030.17 (0.0 to 0.5)
C4, Year 3, Week 16, n=1010.16 (0.0 to 0.4)
C4, Year 3, Week 32, n=1000.17 (0.0 to 0.5)
C4, Year 3, Week 48, n=970.17 (0.0 to 0.5)
C4, Year 4, Week 16, n=970.17 (0.0 to 0.4)
C4, Year 4, Week 32, n=930.17 (0.0 to 0.4)
C4, Year 4, Week 48, n=900.18 (0.0 to 0.4)
C4, Year 5, Week 16, n=830.18 (0.0 to 0.4)
C4, Year 5, Week 32, n=810.19 (0.0 to 0.4)
C4, Year 5, Week 48, n=810.19 (0.0 to 0.4)
C4, Year 6, Week 16, n=780.20 (0.0 to 0.4)
C4, Year 6, Week 32, n=740.19 (0.0 to 0.4)
C4, Year 6, Week 48, n=710.19 (0.0 to 0.4)
C4, Year 7, Week 16, n=660.19 (0.0 to 0.4)
C4, Year 7, Week 32, n=670.20 (0.0 to 0.4)
C4, Year 7, Week 48, n=650.20 (0.0 to 0.5)
C4, Year 8, Week 16, n=610.20 (0.0 to 0.4)
C4, Year 8, Week 32, n=620.20 (0.0 to 0.4)
C4, Year 8, Week 48, n=560.20 (0.1 to 0.6)
C4, Year 9, Week 16, n=620.20 (0.0 to 0.5)
C4, Year 9, Week 32, n=590.19 (0.0 to 0.4)
C4, Year 9, Week 48, n=550.19 (0.0 to 0.4)
C4, Year 10, Week 16, n=540.2 (0.1 to 0.4)
C4, Year 10, Week 32, n=520.19 (0.0 to 0.5)
C4, Year 10, Week 48, n=510.18 (0.0 to 0.4)
C4, Year 11, Week 16, n=500.2 (0.1 to 0.4)
C4, Year 11, Week 32, n=480.20 (0.1 to 0.4)
C4, Year 11, Week 48, n=440.21 (0.1 to 0.4)
C4, Year 12, Week 16, n=410.18 (0.1 to 0.4)
C4, Year 12, Week 32, n=370.21 (0.1 to 0.4)
C4, Year 12, Week 48, n=310.18 (0.1 to 0.3)
C4, Year 13, Week 16, n=160.21 (0.1 to 0.4)
C4, Year 13, Week 32, n=30.29 (0.2 to 0.4)
C4, Exit, n=930.18 (0.0 to 0.4)
SecondaryMedian Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points

Complement C3 and C4 levels were assessed in participants low at Baseline at Baseline, Week 16, 32, and 48 during Year 1 to 12, Week 16 and 32 during Year 13, and Exit visit. The Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Median · Percent change
Median Percent Change From Baseline in Complement C3 and C4 Levels in Participants Low at Baseline at Indicated Time Points
Percent changeBelimumab 10 mg/kg IV
C3, Year 1, Week 16, n=868.87 (-32.1 to 72.1)
C3, Year 1, Week 32, n=888.43 (-68.0 to 68.5)
C3, Year 1, Week 48, n=8611.71 (-33.3 to 56.5)
C3, Year 2, Week 16, n=8313.10 (-29.5 to 83.8)
C3, Year 2, Week 32, n=8313.21 (-19.5 to 135.3)
C3, Year 2, Week 48, n=7617.16 (-25.0 to 74.6)
C3, Year 3, Week 16, n=7515.48 (-50.8 to 129.4)
C3, Year 3, Week 32, n=7519.05 (-42.4 to 176.0)
C3, Year 3, Week 48, n=7316.46 (-61.7 to 182.0)
C3, Year 4, Week 16, n=7422.51 (-34.2 to 178.0)
C3, Year 4, Week 32, n=7230.41 (-56.8 to 158.0)
C3, Year 4, Week 48, n=6726.58 (-34.1 to 148.0)
C3, Year 5, Week 16, n=6527.38 (-47.7 to 156.0)
C3, Year 5, Week 32, n=6523.17 (-39.5 to 148.0)
C3, Year 5, Week 48, n=6535.96 (-26.2 to 129.4)
C3, Year 6, Week 16, n=6129.41 (-20.8 to 158.0)
C3, Year 6, Week 32, n=5931.03 (-21.7 to 138.0)
C3, Year 6, Week 48, n=5728.24 (-36.7 to 151.0)
C3, Year 7, Week 16, n=5020.95 (-32.5 to 149.0)
C3, Year 7, Week 32, n=5429.25 (-63.8 to 168.0)
C3, Year 7, Week 48, n=5239.88 (-51.7 to 186.0)
C3, Year 8, Week 16, n=4628.35 (-62.5 to 167.3)
C3, Year 8, Week 32, n=4830.88 (-34.2 to 138.8)
C3, Year 8, Week 48, n=4532.88 (-34.5 to 200.0)
C3, Year 9, Week 16, n=4936.99 (-45.9 to 208.8)
C3, Year 9, Week 32, n=4621.76 (-26.1 to 186.8)
C3, Year 9, Week 48, n=4723.29 (-34.1 to 180.0)
C3, Year 10, Week 16, n=4322.35 (-35.6 to 206.0)
C3, Year 10, Week 32, n=4523.81 (-60.7 to 186.8)
C3, Year 10, Week 48, n=4426.90 (-38.6 to 172.1)
C3, Year 11, Week 16, n=4326.97 (-48.5 to 146.0)
C3, Year 11, Week 32, n=4230.36 (-36.4 to 148.7)
C3, Year 11, Week 48, n=3720.78 (-39.0 to 149.3)
C3, Year 12, Week 16, n=3115.58 (-43.2 to 181.2)
C3, Year 12, Week 32, n=2826.39 (-39.5 to 123.7)
C3, Year 12, Week 48, n=2814.1 (-58.0 to 114.5)
C3, Year 13, Week 16, n=1235.33 (-8.3 to 97.2)
C3, Year 13, Week 32, n=222.04 (9.6 to 34.5)
C3, Exit, n=7429.19 (-48.8 to 152.6)
C4, Year 1, Week 16, n=11225.00 (-57.1 to 200.0)
C4, Year 1, Week 32, n=11333.33 (-70.0 to 180.0)
C4, Year 1, Week 48, n=11234.52 (-60.0 to 183.3)
C4, Year 2, Week 16, n=11050.00 (-70.0 to 300.0)
C4, Year 2, Week 32, n=11053.33 (-25.0 to 400.0)
C4, Year 2, Week 48, n=10353.85 (-12.5 to 308.3)
C4, Year 3, Week 16, n=10153.33 (-33.3 to 275.0)
C4, Year 3, Week 32, n=10063.39 (-58.3 to 400.0)
C4, Year 3, Week 48, n=9753.33 (-66.7 to 422.2)
C4, Year 4, Week 16, n=9770.00 (-70.0 to 400.0)
C4, Year 4, Week 32, n=9369.23 (-50.0 to 350.0)
C4, Year 4, Week 48, n=9066.67 (-37.5 to 420.0)
C4, Year 5, Week 16, n=8371.43 (-33.3 to 500.0)
C4, Year 5, Week 32, n=8166.67 (-33.3 to 425.0)
C4, Year 5, Week 48, n=8180.00 (-66.7 to 460.0)
C4, Year 6, Week 16, n=7870.33 (-12.5 to 380.0)
C4, Year 6, Week 32, n=7485.71 (-12.5 to 400.0)
C4, Year 6, Week 48, n=71100.0 (-25.0 to 450.0)
C4, Year 7, Week 16, n=6679.29 (-13.3 to 350.0)
C4, Year 7, Week 32, n=6785.71 (-25.0 to 440.0)
C4, Year 7, Week 48, n=65100.0 (-50.0 to 377.8)
C4, Year 8, Week 16, n=6190.00 (-15.4 to 433.3)
C4, Year 8, Week 32, n=6281.67 (-18.2 to 575.5)
C4, Year 8, Week 48, n=5676.36 (-8.3 to 866.7)
C4, Year 9, Week 16, n=6287.86 (-57.1 to 566.7)
C4, Year 9, Week 32, n=5972.73 (-33.3 to 533.3)
C4, Year 9, Week 48, n=5571.43 (-42.9 to 566.7)
C4, Year 10, Week 16, n=5481.82 (-33.3 to 625.0)
C4, Year 10, Week 32, n=5284.52 (-57.1 to 575.0)
C4, Year 10, Week 48, n=5173.33 (-57.1 to 575.0)
C4, Year 11, Week 16, n=5075.71 (-27.3 to 500.0)
C4, Year 11, Week 32, n=4881.67 (-20.0 to 475.0)
C4, Year 11, Week 48, n=44103.33 (-33.3 to 650.0)
C4, Year 12, Week 16, n=4175.0 (-20.0 to 525.0)
C4, Year 12, Week 32, n=37100.0 (-23.1 to 340.0)
C4, Year 12, Week 48, n=3180.0 (-18.2 to 475.0)
C4, Year 13, Week 16, n=16135.0 (0.0 to 400.0)
C4, Year 13, Week 32, n=3190.0 (33.3 to 258.3)
C4, Exit, n=9378.57 (-57.1 to 575.0)
SecondaryPercentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points

Daily prednisone dose reduction was assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13. Percentage of participants with daily prednisone dose reduced to \<=7.5 mg/day from \>7.5 mg/kg at the Baseline are summarized. Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study.

Time frame:
Approximately up to 13 years
Reported as:
Number · Percentage of participants
Percentage of Participants With Daily Prednisone Dose Reduction at Indicated Time Points
Percentage of participantsBelimumab 10 mg/kg IV
Year 1, Week 8, n=910
Year 1, Week 16, n=905.6
Year 1, Week 24, n=9119.8
Year 1, Week 32, n=9119.8
Year 1, Week 40, n=8723.0
Year 1, Week 48, n=8827.3
Year 2, Week 8, n=9028.9
Year 2, Week 16, n=8931.5
Year 2, Week 24, n=9028.9
Year 2, Week 32, n=8834.1
Year 2, Week 40, n=8435.7
Year 2, Week 48, n=8334.9
Year 3, Week 8, n=8135.8
Year 3, Week 16, n=8134.6
Year 3, Week 24, n=7334.2
Year 3, Week 32, n=7736.4
Year 3, Week 40, n=7833.3
Year 3, Week 48, n=7530.7
Year 4, Week 8, n=7240.3
Year 4, Week 16, n=7441.9
Year 4, Week 24, n=7145.1
Year 4, Week 32, n=6937.7
Year 4, Week 40, n=6737.3
Year 4, Week 48, n=6838.2
Year 5, Week 8, n=6741.8
Year 5, Week 16, n=6342.9
Year 5, Week 24, n=6445.3
Year 5, Week 32, n=6538.5
Year 5, Week 40, n=5848.3
Year 5, Week 48, n=6041.7
Year 6, Week 8, n=6144.3
Year 6, Week 16, n=5743.9
Year 6, Week 24, n=5848.3
Year 6, Week 32, n=5944.1
Year 6, Week 40, n=5541.8
Year 6, Week 48, n=5538.2
Year 7, Week 8, n=5246.2
Year 7, Week 16, n=5139.2
Year 7, Week 24, n=5141.2
Year 7, Week 32, n=5139.2
Year 7, Week 40, n=5139.2
Year 7, Week 48, n=5139.2
Year 8, Week 8, n=5040.0
Year 8, Week 16, n=4938.8
Year 8, Week 24, n=5038.0
Year 8, Week 32, n=4936.7
Year 8, Week 40, n=4938.8
Year 8, Week 48, n=4841.7
Year 9, Week 8, n=4839.6
Year 9, Week 16, n=4938.8
Year 9, Week 24, n=4938.8
Year 9, Week 32, n=4839.6
Year 9, Week 40, n=4835.4
Year 9, Week 48, n=4537.8
Year 10, Week 8, n=4637.0
Year 10, Week 16, n=4339.5
Year 10, Week 24, n=4431.8
Year 10, Week 32, n=4431.8
Year 10, Week 40, n=4334.9
Year 10, Week 48, n=4332.6
Year 11, Week 8, n=4436.4
Year 11, Week 16, n=4134.1
Year 11, Week 24, n=4032.5
Year 11, Week 32, n=3935.9
Year 11, Week 40, n=4040.0
Year 11, Week 48, n=3534.3
Year 12, Week 8, n=3534.3
Year 12, Week 16, n=3231.3
Year 12, Week 24, n=2934.5
Year 12, Week 32, n=3040.0
Year 12, Week 40, n=3046.7
Year 12, Week 48, n=2653.8
Year 13, Week 8, n=1947.4
Year 13, Week 16, n=1338.5
Year 13, Week 24, n=650.0
Year 13, Week 32, n=250.0
Year 13, Week 40, n=10.0
SecondaryAbsolute Serum Immunoglobulin G Values at Indicated Time Points

Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study.

Time frame:
Approximately up to 13 years
Reported as:
Median · grams per liter
Absolute Serum Immunoglobulin G Values at Indicated Time Points
grams per literBelimumab 10 mg/kg IV
Baseline, n=29312.90 (3.3 to 39.5)
Year 1, Week 8, n=28812.10 (3.4 to 38.1)
Year 1, Week 16, n=29211.70 (3.3 to 34.3)
Year 1, Week 24, n=29311.60 (3.6 to 48.5)
Year 1, Week 32, n=29111.50 (3.8 to 32.6)
Year 1, Week 40, n=28811.40 (3.5 to 34.6)
Year 1, Week 48, n=28911.50 (3.5 to 33.8)
Year 2, Week 8, n=28611.20 (3.8 to 42.0)
Year 2, Week 16, n=28411.30 (3.2 to 41.7)
Year 2, Week 24, n=28811.55 (3.4 to 35.6)
Year 2, Week 32, n=28411.40 (3.2 to 32.2)
Year 2, Week 40, n=26911.30 (4.0 to 23.8)
Year 2, Week 48, n=26911.30 (3.1 to 24.5)
Year 3, Week 8, n=26511.40 (2.8 to 24.9)
Year 3, Week 16, n=26011.45 (3.2 to 27.2)
Year 3, Week 24, n=24411.15 (3.5 to 30.9)
Year 3, Week 32, n=25011.40 (3.2 to 27.0)
Year 3, Week 40, n=24611.70 (2.8 to 25.8)
Year 3, Week 48, n=24411.70 (3.3 to 28.3)
Year 4, Week 8, n=24011.50 (3.0 to 26.9)
Year 4, Week 16, n=24011.60 (3.0 to 28.5)
Year 4, Week 24, n=22811.35 (3.0 to 26.3)
Year 4, Week 32, n=23311.20 (3.0 to 24.0)
Year 4, Week 40, n=22011.40 (3.0 to 24.6)
Year 4, Week 48, n=22211.35 (3.0 to 26.8)
Year 5, Week 8, n=21811.45 (2.5 to 28.1)
Year 5, Week 16, n=21511.00 (2.8 to 26.7)
Year 5, Week 24, n=21210.80 (2.3 to 29.2)
Year 5, Week 32, n=21111.00 (2.8 to 27.1)
Year 5, Week 40, n=19911.10 (2.6 to 31.3)
Year 5, Week 48, n=20910.80 (2.7 to 28.2)
Year 6, Week 8, n=20710.80 (2.9 to 25.0)
Year 6, Week 16, n=19910.30 (2.7 to 23.6)
Year 6, Week 24, n=19210.20 (2.7 to 26.7)
Year 6, Week 32, n=19710.30 (2.7 to 24.9)
Year 6, Week 40, n=18610.30 (2.4 to 24.4)
Year 6, Week 48, n=1889.78 (2.1 to 23.7)
Year 7, Week 8, n=18310.10 (2.2 to 19.5)
Year 7, Week 16, n=18210.15 (2.0 to 24.6)
Year 7, Week 24, n=17610.10 (2.1 to 26.3)
Year 7, Week 32, n=1829.98 (2.0 to 23.4)
Year 7, Week 40, n=1779.85 (1.7 to 23.2)
Year 7, Week 48, n=1779.64 (1.7 to 22.6)
Year 8, Week 8, n=1739.64 (2.6 to 26.3)
Year 8, Week 16, n=1729.40 (2.0 to 22.7)
Year 8, Week 24, n=1699.67 (3.5 to 23.6)
Year 8, Week 32, n=1709.72 (2.9 to 18.8)
Year 8, Week 40, n=1639.41 (2.2 to 22.6)
Year 8, Week 48, n=1619.42 (2.3 to 22.4)
Year 9, Week 8, n=1679.41 (2.0 to 24.6)
Year 9, Week 16, n=1639.24 (4.0 to 21.7)
Year 9, Week 24, n=1639.39 (1.6 to 25.6)
Year 9, Week 32, n=1649.25 (2.0 to 24.2)
Year 9, Week 40, n=1599.06 (2.8 to 24.5)
Year 9, Week 48, n=1519.01 (3.0 to 23.9)
Year 10, Week 8, n=1539.02 (3.2 to 25.4)
Year 10, Week 16, n=1468.96 (2.7 to 27.3)
Year 10, Week 24, n=1468.98 (2.7 to 26.6)
Year 10, Week 32, n=1428.97 (2.4 to 23.1)
Year 10, Week 40, n=1389.09 (0.3 to 25.7)
Year 10, Week 48, n=1379.25 (2.6 to 26.3)
Year 11, Week 8, n=1399.54 (2.3 to 24.1)
Year 11, Week 16, n=1299.36 (2.5 to 15.3)
Year 11, Week 24, n=1319.53 (2.5 to 23.9)
Year 11, Week 32, n=1289.46 (2.5 to 23.0)
Year 11, Week 40, n=1249.68 (2.3 to 16.9)
Year 11, Week 48, n=1089.41 (2.6 to 16.8)
Year 12, Week 8, n=1118.92 (2.4 to 18.9)
Year 12, Week 16, n=999.55 (2.2 to 17.0)
Year 12, Week 24, n=879.33 (3.0 to 17.0)
Year 12, Week 32, n=889.19 (2.1 to 17.1)
Year 12, Week 40, n=848.79 (1.1 to 16.0)
Year 12, Week 48, n=739.39 (3.2 to 15.6)
Year 13, Week 8, n=539.62 (2.6 to 15.6)
Year 13, Week 16, n=439.40 (2.6 to 16.4)
Year 13, Week 24, n=209.77 (2.7 to 14.6)
Year 13, Week 32, n=710.60 (6.8 to 11.2)
Year 13, Week 40, n=111.50 (11.5 to 11.5)
Exit, n=2489.62 (1.8 to 23.5)
8-Week follow-up, n=2229.88 (1.8 to 30.3)
24-Week follow-up, n=2009.89 (1.3 to 29.1)
SecondaryMedian Percent Change From Baseline in Immunoglobulin G at Indicated Time Points

Serum immunoglobulin G values were assessed at Baseline, Week 8, 16, 24, 32, 40, and 48 during Year 1 to 12 and Week 8, 16, 24, 32, and 40 during Year 13, Exit visit and at follow-up (up to 8 weeks and 24 weeks post last infusion). Baseline is defined as the last available value prior to belimumab start date, for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. For Year 1, Baseline included Extension Year 1 Day 0 values for MITT participants treated with placebo in the parent study, and the last pre-treatment value in the parent study for MITT participants treated with belimumab in the parent study. Percent change from Baseline is defined as the percentage of the difference between the post-dose post-Baseline visit value and the Baseline value.

Time frame:
Baseline and approximately up to 13 years
Reported as:
Median · Percent change
Median Percent Change From Baseline in Immunoglobulin G at Indicated Time Points
Percent changeBelimumab 10 mg/kg IV
Year 1, Week 8, n=285-6.09 (-46.4 to 116.5)
Year 1, Week 16, n=289-7.69 (-47.7 to 82.4)
Year 1, Week 24, n=290-8.78 (-69.6 to 165.0)
Year 1, Week 32, n=288-8.84 (-47.6 to 41.6)
Year 1, Week 40, n=285-10.32 (-44.4 to 32.2)
Year 1, Week 48, n=286-9.34 (-46.3 to 33.8)
Year 2, Week 8, n=283-11.40 (-46.0 to 43.3)
Year 2, Week 16, n=281-10.76 (-50.8 to 47.3)
Year 2, Week 24, n=285-11.19 (-51.7 to 66.3)
Year 2, Week 32, n=281-11.40 (-52.9 to 54.0)
Year 2, Week 40, n=266-10.29 (-49.9 to 93.0)
Year 2, Week 48, n=267-10.54 (-58.0 to 103.0)
Year 3, Week 8, n=263-10.28 (-50.4 to 62.9)
Year 3, Week 16, n=258-9.92 (-53.3 to 52.9)
Year 3, Week 24, n=242-9.77 (-56.6 to 60.3)
Year 3, Week 32, n=248-8.93 (-52.0 to 45.7)
Year 3, Week 40, n=244-8.04 (-54.9 to 46.3)
Year 3, Week 48, n=242-10.40 (-52.3 to 45.0)
Year 4, Week 8, n=238-10.70 (-55.3 to 46.2)
Year 4, Week 16, n=238-10.77 (-54.9 to 145.1)
Year 4, Week 24, n=226-11.73 (-72.6 to 37.5)
Year 4, Week 32, n=231-10.99 (-53.5 to 48.2)
Year 4, Week 40, n=218-10.47 (-54.9 to 47.7)
Year 4, Week 48, n=220-11.69 (-59.2 to 57.3)
Year 5, Week 8, n=216-13.20 (-61.8 to 45.6)
Year 5, Week 16, n=213-14.62 (-64.2 to 45.5)
Year 5, Week 24, n=210-14.61 (-59.9 to 89.6)
Year 5, Week 32, n=209-13.24 (-54.5 to 29.7)
Year 5, Week 40, n=197-15.97 (-54.8 to 42.4)
Year 5, Week 48, n=207-15.47 (-57.0 to 38.6)
Year 6, Week 8, n=205-17.13 (-73.7 to 40.9)
Year 6, Week 16, n=197-18.16 (-75.0 to 32.6)
Year 6, Week 24, n=190-18.67 (-64.5 to 36.4)
Year 6, Week 32, n=195-19.83 (-65.0 to 42.4)
Year 6, Week 40, n=184-19.84 (-61.9 to 26.6)
Year 6, Week 48, n=186-22.36 (-79.4 to 39.2)
Year 7, Week 8, n=181-21.26 (-64.4 to 29.4)
Year 7, Week 16, n=180-21.22 (-68.7 to 45.0)
Year 7, Week 24, n=175-21.39 (-71.5 to 39.9)
Year 7, Week 32, n=180-22.03 (-71.8 to 45.5)
Year 7, Week 40, n=175-22.31 (-71.7 to 24.5)
Year 7, Week 48, n=175-22.20 (-69.0 to 25.4)
Year 8, Week 8, n=171-24.44 (-74.3 to 46.9)
Year 8, Week 16, n=170-25.51 (-76.3 to 26.6)
Year 8, Week 24, n=167-24.91 (-76.6 to 32.4)
Year 8, Week 32, n=168-24.48 (-76.3 to 59.9)
Year 8, Week 40, n=161-25.50 (-76.8 to 87.8)
Year 8, Week 48, n=159-24.58 (-76.0 to 78.9)
Year 9, Week 8, n=165-25.41 (-77.8 to 100.4)
Year 9, Week 16, n=161-25.44 (-80.6 to 23.7)
Year 9, Week 24, n=161-27.23 (-78.8 to 155.8)
Year 9, Week 32, n=162-26.92 (-79.6 to 168.3)
Year 9, Week 40, n=157-27.63 (-78.9 to 164.8)
Year 9, Week 48, n=149-26.48 (-79.4 to 184.4)
Year 10, Week 8, n=151-28.65 (-78.7 to 125.4)
Year 10, Week 16, n=144-28.45 (-74.0 to 130.8)
Year 10, Week 24, n=144-28.78 (-73.8 to 211.3)
Year 10, Week 32, n=140-27.98 (-74.4 to 161.2)
Year 10, Week 40, n=137-28.57 (-97.6 to 98.6)
Year 10, Week 48, n=136-28.86 (-72.9 to 164.8)
Year 11, Week 8, n=138-28.91 (-71.9 to 61.7)
Year 11, Week 16, n=128-29.34 (-69.8 to 48.1)
Year 11, Week 24, n=130-29.64 (-68.0 to 180.9)
Year 11, Week 32, n=127-29.50 (-67.6 to 72.5)
Year 11, Week 40, n=123-27.58 (-68.9 to 202.3)
Year 11, Week 48, n=107-27.13 (-67.0 to 200.5)
Year 12, Week 8, n=110-29.27 (-68.5 to 220.2)
Year 12, Week 16, n=98-30.30 (-70.5 to 14.4)
Year 12, Week 24, n=86-30.25 (-66.0 to 28.5)
Year 12, Week 32, n=87-30.72 (-72.6 to 12.2)
Year 12, Week 40, n=83-32.96 (-96.4 to 9.9)
Year 12, Week 48, n=72-31.72 (-65.5 to 13.2)
Year 13, Week 8, n=52-32.23 (-65.7 to 5.3)
Year 13, Week 16, n=42-31.91 (-67.0 to 3.5)
Year 13, Week 24, n=20-28.18 (-54.9 to 5.3)
Year 13, Week 32, n=7-33.06 (-58.2 to -7.8)
Year 13, Week 40, n=1-12.9 (-12.9 to -12.9)
Exit, n=245-23.37 (-72.0 to 200.5)
8-Week follow-up, n=220-24.79 (-75.1 to 270.3)
24-Week follow-up, n=198-22.09 (-77.9 to 245.3)

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from Day 1 until follow-up (approximately up to 13 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belimumab 10 mg/kg IV—182/296 (61.5%)293/296 (99%)
Most frequent serious events
Showing 10 of 305
Most frequent serious events
EventBelimumab 10 mg/kg IV
PneumoniaInfections and infestations20/296
OsteoarthritisMusculoskeletal and connective tissue disorders14/296
Non-cardiac chest painGeneral disorders12/296
PyrexiaGeneral disorders11/296
CellulitisInfections and infestations10/296
Abdominal painGastrointestinal disorders9/296
CholelithiasisHepatobiliary disorders8/296
Gastroenteritis viralInfections and infestations8/296
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders7/296
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders7/296
Most frequent other events
Showing 10 of 180
Most frequent other events
EventBelimumab 10 mg/kg IV
Upper respiratory tract infectionInfections and infestations217/296
ArthralgiaMusculoskeletal and connective tissue disorders196/296
HeadacheNervous system disorders155/296
SinusitisInfections and infestations141/296
NauseaGastrointestinal disorders140/296
FatigueGeneral disorders137/296
Urinary tract infectionInfections and infestations137/296
Back painMusculoskeletal and connective tissue disorders124/296
CoughRespiratory, thoracic and mediastinal disorders124/296
DiarrhoeaGastrointestinal disorders114/296

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Belimumab 10 mg/kg IV
Mean43 ± 11.58
Sex: Female, Male
Sex: Female, Male(Participants)Belimumab 10 mg/kg IV
Female276
Male20
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Belimumab 10 mg/kg IV
American Indian or Alaska Native6
Asian6
Black or African American68
Native Hawaiian or Other Pacific Islander1
White215
08

Study locations

57 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Scottsdale, Arizona 85260, United States
  • GSK Investigational Site
    Tucson, Arizona 85724, United States
  • GSK Investigational Site
    La Jolla, California 92037, United States
  • GSK Investigational Site
    Los Angeles, California 90033, United States
  • GSK Investigational Site
    Los Angeles, California 90048, United States
  • GSK Investigational Site
    Sacramento, California 95817, United States
  • GSK Investigational Site
    San Jose, California 95124, United States
  • GSK Investigational Site
    Upland, California 91786, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80920, United States
  • GSK Investigational Site
    Washington, District of Columbia 20010, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Orlando, Florida 32806-6264, United States
  • GSK Investigational Site
    Tampa, Florida 33614, United States
  • GSK Investigational Site
    Atlanta, Georgia 30303, United States
  • GSK Investigational Site
    Boise, Idaho 83704, United States
  • GSK Investigational Site
    Idaho Falls, Idaho 83401, United States
  • GSK Investigational Site
    Chicago, Illinois 60611, United States
  • GSK Investigational Site
    Chicago, Illinois 60612, United States
  • GSK Investigational Site
    Munster, Indiana 46321, United States
  • GSK Investigational Site
    Kansas City, Kansas 66160, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Baton Rouge, Louisiana 70809, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70121, United States
  • GSK Investigational Site
    Baltimore, Maryland 21201, United States
  • GSK Investigational Site
    Baltimore, Maryland 21287, United States
  • GSK Investigational Site
    Cumberland, Maryland 21502, United States
  • GSK Investigational Site
    Wheaton, Maryland 20902, United States
  • GSK Investigational Site
    Boston, Massachusetts 02111, United States
  • GSK Investigational Site
    Ann Arbor, Michigan 48109-5542, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63110, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68516, United States
  • GSK Investigational Site
    Concord, New Hampshire 03301, United States
  • GSK Investigational Site
    Dover, New Hampshire 03820, United States
  • GSK Investigational Site
    Albany, New York 12206, United States
  • GSK Investigational Site
    Brooklyn, New York 11203, United States
  • GSK Investigational Site
    Great Neck, New York 11021, United States
  • GSK Investigational Site
    Manhasset, New York 11030, United States
  • GSK Investigational Site
    Rochester, New York 14618, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28210, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27157, United States
  • GSK Investigational Site
    Dayton, Ohio 45417, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73103, United States
  • GSK Investigational Site
    Oklahoma City, Oklahoma 73104, United States
  • GSK Investigational Site
    Tulsa, Oklahoma 74104, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15217, United States
  • GSK Investigational Site
    Willow Grove, Pennsylvania 19090, United States
  • GSK Investigational Site
    Dallas, Texas 75246, United States
  • GSK Investigational Site
    Dallas, Texas 75390-8550, United States
  • GSK Investigational Site
    Houston, Texas 77074, United States
  • GSK Investigational Site
    Sugar Land, Texas 77479, United States
  • GSK Investigational Site
    Arlington, Virginia 22205-3606, United States
  • GSK Investigational Site
    Seattle, Washington 98133, United States
  • GSK Investigational Site
    Spokane, Washington 99204, United States
  • GSK Investigational Site
    Milwaukee, Wisconsin 53226, United States
  • GSK Investigational Site
    Onalaska, Wisconsin 54650, United States
  • GSK Investigational Site
    Montreal, Quebec H3G 1A4, Canada
09

References and documents

Publications

  • Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1. PubMed 24187095 ↗
  • Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZJ, Pineda L, Klein J, Freimuth WW; LBSL02/99 Study Group. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct;64(10):3364-73. doi: 10.1002/art.34564. PubMed 22674457 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2005 to primary completion in Feb 2016, 129 months.

Results were first posted in Apr 2017, 1 year 2 months after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 129 months is above that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2007
First posted
Dec 31, 2007
StartActual
May 4, 2005
Primary completionActual
Feb 23, 2016
CompletionActual
Feb 23, 2016
Results first posted
Apr 28, 2017
Last update
Jul 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00583362
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 31, 2007
Start date
May 4, 2005
Primary completion
Feb 23, 2016
Completion
Feb 23, 2016
Results posted
Apr 28, 2017
Last update
Jul 23, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline (for GlaxoSmithKline; Human Genome Sciences Inc., a GSK Company; Sirtris, a GSK Company; Stiefel, a GSK Company; ViiV Healthcare)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belimumab

Start the discussion